Clinical Development
Dabrafenib (DRB436), Trametinib (TMT212)
Oncology Clinical Protocol CDRB436G2201 / [STUDY_ID_REMOVED]
Phase II open -label global study to ev aluate the effect of 
dabrafenib in combination w ith trametinib in children and 
adolescent patients w ith BRAF V600 mutation positiv e Low 
Grade Glioma (LGG) or relapsed or refractor y High Grade 
Glioma (HGG)
Document type Amended Protocol Version
EUDRACT number 2015 -004015 -20
Version nu mber v05 (Clean )
Development phase II
Document status Final
Release date 12-Dec- [ADDRESS_967392] of abbreviations ............................................................................................................ 9
Glossary  of terms ............................................................................................................... 12
Protocol summary :
............................................................................................................. 14
Amendment 5 (26 -Nov-2019) ........................................................................................... 21
Amendment 3 (07 -Aug-2018) ........................................................................................... 24
Amendment 2 (23 -Feb-2018) ............................................................................................ 24
Amendment 1 (07 -Jun-
2017) ............................................................................................ 24
1Background ................................ ................................ ................................ ........................ 26
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_013] .............. 26
1.1.1 Pathogenesis .......................................................................................... 26
1.1.2 Epi[INVESTIGATOR_623] ........................................................................................ 26
1.1.3 Current Treatments and Unmet Medical Need ..................................... 27
1.2
Introduction to investigational treatment(s) a nd other study  treatment(s) ............. [ADDRESS_967393] Treatment Follow up ..................................................................... 60
4.1.4 Survival follow -
up ................................................................................ 60
4.2 Timing of interim anal yses and design adaptations ............................................... 60

[COMPANY_001] Confidential Page 3
Protocol Amended Version 05 Protocol No. C DRB436G2201
4.3 Definition of end of study ................................ ................................ ...................... 61
4.4 Early study termination .......................................................................................... 61
5Population .......................................................................................................................... 61
5.1 Patient population .................................................................................................. 61
5.2 Inclusion criteria .................................................................................................... 62
5.3 Exclusion criteria ................................................................................................... 63
6Treatment ........................................................................................................................... 65
6.1 Study  treatment ...................................................................................................... 65
6.1.1 Dabrafenib and Trametinib Dosing regimen ......................................... 65
6.1.2 Carboplatin and Vincristine Dosing Regimen ...................................... 70
6.1.3 Ancillary  treatments .............................................................................. 71
6.1.4
Rescue medication ................................................................................ 72
6.1.5 Guidelines for continuation of treatment .............................................. 72
6.1.6 Treatment duration ................................................................................ 72
6.2 Dose escalation guidelines ..................................................................................... 72
6.3 Dose modifications ................................................................................................ 73
6.3.1 Dose modification and dose delay ........................................................ 73
6.4
Concomitant medications ...................................................................................... 93
6.4.1 Permitted concomitant therap y
............................................................. 93
6.4.2 Permitted concomitant therap y requiring caution and/or action ........... [ADDRESS_967394] to f ollow-up................................................................................. 122
7.2 Assessment ty pes................................................................................................. 122
7.2.1 Efficacy  assessments ........................................................................... 122
7.2.2 Safety  and tolerability  assessments ..................................................... 124
7.2.3 Pharmacokinetics ................................................................................ 130
132
7.2.5 Resource utilization ............................................................................. 134
7.2.6 Patient reported outcomes (LGG cohort onl y).................................... [ADDRESS_967395]....................................................... 136
8.2 Serious adverse events ......................................................................................... 137
8.2.1
Definitions........................................................................................... 137
8.2.2
Reporting............................................................................................. 138
8.3 Emergency  unblinding of treatment assignment ................................................. 139
8.4 Pregnancies .......................................................................................................... 139
8.5 Warnings and precautions .................................................................................... 139
8.6 Data Monitoring Committee ................................................................................ 139
8.7 Steering Committee ............................................................................................. 140
9Data collection and management ................................ ................................ ..................... 140
9.1 Data confidentiality ............................................................................................. 140
9.2 Site monitoring .................................................................................................... 141
9.3
Data collection..................................................................................................... 141
9.4 Database management and quality  control ................................ .......................... 142
10Statistical methods and data anal ysis.............................................................................. 142
10.1 Analy sis sets ........................................................................................................ 143
10.1.1 Full Anal ysis Set ................................................................................. 143
10.1.2 Safety  set............................................................................................. 143
10.1.3
Per-Protocol Set .................................................................................. 143
10.1.4 Dose -
determining anal ysis set............................................................. 143
10.1.5 Pharmacokinetic anal ysis set
............................................................... 143

[COMPANY_001] Confidential Page 5
Protocol Amended Version 05 Protocol No. C DRB436G2201
10.1.6 Other anal ysis sets ............................................................................... 144
10.2 Patient demographics/other baseline characteristics ........................................... 144
10.3 Treatments (stud y treatment, concom itant therapi[INVESTIGATOR_014], compliance) ..................... 144
10.4 Primary  objective ................................................................................................. 145
10.4.1 Variabl e
............................................................................................... 145
10.4.2 Statistical hy pothesis, model, and method of analy sis........................ 145
10.4.3 Handling of missing values/censoring/discontinuations ..................... 146
10.4.4 Supportive and sensitivity anal yses.................................................... 146
10.5 Secondary  objectives ........................................................................................... 147
10.5.1 Safety  objectives ................................................................................. 149
10.5.2 Pharmacokinetics ................................................................................ 151
153
10.5.4 Resource utilization ............................................................................. 154
10.5.5
Patient- reported outcomes ................................................................... 155
155
10.7 Interim anal ysis.................................................................................................... 155
10.7.1 HGG Cohort ........................................................................................ 155
10.7.2 LGG Cohort ........................................................................................ 157
10.8
Sample size calculation........................................................................................ 157
10.8.1 HGG Cohort ........................................................................................ 157
10.8.2 LGG Cohort ........................................................................................ 159
10.9 Power for anal ysis of key secondary  variables
.................................................... 160
11Ethical considerations and administrative procedures .................................................... 160
11.1 Regulatory
 and ethical compliance ...................................................................... 160
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... [ADDRESS_967396] keepi[INVESTIGATOR_5304]
..................... 162
11.7 Confidentiality  of study  documents and patient records ..................................... 162
11.8
Audits and inspections......................................................................................... 163
11.9 Financial disclosures ............................................................................................ 163
12Protocol adherence ................................ ................................ ................................ .......... 163
12.1 Amendments to the protocol ................................................................................ 163
13References (available upon request) ................................ ................................ ................ 164
14Appendices ................................ ................................ ................................ ...................... 168

[COMPANY_001] Confidential Page 6
Protocol Amended Version 05 Protocol No. C DRB436G2201
14.1 Appendix 1 – Concomitant medications ................................ .............................. 168
14.2 Appendix 2 – Performance Status Criteria .......................................................... 170
14.3 Appendix 3 
–Response Assessment in Neuro- oncology  (RANO) Criteria ........ 171
14.4 Appendix 4 – WHO (2016) Grading of Tumors of the CNS .............................. [ADDRESS_967397] of tables
Table 1
-1 Efficacy  Outcomes in Trials for Relapsed, Refractory  Pediatric 
HGG ...................................................................................................... 28
Table 1
-2 Median Stead y-State Dabrafenib AUC (ng*h/mL) (day  15) b y 
Dose and Age Cohorts .......................................................................... 36
Table 1
-3 Geometric mean Stead y-State Dabrafenib AUC(ng*h/mL) (day  15) 
by [CONTACT_711211] 2 ....................................................................... 36
Table 1
-4 Median trametinib PK (day  15) by  [CONTACT_164737] ..................................... 41
Table 3
-1 Objectives and related endpoints .......................................................... 51
Table 6
-1 Dose and treatment schedule for dabrafenib (DRB436) capsules for 
patients less than 12 y ears of age (5.25 mg/kg/day) ............................. 66
Table 6-2 Dose and treatment schedule for dabrafenib (DRB436) capsules for 
patients greater or equal 12 y ears of age (4.5 mg/kg/day ) .................... 66
Table 6-3 Dose and treatment schedule for dabrafenib (DRB436) dispersible 
tablets for patients less than 12 years of age (5.25mg/kg/day ) ............. 66
Table 6-4 Dose and treatment schedule for dabrafenib (DRB436) dispersible 
tablet for patients greater than or equal 12 years of age (4.5 
mg/kg/day ) ............................................................................................ 67
Table 6
-5 Dose and treatment schedule for trametinib (TMT212) oral 
solution for patients less than 6 y ears old (0.032 mg/kg/day )............... 67
Table 6-6 Dose and treatment schedule for trametinib (TMT212) oral 
solution for patients greater or equal to 6 y ears old (0.025 
mg/kg/day ) ............................................................................................ 68
Table 6
-7 Dose and treatment schedule for trametinib (TMT212) tablets for 
patients less than 6 y ears and weight greater or equal 26kg (0.032 
mg/kg/day ) ................................ ................................ ............................ 68

[COMPANY_001] Confidential Page 7
Protocol Amended Version 05 Protocol No. C DRB436G2201
Table 6-8 Dose and treatment schedule for trametinib (TMT212) tablets for 
patients greater or equal to 6 and weight greater or equal 33kg 
(0.025 mg/kg/day ) ................................................................................. 68
Table 6
-9 Induction therap y .................................................................................. 71
Table 6
-10 Maintenance therap y ............................................................................. 71
Table 6
-11 General guidelines for dose modification for adverse events 
considered related to dabrafenib and trametinib combination 
treatment ................................ ................................ ................................ 73
Table 6-12 Dose Modification for trametinib (TMT212) oral solution for 
patients greater or equal to 6 y ears old .................................................. 74
Table 6
-13 Dose Modification for trametinib (TMT212) for oral solution for 
patients less than 6 y ears old ................................ ................................ .75
Table 6-14 Dose Modification for dabrafenib (DRB436) dispersible tablet for 
patients less than 12 y ears of age .......................................................... 75
Table 6
-15 Dose Modification for dabrafenib (DRB436) dispersible tablet for 
patients greater or equal 12 y ears of age ............................................... 75
Table 6
-16 Mandatory  dose modi fication and recommended clinical 
management for p yrexia syndrome suspected to be related to 
dabrafenib and/or trametinib treatment ................................................. 77
Table 6
-17 Mandatory  dose modi fications and recommended clinical 
management guidelines for renal function alterations .......................... 78
Table 6-18 Mandatory  dose modifications and recommended clinical 
management guidelines for pneumonitis .............................................. 80
Table 6
-19 Mandatory  dose modification and recommended clinical 
management for visual changes and/or ophthalmic examination 
findings suspected to be related to trametinib treatment....................... 81
Table 6-20 Mandatory  dose modification and recommended clinical 
management for retinal pi[INVESTIGATOR_711154] l detachments (RPED) 
suspected to be related to trametinib treatment ..................................... 82
Table 6
-21 Mandatory  dose modification and recommended clinical 
management for uveitis, incl uding iritis suspected to be related to 
dabrafenib treatment ................................ ................................ .............. 82
Table 6-22 Withholding and Stoppi[INVESTIGATOR_482935] -Prolongation ................... 84
Table 6-23 Mandatory  dose modification and recommended clinical 
management for LVEF suspected to be related to dabrafenib and/or 
trametinib treatment .............................................................................. 85
Table 6
-24 Mandatory  dose modifications and recommended clinical 
management guidelines for rash ................................ ............................ 86
Table 6-25 Mandatory  dose modification and recommended clinical 
management for h ypertension ............................................................... 88
Table 6
-26 Packaging and labeling ......................................................................... 97

[COMPANY_001] Confidential Page 8
Protocol Amended Version 05 Protocol No. C DRB436G2201
Table 7-1 Visit evaluation schedule for HGG and LGG dabrafenib and 
trametinib treatment arm ..................................................................... 100
Table 7
-2 Visit evaluation schedule for LGG crossover patients ........................ 107
Table 7-3 Visit evaluation schedule for LGG chemotherap y arm....................... 111
Table 7-4 Imaging Assessment Collection Plan.................................................. 123
Table 7
-5 Central Clinical laboratory parameters col lection plan ....................... 127
Table 7-6 Full Pharmacokinetic blood collection log –HGG cohort and 
subset of LGG cohort .......................................................................... 131
Table 7
-7 Sparse Pharmacokinetic blood collection log for subset of LGG 
cohort ................................ ................................ ................................ ...131
133
Table 10-1 Non-compartmental pharmacokinetic parameters .............................. 152
Table 10-2 Predictive probability  of the lower bound of 95% CI  exceeding 
20% at the primary  anal ysis under different interim results ............... [ADDRESS_967398] Binomial 95 and 80 percent Confidence Intervals Around 
Potential Observed ORRs for N=[ADDRESS_967399] to the 95% CI  excluding 
20% response rate ............................................................................... [ADDRESS_967400] to the 95% and 80% CI s 
excluding 32% resp onse rate ............................................................... [ADDRESS_967401] of abbreviations
ADL Activities of daily living
AE Adverse event
ALP Alkaline phosphatase
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
AUC Area under the curve 
b.i.d. bis in diem /twice a day
BAL Bronchoalveolar lavage
BCC Basal cell carcinoma
Cavg Average concentration
CBDCA Carboplatin
CBR Clinical benefit rate
 
Cmax The observed maximum (peak) plasma concentration after drug administration
CHMP Committee for Medicinal Products for Human Use
CI Confidence interval 
CMO&PS Chief Medical Office and Patient Safety
CMV Cytomegalovirus
CNS Central nervous system
COG
CRChildren’s Oncology Group
Complete response
CRF Case report/ record form; the term CRF can be applied to either EDC or p aper
CRO Contract research organization
CRP C reactive protein 
CSF Cerebrospi[INVESTIGATOR_711155] (CSR) that captures all the additional information that is 
not included in the CSR
CTCAE Common terminology criteria for adverse event 
DILI Drug -induced liver injury
DLT
DMCDose l imiting toxicity
Data monitoring committee
DOR Duration of response
DRESS Drug reaction with eosinophilia and systemic symptoms
EBV
EEAEpstein -Barr virus
European Economic Area
ECG Electrocardiogram
eCRF Electronic case report forms for EDC
ECHO Echocardiogram
EDC Electronic data capture
EMA
EUThe European Medicines Agency
European Union
eSAE Electronic serious adverse event 
FAS
FFPEFull analysis set 
Formalin -fixed, paraffin -embedded
FDA Food and Drug Administration
GBM
GDPRGlioblastoma multiforme
General Data Protection Regulation

[COMPANY_001] Confidential Page 10
Protocol Amended Version 05 Protocol No. C DRB436G2201
HBV Hepatitis B Virus 
HCV Hepatitis C Virus 
HGG High Grade Glioma 
HPMC Hydroxypropylmethyl cellulose 
HSV Herpes simplex virus
i.v. intravenous(ly)
IB Investigator’s brochure
ICF Informed consent form 
ICH International Conference on Harmonization
IEC Independent Ethics Committee
INR International normalized ratio 
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
IUD Intrauterine device
IUS Intrauterine system
Kg Kilogram 
LCH Langerhans Cell Histiocytosis
LFT Liver function test
LGG Low Grade Glioma
MAP Master analysis plan documents project standards in the statistical methods which will be used 
within the individual clinical trial RAP documentation
MRI Magnetic resonance imaging 
MTD Maximum tolerated dose
NGS Next-generation sequencing
NSCLC Non-small cell lung cancer
q.d. omnia die /once a day
ORR Overall response rate 
OS Overall survival 
PAS Pharmacokinetic analysis set 
PD Progression of disease 
PFS Progression free survival
PHI Protected Health Information
PK Pharmacokinetics 
p.o. per os /by [CONTACT_1966]/orally
POS Probability of success
PPS Per-protocol set 
PR Partial Response
PRO Patient reported outcomes
PTC Papi[INVESTIGATOR_711156] Q to T interval (ECG)
QTcF QT interval corrected using Fridericia method 
RANO Response Assessment in Neuro -Oncology Criteria
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analyses
REB Research Ethics Board
RP2D
RPEDRecommended phase two dose
Retinal pi[INVESTIGATOR_711157] 11
Protocol Amended Version 05 Protocol No. C DRB436G2201
R Value ALT/ALP in x ULN
RVO Retinal vein occlusion
SAE Serious adverse event
SC Steering committee 
SCAR Severe cutaneous adverse reactions
SIADH Syndrome of inappropriate antidiuretic hormone secretion 
SmPC Summary of product characteristics
SOC Standard of care
SOP Standard operating p rocedure
TBIL Total bilirubin
TTR Time to response
ULN Upper limit of normal 
VCR Vincristine
WBC White blood cells 
WHO World Health Organization

[COMPANY_001] Confidential Page 12
Protocol Amended Version 05 Protocol No. C DRB436G2201
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_64058] A biological speci men including, for ex ample, blood (plas ma, serum), saliva, 
tissue, urine, stool, etc. t aken fr om a study patient 
Control drug A study treatment used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or evaluate 
comparative effects of the investigati onal drug
Cohort A group of newly enrolled patients treated at a specific dose and regimen (i.e. 
treatment group) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually expressed 
as number of days (e.g.: q28 days)
Dose level The dose of drug given to the patient (total daily or weekly etc.) 
Enrollment Point/time of patient entry into the study; the point at which informed consent must 
be obtained (i.e. prior to starting any of the procedures described in the protoco l)
Investigational drug The study treatment whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug.”
Investigational treatment Drug whose properties are being tested in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes 
approved drugs used outside of their indication/approved dosage, or that are 
tested in a fixed combination. Investigational tr eatment generally does not include 
other study treatments administered as concomitant background therapy required 
or allowed by [CONTACT_230753]/dosage
Medication number A unique identifier on the label of each study tr eatment package which is linked to 
one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study procedures that 
was not included in the investigational treatment
Subject Number (Subject 
No.)A unique identifying number assigned to each patient who enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional segments 
such as screening, baseline, titration, washout, etc.
Personal Data Subject information collected by [CONTACT_64130].  This data includes subject identifier information, 
study information and biological samples.
Randomization number A unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Stage related to study 
timelineA major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, random ization, completion of treatment, etc.
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size of the 
tumor, whether lymph nodes contain cancer, and whether the cancer has spread 
from the original site to other parts of th e body
Stop study participation Point/time at which the patient came in for a final evaluation visit or when study 
treatment was discontinued and post treatment follow-up is complete, whichever is 
later
Study treatment Includes any drug or combination of drugs in any study arm administered to the 
patient (subject) as part of the required study procedures, including placebo and 
active drug run -ins.
In specific examples, it is important to judge investigational treatment component 
relationship relative to a study treatment combination; study treatment in this case 
refers to the investigational and non -investigational treatments in combination.
Study treatment 
discontinuationPoint/time when patient permanently stops taking study treatment for any reason
Supportive treatment Refers to any treatment required by [CONTACT_140946] a study treatment, e.g. 
premedication of vitamin supplementation and corticosteroid for pemetrexed 
disodium.

[COMPANY_001] Confidential Page [ADDRESS_967402] of 1 or more cohorts. Cohorts are not expanded, new cohorts are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified timepoints
Withdrawal of study 
consentWithdrawal of co nsentfrom study occurs only wh en a patient d oes not want to 
partic ipate in the study any longer, a nd does not allow any further collection of 
personal data

[COMPANY_001] Confidential Page 14
Protocol Amended Version 05 Protocol No. C DRB436G2201
Protocol summary : 
Title Phase II open -label global study to evaluate the effect of dabrafenib in 
combination with trametinib in children and adolescent patients with BRAF V600 
mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade 
Glioma (HGG)
Brief title Study of efficacy and safety of dabrafenib in combination with trametinib in 
pediatric patients with BRAF V600 mutation positive LGG or relapsed or refractory 
HGG tumors
Sponsor and Clinical 
Phase[COMPANY_001]
Phase II
Investigation ty pe Drug
Study  type Interventional 
Purpose and rationale Relapsed, refractory or resistant pediatric HGG lacks a standard of care. Multiple 
chemotherapi[INVESTIGATOR_711158] . Targeted agents in this disease setting have shown a 
lack of efficacy. 
Preliminary results from [BRF116013, CDRB436A2102 , data cut off of 12-Sept -
2017 ]showed that 14of 31patients (45% ) with relapsed or refractory BRAF V600 
mutant HGG had central independent radiologic review confirmed responses (CRs 
+ PRs) following dabrafenib monotherapy. These results indicate that dabrafenib 
may offer improvement in treatment outcome for these patients. For this reason, 
the historical response rate (RR) in BRAF V600 mutant pediatric relapse d 
refractory HGG may be higher than that observed in unselected populations, 
where the RR is less than 12%.
Pediatric patients with BRAF V600 mutant LGG that is progressing following 
optima l surgical resection often require systemic treatment. The standard of care 
in this setting has been a regimen of carboplatin and vincristine, which may not be 
as effective in patients whose tumo r harbors the BRAF V600 mutation, with lower 
response rate, PF S and OS than those without this mutation. Furthermore , in 
patients with BRAF V600 mutant LGG who have failed prior systemic 
chemotherapy, independently confirmed response of dabrafenib monotherapy 
exceeds historical expectations for this subgroup of patie nts.
The combination of dabrafenib with trametinib in adults with BRAF V600 mutant 
melanoma, non-small cell lung cancer (NSCLC )and other tumors have resulted in 
improved efficacy over dabrafenib monotherapy and suggests that greater efficacy 
may also be s een in the pediatric patients with a BRAF V600 mutant malignancy.
Given the high unmet medical need in pediatric HGG and LGG , the encouraging 
efficacy of dabrafenib monotherapy in pediatric patients with BRAF V600 mutant 
HGG and LGG , and the improved efficacy seen in adult cancer studies upon the 
addition of trametinib to dabrafenib, this study aims to demonstrate the 
effectiveness of dabrafenib with trametinib in pediatric patients with BRAF V600 
mutant LGG and relapsed refractory H GG.
Primary  Objective(s) The primary objective of the HGG cohort is to evaluate the anti-tumor activity of 
dabrafenib in combination with trametinib , as measured by [CONTACT_34426] 
(ORR) by [CONTACT_711212].
The primary objective of the LGG cohort is to compare the anti -tumor activity of 
dabrafenib in combination with trametinib tothe combination of carboplatin and 
vincristine, as measured by [CONTACT_34426] (ORR) by [CONTACT_711213].
Secondary  Objectives HGG Cohort:
1.Evaluate ORR by [CONTACT_3138]
2.Evaluate duration of response (DOR) by [CONTACT_711214]
3.Evaluate progression free survival (PFS) by [CONTACT_711215]
4.Evaluate time to response (TTR) by [CONTACT_711216] 15
Protocol Amended Version 05 Protocol No. C DRB436G2201
5.Evaluate clinical benefit rate (CBR) by [CONTACT_711214]
6.Evaluate overall survival (OS)
7.Evaluate the safety and tolerability profile of dabrafenib in combination with 
trametinib in the study population
8.Evaluate the palatability of dabrafenib oral suspension and trametinib oral 
solution
9.Characterize the pharmacokinetics of dabrafenib , itsmetabolites and tramet inib 
in the study population
LGG Cohort:
10.Evaluate ORR of dabrafenib in combination with trametinib versu s carboplatin 
with vincristine, as measured by [CONTACT_3138] .
11.Evaluate the DOR of dabrafenib in combination with trametinib versus 
carboplatin with vincristine by [CONTACT_711217].
12.Evaluate PFS of dabrafenib in combination with trametinib versus carboplatin 
with vincristine, as measured by [CONTACT_711218] .
13.Evaluate TTR of dabrafenib in combination with trametinib versus carboplatin 
with vincristine, as measured by [CONTACT_711218] .
14.Evaluate CBR of dabrafenib in combination with tramet inib versus carboplatin 
with vincristine, as measured by [CONTACT_711219] .
15.Evaluate the overall survival of dabrafenib in combination with trametinib 
versus carboplatin with vincristine.
16.Evaluate the safety and tolerabil ity of dabrafenib in combination with trametinib 
versus carboplatin with vincristine.
17.Evaluate the palatability of dabrafenib oral suspension and trametinib oral 
solution
18.Characterize the pharmacokinetics of dabrafenib, its metabolites and trametinib 
in the study population .
19.Assess patient reported outcomes of dabrafenib in combination with trametinib 
versus carboplatin with vincristine .
Study  design CDRB436G2201 combines two pediatric glioma cohorts into a single multi -center, 
global, open -label, phase II study. The HGG cohort is a single arm part evaluating 
the effect of dabrafenib in combination with trametinib in children and adolescent 
patients with BRAF V600 mutation positive relapsed, refractory HGG. 
Approximately [ADDRESS_967403] atinand 
vincristine in children and adolescents with BRAF V600 mutation positive LGG . 
Approximately 102 patients will be randomized in a 2:[ADDRESS_967404]
study treatment (except if consent is withdrawn, patient death, lost to follow -up or 
study is discontinued). An interim analysis for futility for the HGG cohort will be 
implemented to allow possible termination of recruitment into the HGG cohort in 
the event that there is insufficient efficacy . An independent DMC will be instituted 
to review safety data during the study for all patients in LGG and HGG cohorts.  
For full details of study design refer to Section 4 .
Population This study will be conducted in two cohorts of pediatric patients, HGG cohort and 
LGG cohort.

[COMPANY_001] Confidential Page 16
Protocol Amended Version 05 Protocol No. C DRB436G2201
For the HGG cohort, approximately 40 male or female children or adolescent 
patients between ≥12 months and <[ADDRESS_967405] therapy will be enrolled . 
For the LGG cohort, approximately 102 male or female children or adolescent 
patients between ≥12 months and <[ADDRESS_967406] systemic treatment because of a risk of 
neurological impairment with progression .
Inclusion criteria Key Inclusion criteria:
-Male or female ≥12 months and <[ADDRESS_967407] weigh ≥7kg at 
the time of enrollment.
-Locally determined HGG or LGG as defined by W HO histological classification 
system, revised 2016 . 
For HGG cohort only: locally confirmed histologic diagnosis of High 
Grade Glioma (Grade III or IV ), including a naplastic p leomorphic 
xanthoastrocytoma (aPXA) andanaplastic ganglioglioma. 
For LGG cohort only: locally confirmed histologic diagnosis of Low Grade 
Glioma (Grade I or II).
-HGG cohort: Relapsed, progressed, or failed to respond to frontline therapy. 
-LGG cohort: Patients with progressive disease following surgical excision, or 
non-surgical candidates with necessity to begin systemic treatment because of 
a risk of neurological impairment with progression.
-BRAF V600 mutation -positive tumor as sessed locally , or at a [COMPANY_001] 
designated central reference laboratory if local BRAF V600 testing is 
unavailable. 
-Locally determined and c entrally confirmed measurable disease with minimal 
bi-perpendicular diameter that must be at least twice the imaging slice 
thickness to be used for efficacy assessments .
-Tumor tissue must be provided for central confirmatory testing of BRAF
mutational status (LGG and HGG cohorts) , and for HGG histopathology (HGG 
cohort only).
-Karnofsky/Lansky performance score of ≥50% .
-Adequate bone marrow function per central or local lab in the absence of 
growth fac tor support .
-Adequate renal function, liver function, and cardiac function .
-If receiving glucocorticoids, patient must be on a stable or weaning dose for at 
least [ADDRESS_967408] dose of study treatment .

[COMPANY_001] Confidential Page 17
Protocol Amended Version 05 Protocol No. C DRB436G2201
Exclusion criteria Key Exclusion criteria:
-Malignancy OTHER than BRAF V600 mutant HGG or LGG .
-Previous treatment with dabrafenib oranother RAF inhibitor, trametinib or 
another MEK inhibitor, or an ERK inhibitor.
-HGG patients: Cancer therapy (chemotherapy with delayed toxicity, 
immunotherapy, biolo gic therapy, v accine therapy ) or investigational drugs 
within [ADDRESS_967409] dose of study treatment. LGG patients: Any 
systemic anticancer therapy (chemotherapy, immunotherapy, biologic therapy 
or vaccine therapy) or investigational drugs prior to enrollment. 
-HGG patients: Radiotherapy to CNS glioma lesions within [ADDRESS_967410] 
dose of study t reatment, unless there is clear evidence of radiologic 
progression outside of the field of radiation. LGG patients: Radiotherapy to 
CNS glioma lesions at any point prior to enrollment. 
-History of malignancy with confirmed activating RAS mutation or with BRAF
fusion such as BRF -KIAA1549. 
-Current use of a prohibited medication or herbal preparation or requires any of 
these medications during the study. See Section 6.4 for details. 
-Unresolved toxicity gre ater than NCI CTCAE v 4.03 grade 2 from previous anti-
cancer therapy, including major surgery, except those that in the opi[INVESTIGATOR_711159]/toxicity profile of 
the study treatment (e.g., alopecia a nd/or peripheral neuropathy related to 
platinum or vinca alkaloid based chemotherapy).
-History of allergic reactions attributed to compounds of similar chemical or 
biologic composition to dabrafenib , trametinib and their excipi[INVESTIGATOR_840]. For LGG 
patients only: history of allergic reactions or contraindications to the use of 
carboplatin or vincristine (refer to local product label or SmPC)
-Autologous or allogeneic stem cell transplant within [ADDRESS_967411] 
dose of study treatment [NOTE: patients with evidence of active graft versus 
host disease are excluded regardless of elapsed time].
-History or current diagnosis of cardiac disease indicating significant risk of 
safety for patients participating in the study such as uncontrolled or significant 
cardia c disease.
- Uncontrolled medical conditions (e.g., diabetes mellitus, hypertension, liver 
disease or uncontrolled infection), psychological, familial, sociological, or 
geographical conditions that do not permit compliance with the protocol; or 
unwillingness or inability to follow the procedures required in the protocol.
-Presence of active GI disease or other condition (e.g., small bowel or large 
bowel resection) that will interfere significantly with the absorption of drugs. 
-A history of Hepatitis B Virus o r Hepatitis C Virus infection (patients with 
laboratory evidence of cleared Hepatitis B Virus and/or Hepatitis C Virus may 
be enrolled).
-Women of child -bearing potential, defined as all women physiologically capable 
of becoming pregnant (e.g. are menstruat ing), unless they are using highly 
effective methods of contraception during dosing of study treatment and for 16
weeks after stoppi[INVESTIGATOR_711160], and 2 weeks after stoppi[INVESTIGATOR_711161], whichever is longer .Note: Hormonal -based 
methods are not permitted as a method of contraception due to potential drug -
drug interactions with dabrafenib.
-Women who are pregnant or actively breast feeding.
-Sexually active males (including those that have had a vasectomy) unless they 
use a condom during intercourse while on study and for 16weeks after 
stoppi[INVESTIGATOR_262], and agree not to father a child during this period.
-A history or current evidence of retinal vein occlusion (RVO) or central serous 
retinopathy . See Section 5.3 for details

[COMPANY_001] Confidential Page 18
Protocol Amended Version 05 Protocol No. C DRB436G2201
Investigational and 
reference therapyDabrafenib (DRB436 ) oral administration, twice daily based on weight , age and
appropriate dose level . Trametinib (TMT212 ) oral administration, once daily based 
on weight and/or age . See dosing regimen in Section 6.1.1.
LGG patients randomized to receive carboplatin plus vincristine areadministered 
one course of induction ([ADDRESS_967412]) followed 
by 8 cycles of maintenance chemotherapy. Each maintenance cycle is 6 weeks. 
See dosing regimen in Section 6.1.2
Efficacy  assessments HGG and LGG cohorts : Brain MRI every [ADDRESS_967413] -treatment follow -up, and 
at any time there is suspi[INVESTIGATOR_711162]. Partial Response 
(PR) and Complete Response (CR) must be confirmed by [CONTACT_711220] ≥[ADDRESS_967414] met.
Tumor evaluation by [CONTACT_711221] a nd central 
independent assessment .
Safety  assessments HGG and LGG cohorts:
Medical history
Physical examination, vital signs, height and weight, 
Performance status
Laboratory evaluations (hematology, clinical chemistry and urinalysis)
Monthly pregnancy testing fo r women of childbearing potential
Cardiac assessment, including ECG and cardiac imaging
 
Dermatology evaluation
Ophthalmologic exam
 
Adverse events, the severity, the seriousness, the relationship to study drug ,and 
AEs of special interest
Other assessments HGG and LGG cohorts:
Pharmacokinetics (PK) blood collection to summarize exposure (dabrafenib, 
dabrafenib metabolites and trametinib)  
Taste questionnaires for dabrafenib oral suspension and trametinib oral solution .
Tumor samples for confirmatory testing of HGG histopathology (HGG patients 
only)
Tumor samples for confirmatory testing of BRAF mutational status for both LGG 
and HGG patients . 
 
Survival status follow -up 
LGG cohort only :
Patient reported outcomes on PROMIS Parent Proxy Global 7+2 Health 
questionnaire 

[COMPANY_001] Confidential Page 19
Protocol Amended Version 05 Protocol No. C DRB436G2201
Data analy sisData analy sis to address the primary  objective :
The primary analysis will be performed on the full analysis set (FAS ). For HGG 
cohort, point estimate and the exact binomial confidence intervals (CIs) of ORR by 
[CONTACT_711222]. The lower bound of the CIs will 
be used to provide evidence that the true ORR is greater than a certain specific 
response rate. For LGG cohort, theORR by [CONTACT_711223]- square test 
at one -sided 2.5% level of significance. ORR will be summarized using descriptive 
statistics by [CONTACT_711224] -sided exact binomial 95% CIs ( Clopper 
and Pearson 1934 ).
Data analy sis to address secondary  objectives:
ORR per investigator assessment for HGG cohort and LGG cohort will also be 
analyzed .
TTR, DOR , CBR and PFS will be analyzed as per investigator and independent 
assessment. Confirmation of response is required for all response endpoints, as 
per RANO.
DOR, PFS and OS will be described using Kaplan -Meier methods and appropriate 
summary statis tics.
Efficacy :The efficacy analysis will be performed on all patients who receive at 
least one dose of study treatment. Sensitivity analysis on the primary and 
secondary efficacy endpoints will be performed on the evaluable set of patients .
Safety :
The assessment of safety will be based mainly on the frequency of adverse events 
and on the number of laboratory values that fall outside of pre-determined ranges. 
Other safety data (e.g. vital signs, ECG, ECHO) will be considered as required . 
The safety s ummary tables will include only assessments collected no later than 
[ADDRESS_967415] one dose of study 
treatment.
The palatabilit y of dabrafenib oral suspension and trametinib oral solution will be 
evaluated.
The patient reported outcome for the LGG cohort will be summarized.
Interim analy sis:
An interim analysis for futility will be implemented to allow possible termination of 
recruitment of the HGG cohort in the event that there is insufficient efficacy. The 
patients for inclusion in the formal interim analysis for futility will be determined 
shortly after [ADDRESS_967416] withdrawn early. If the observed ORR 
assessed by [CONTACT_711225] ≤ 25% there may be a 
consideration to stop the enrollment into the HGG cohort due to insufficient 
efficacy. The final decision on whether to stop enrollment into this cohort will also 
take into account all available study information at the IA cut -off including safety 
data and al l efficacy endpoints. Any decision to halt further enrollment into the 
HGG cohort will not impact the treatment options for patients already enrolled into 
this cohort. HGG patients deriving benefit as per investigator discretion may 
continue receiving dabrafenib plus trametinib treatment on study.
In addition, an additional interim analysis of key safety and PK data of the 
adolescent patients in the HGG cohort may be p erformed to support a hea lth 
authority request for data in adolescent patients.
Sample size for HGG cohort:
Approximately 40 patients will be enrolled in HGG cohort if the study is not 
stopped for futility at the time of IA. 

[COMPANY_001] Confidential Page 20
Protocol Amended Version 05 Protocol No. C DRB436G2201
With a total of 40 patients and with 16 patients included in the futility interim 
analysis and when the true ORR is ≤ 20% :
the probability of meeting the futility consideration criteria at IAis > 79%, 
the probability of the 95% CI excluding 20% at th e primary analysis is < 1.6%,
and the probabilities of the 95% CI and the 80% CI excluding 32% at the 
primary analysis are both < 0.1% respectively .
With a total of 40 patients and with 16 patients included in the futility interim 
analysis and if the true ORR is 55% or higher, then:
the probability of meeting the futility consideration criteria at IA is < 2%, 
the probabilities of the 95% CI excluding 20% and the 80% CI excluding 32% 
at the primary analysis are both > 90% respectively , 
and the probability that the 95% CI excludes 32% is > 78%.
Sample size for LGG cohort:
For LGG cohort, to detect a 30% improvement in ORR based on central independent 
assessment response of 50% in the dabrafenib in combination with trametinib arm 
vs 20% in the carboplatin plus vincristine arm with at least 80 %power, 102 patients 
are required to be randomized in the two treatment arms in a 2:[ADDRESS_967417], and one -sided alpha = 2.5%.
Key words High grade glioma, HGG, Low grade glioma, LGG, BRAF , DRB436, dabrafenib,
TMT212, trametinib, carboplatin and vincristine, children , adolescent

[COMPANY_001] Confidential Page 21
Protocol Amended Version 05 Protocol No. C DRB436G2201
Amendment 5 (26-Nov -2019)
As of 26-Nov-2019, twenty  six(26) patients have been enrolled and treatedin the H GG cohort 
of CDRB436G2201 and forty  four (
44) patients have been randomized in the LGG cohort of 
CDRB436G2201.
Amendment Rational e
The main purpose of this amendment is (1) to add dose modification requirements for cases of 
severe cutaneous adverse reactions (SCARs) which have 
been reported during treatment with 
dabrafenib in combination with trametinib outside this clinical study, and (2) to change the duration 
of male and female contraception following the last dose of dabrafenib from [ADDRESS_967418] dose of trametinib from 6 months to 16 weeks . 
These changes were made in order to align with updated information available in dabrafenib and 
trametinib Investigator’s Brochure Edition 11.
Further, inclusion criterion 3 was clarified as local histolo gical diagnosis of HGG is sufficient for 
thestudy entry  and criteria for patients with Gilbert ’ssyndrome were established for inclusion 
criterion 11.
Other clarifications and corrections are also applied throughout the protocol.
Changes to the protocol 
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for inse rtions.
Updated Section [IP_ADDRESS]: Section has been corrected to clarify  that for LGG patient, Day [ADDRESS_967419] centrall y confirmed 
progression.  
Updated Section 5.2: Inclusion criterion 3 has been clarified by [CONTACT_711226] , inclusion criterion 11 has 
been modified to allow specific laboratory  criteria for enrollment of patients with Gilbert ’s
syndrome . Exclusion criteria [ADDRESS_967420] the modified 
contraception requirement s.
Updated Section [IP_ADDRESS]: Management of sever e skin cutaneous adverse reactions ha s been 
modified in line with DRB436 Investigator Brochure 11 and provide guidance on SCAR event 
management .
Section 8.4: wording regarding the duration of reporting period forpregnancy  after patient 
discontinued treatme nt has been modified to [ADDRESS_967421] (IRB)/Independent Ethics Committee (IEC)/Research 
Ethics Board (REB)
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) /Research Ethics Board (REB) and Health 
Authorities.
The changes described in this amended protocol require IRB/IEC /REB approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Summary  of previous amendment
Amendment 4 (11- Mar-2019)
As of 28-Feb-2019, fifteen ( 15) patients have been enrolled and treatedin the HGG cohort of 
CDRB436G2201 and fourteen (14) patients have been randomized in the LGG cohort of 
CDRB436G2201. 
Amendment rationale
The purpose of this amendment is to add an additional interim analy sis of key safety and 
pharmacokinetics (PK)data of the adolescent patients (ages ≥12 to <18 years) inthe HGG 
cohort to support a health authority  request in the 1sthalf of 2019 for data in adolescent patients . 
In addition, exclusion criteria #[ADDRESS_967422] language for all studies with trametinib and was inadvertently  omitted from previous 
versions of CDRB436G2201. 
Also, optional cerebrospi[INVESTIGATOR_872] (CSF) collection was removed.  Based on experience to date, 
CSF samples are expected to be very limited (1/30 patients provide a sample).  Hence, the value 
of the anal yses is limited.  
Other clarifications and corrections are also applied throughout the protocol. 
Change s to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
Updated protocol summary  table to match changes throughout protocol
Updated Table 3 -1 to remove optional CSF sample collection
Updated Figures 4 -1 and 4 -2 to reflec t that trametinib dosing is age and weight based
Updated Section 4.1.2 to reference Visit Evaluation Schedule Table 7 -3 created for the 
chemotherap y arm
Updated Section 4.[ADDRESS_967423]

[COMPANY_001] Confidential Page 23
Protocol Amended Version 05 Protocol No. C DRB436G2201
Updated Section 5.2
Inclusion criterion #5: Removed CLIA -approved laboratory  (US onl y) or local 
equivalent , removed requirement for molecular testing for BRAF V600 confirmation 
Updated Section 5.3
Added Exclusion criterion #18: To exclude patients with history  or current evidence of 
retinal vein occlusion (RVO) or central serous retinopathy
Exclusion criterio n #14: Added the option to use hormonal IUD or IUS in addition to 
non-hormonal IUD or IUS as a form of birth control . Removed the term “Hormonal-
based methods” from the note. 
Updated Table 6 -16 for py rexia dose modifications to indicate that patients and parents 
should be re -educated about py rexia s yndrome
Changed “renal toxicity ” to nephrotoxicity  in Section [IP_ADDRESS] to be consistent with 
language in Section [IP_ADDRESS]
Corrected reference to RPED dose modiciation table in Table 6-19
Clarified in Section 6.3. 1.16 that the induction cy cle of chemotherapy  should only  be 
modified in the event of grade 3 neurotoxicity , grade 2 nephro toxicity , grade 4 
hematologic toxicity , or disease progression.
Updated Section [IP_ADDRESS] to clarify  that anti -cancer surgery  is allowed in HGG patients 
once investigator has declared progressive disease. 
Updated Section 6.4.3 to remove the reference to dabrafenib concentrations as the 
prohibited concomitant therap y isfor vincristine.  
Updated Tables 7 -1 and 7 -2 to remove optional CSF sample collection , remove reference 
to chemotherap y patients as this was moved to Tablet 7 -3 for clarity
Added Table 7 -3 in Section 7.1 for LGG chemotherap y patients . Updated protocol 
throughout with Table 7 -3 reference. 
Updated table number throughout Section 7
Updated Section 7.1.2 to remove exclusion of immunohistochemistry  testing for local 
testing for 
BRAF V600 confirmation. 
. 
Updated Table 7 -7 and Section [IP_ADDRESS] to remove the optional CSF sample collection
Updated Section 8.1.3 to combine Cutaneous squamous cell carcinoma (cuSCC), 
keratoacanthomas, noncutaneous treatment emergent malignancies (exclu ding cuSCC 
keratoacanthomas and BCC) and new primary  malignant melanoma into one Adverse 
Event of Special Interest of “New primary /secondary  malignancy ” 
Updated Section [IP_ADDRESS] to remove optional CSF sample collection 
Updated Section 10.7.[ADDRESS_967424]
Updated Table [ADDRESS_967425] of prohibited m edications during 
study  treatment

[COMPANY_001] Confidential Page 24
Protocol Amended Version 05 Protocol No. C DRB436G2201
Amendment 3 (07 -Aug-2018)
Protocol amendment 3 changed the age range of patients eligible to enroll in the stud y from ≥6 
to <18 years of age to ≥12 months to <[ADDRESS_967426] had any prior systemic anticancer therapy  or 
antitumor radiotherap y are excluded.
In addition, the primary endpoint for the High Grade Glioma cohort was changed from 
investigator assessment of Overall Response Rate (ORR) to central independent review of ORR. 
This change may lessen the potential for bias that may be introduced due to investigator 
assessment in a single arm trial. I nvestigator assessment of ORR has therefore been added as a 
secondary  endpoint. 
Amendment 2 (2 3-Feb -2018)
Protocol amendment 2 added a new cohort of BRAF V600 mutant Low Grade Glioma children 
and adolescent patients whose tumor is unresectable and require systemic treatment.  
Additionally  the amendment also added a pediatric formulation of dabrafenib as a dispersible 
tablet. 
The LGG cohort was added to enroll approximately  102pediatric patients with BRAF V600 
mutant low grade glioma, randomized 2:1 dabrafenib with trametinib versus carboplatin plus 
vincristine, with overall response rate (PR+CR) as primary  endpoint. 
In addition, taste questionnaires for trametinib and dabrafe nib pediatric formulations were 
implemented for all patients who receive the trametinib oral solution and/or dabrafenib oral 
suspension.  The PROMIS Patient Reported Outcome questionnaire was added for the LGG 
cohort of patients. Sparse PK collection was included for a subset of LGG patients.  The specific 
RANO criteria for LGG were added into Appendix 2. 
Amendment 1 (07-Jun -2017 )
Protocol amendment 1 revise dthe investigational treatment regimen from dabrafenib 
monotherap y toinclude trametinib with dabra fenib for children and adolescents with BRAF
V600 mutation positive relapsed orrefractory  HGG. Guidance provided to the sponsor by [CONTACT_711227], in addition to updated efficacy  data from the ongoing dabrafenib monotherap y 
study  [BRF116013, CDRB436A2102] supported the use of combination treatment in pediatric 
glioma clinical studies. Safet y related changes were alsoimplemented to include
:
Requirement to obtain i nforme d consent/assent for patients who continue treatment 
beyond progression per RANO criter ia.
Added o phthalmic examinations to follow any  visual changes in patients receiving 
trametinib and dabrafenib combination therap y.

[COMPANY_001] Confidential Page 25
Protocol Amended Version 05 Protocol No. C DRB436G2201
Updated dose modification guidance for combination treatment.
Revised cardiac toxicity  monitoring and the co nditions for re -starting study treatment per 
FDA advice .
 
Updated the adverse events of spec ial interest pertaining to dabrafenib and trametinib

[COMPANY_001] Confidential Page 26
Protocol Amended Version 05 Protocol No. C DRB436G2201
1 Background
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_5307]
1.1.1 Pathogenesis
High grade glioma ( HGG )typi[INVESTIGATOR_1306] y arise sfrom cells within the glial lineage and are classified 
by [CONTACT_38375] (WHO) as either grade III or IV meaning that they are highl y 
aggressive tumors with characteristic pathological findings (Louis 2007). HGG include a 
variet y of heterogeneous l
esions with differing histologies, the most common being anaplastic 
astrocy toma (WHO Grade III) and glioblastoma multiforme (GBM; WHO grade IV). There are 
also less frequentl y occurring pediatric HGGs of grade III (anaplastic oligodendroglioma, 
anaplastic oligoastrocy toma, anaplastic ganglioglioma, anaplastic pleomorphic 
xanthoastrocy toma, and anaplastic pi[INVESTIGATOR_711163]) and grade IV (giant cell glioblastoma , 
epi[INVESTIGATOR_711164]).
Low grade glioma ( LGG )also represent sa diverse group of histologicall y distinct tumor ty pes, 
including pi[INVESTIGATOR_711163], ganglioglioma, pi[INVESTIGATOR_711165], pleomorphic 
xanthoastrocy toma and others
. They  are distinguished historicall y from HGG generally  by [CONTACT_711228] ( Louis 2016, Lassaletta 2017). 
1.1.2 Epi[INVESTIGATOR_711166], and comprise approximately  8–12% of all 
primary , pediatric central nervous system (CNS) tumors (Bond y 2008 ; Broniscer 2006 )
.  
Among patients 0–19 years old in the [LOCATION_003], the overall total incidence of HGGs (including 
anaplastic astrocy toma, anaplastic oligodendroglioma, glioblastoma, mixed glioma, and 
malignant glioma) was approximately  0.85 per 100,000 (CBTRUS 
2012 ). Similar incidence 
estimates for pediatric HGG have been reported from the German Childhood Cancer Registry 
(Kaatsch 2001). Thus, approximately  350-400 new cases of pediatric HGG are diagnosed in 
Europe yearly (EMA 2011 )
. Grade III tumors are believed to have a more favorable natural 
history  than grade IV tumors but the impact of tumor grade on prognosis is relatively  minor. 
Thus for the purposes of clinical trials there has been expert consensus that grade III and IV 
tumors should be studied together ( EMA 2011 ).
Although LGGs are also rare pediatric tumor t ypes, they are approximately 2 times as common 
(incidence 1.68 
cases per 100,000) as HGG (CBTRUS 2015).  This is a heterogeneous group 
of tumors in children with different locations, histologic subty pes, ages at presentation, and 
clinical behavior.  Pi[INVESTIGATOR_711167].  Evolving 
molecular characterization of this group of tumors reveals most will have only  a small number 
of mutations, and these mutations often converg e on the activation of the RAS/MAPK pathway 
(Lassaletta 2017
).

[COMPANY_001] Confidential Page 27
Protocol Amended Version 05 Protocol No. C DRB436G2201
1.1.3 Current Treatments and Unmet Medical Need
[IP_ADDRESS] High Grade Glioma
Current therapi[INVESTIGATOR_711168]. The current standard of care for newl y 
diagnosed children is gross total surgical resection, followed by [CONTACT_711229]  (MacDonald 2011 ). Independent of other known prognostic 
factors such as age, tumor location and histology , the extent of surgical resection is one of the 
strongest predictors of survival in children with HGG (Finlay  1995; Jones 2012). Given the 
infiltrative nature of HGGs, there is high likelihood of local 
recurrence. Thus for older children 
(>3 years of age), adjuvant radiotherapy  to the tumor bed and surrounding margin has become 
a standard. Multi -agent chemotherap y is routinel y used in conjunction with radiotherap y to treat 
children with newl y diagnosed HGGs. However, while a number of trials have explored the use 
of varying agents and schedules, the toxicity  is burdensome, results are contradictory  and the 
exact role of chemotherap y and the true survival benefit are disputed (Fangusaro 2012; 
Broniscer 2004; Finlay 2005; EMA 2011 ). Among younger patients (<3 years of age), 
radiotherap y is generall y not used due to its substantial neurocognitive toxicity . These patients 
are often treated with radiation sparing approaches such as chemotherapy alone (Broniscer 
2004).  Multiple trials have also been conducted in pediatric patien ts with HGGs utilizing 
biologic agents in combination with focal radiotherap y, but none have demonstrated a benefit 
in overall survival (OS) (MacDonald 2011 ).
Long -term outcomes for patients with pediatric HGGs are poor despi[INVESTIGATOR_711169] y and improvements in neurosurgery , radiotherap y, and chemotherap y. 
After a new diagnosis of HGG, the median duration of survival is approximately 18 -24 mon ths 
in children (Qaddoumi 2009 ; EMA 2011). Five-year survival outcomes range from 10 to 35% 
with the large majority  of children ultimatel y succumbing to their disease (Broniscer 2004; 
Finlay  2005; Broniscer 2006 ; Cohen 2011; Wolff 2010). The majority  of patients do develop 
recurrent disease and in these cases the therapeutic options are limited, with very few treatment 
options providing clinica lly meaningful responses. Temozolomide is most often used in the 
recurrent disease setting. However, in 5 trials evaluating temozolomide monotherapy  or 
temozolomide -based combinations, the RR in recurrent or refractory , pediatric HGG ranged 
from 0-12% ( Lashford 2002 ;Nicholson 2007 ; Ruggiero 2006; Warren 2012 ; Hummel 2013 ). 
A variet y of targeted agents have also been evaluated in this patient population and response 
rates have been noted to be less than 10%. Given the lack of clinically  meaningful activity , there 
have been no targeted agents that have been approved for patients with pediatric HGG. Due to 
the lack of an efficacious standard of care, participation in clinical trials is highl y encouraged 
for these patients. 
One approach to recurrent disease has been the use of high dose chemotherap y followed by 
[CONTACT_711230]. This is still considered very controversial, but there 
may be a role for 
this strategy  in a specific group of children (Guruangan 1998; Finlay  2008; 
Massimino 2010). The limitations of this strategy are significant treatment -related morbidit y, 
andthe fact that despi[INVESTIGATOR_241608], a minority  of patients with HGG have 
long term survival. 
Studies of rational chemotherapy combinations and targeted agents in this disease setting have 
also failed to show clinical activity  in pediatric HGG patients and emphasise the poor outcomes 
for this patient population. Given that refractory  or recurrent pediatric HGG is a rare tumor type, 

[COMPANY_001] Confidential Page [ADDRESS_967427] and reliable prospective study  to describe the natural history  in a large 
population. 
A comprehensive litera ture review was performed by [CONTACT_23983]/[COMPANY_001] for trials that treated a 
minimum of 5 pediatric patients with recurrent or refractory  HGG (Table 1-1). Trials that 
included myeloablative therapy  with stem cell rescue were excluded from this review. Trials 
that did not specify  low vs. high grade glioma were also excluded. Limitations of all the trials 
were limited sample size, non -randomized design, limited efficacy  endpoints (response but no 
duration of response or time to event endpoint data) and a likely  selection bias. It is also unclear 
how these results apply  to pediatric HGG patients harbouring a BRAF V600 mutation as the 
predictive and prognostic effect of this mutation in this particular 
disease is unknown. These 
data demonstrate that for both chemotherap y and/or targeted agents, the response rate to second 
line therapy  is ty pi[INVESTIGATOR_897]  <10%. To suppleme nt the limited data available in the literature, [COMPANY_004] 
has sought the insight ofclinicians with expertise in pediatric neuro -oncology . These 
consultants estimate that pediatric HGG patients who have failed frontline therap y have 
response rate of 10-12% to second line temozolomide therap y. Given the low response rates, 
they felt that there is no true standard of care in this setting.
Table 1
-1 Efficacy  Outcomes in Trials for Rel apsed, Refractory  Pediatric HGG
Agent n RR (%) mPFS (m) 6m PFS (% ) OS (m) Reference
Irinotecan 5e3 (60) NR NR NR Turner 2002
Paclitaxel 13e1 (8) NR NR NR Hurwitz 2001
Carboplatin 15e0 (0) NR NR NR Gaynon 1990
Etoposide 14e3 (21) NR NR NR Chamberlain 1997
Erlotinib 29 0 (0) 1.5 34 4.1 Geoerger 2011
Nimotuzumab 46 4 (9) NR NR 4.4 Bode 2007
Imatinib 40 0 (0) NR 17.9-18.2bNR Pollack 2007
Bevacizumab + 
Irinotecan15 0 (0) 4.2 41.8 Guruangan 2010
Cilengitide 24 0 (0) 0.92cNR NR MacDonald 2013
Temsirolimus 6 0 (0) 2a38%a,dNR Geoerger 2012
Tipi[INVESTIGATOR_7734] 31 1 (3) NR NR NR Fouladi 2007
Temozolomide 25 3 (12) NR NR 4.[ADDRESS_967428] 2002
Temozolomide 23 1 (4) NR NR NR Nicholson 2007
Temozolomide 24 0 (0) 3 NR NR Ruggiero 2006
O6-
Benzylguanine 
+Temozolomide25 1 (4) 1.7 16 NR Warren 2012
Temozolomide 
+Vorinostat7 0 (0) NR NR NR Hummel 2013
Lobradimil + 
carboplatin9 0 (0) 2.6cNR NR Warren 2006
Poly-ICLC 12 1 (8) NR NR NR Hartman 2014
a.Includes patients with HGG and diffuse pontine intrinsic glioma
b.Six month event free survival
c.Median time to progression
d.mPFS at 12 weeks
e.Trial accrued patients with refractory brain tumors of various types. The results reported are those f or 
recurrent, pediatric HGG

[COMPANY_001] Confidential Page 29
Protocol Amended Version 05 Protocol No. C DRB436G2201
The European Medicines Agency  (EMA) hosted a pediatric research expert meeting in 2011 
that focused on current pediatric HGG treatment modalities and research. The outcomes 
highlighted the inadequacy  of current treatment options, and suggested that pediatr ic patient s 
with relapsed, refractory , and or resistant HGGs should consider experimental treatments 
available in clinical trials. The committee minutes indicate agreement that outcomes in pediatric 
patient s with HGG are generall y very unfavourable with the different multi- agent chemotherapy  
regimens in current use, often with burdensome toxicity  and limited benefit. For children, only 
one anticancer substance, temozolomide, is currently  authorized in some jurisdictions (i.e.
European Union, EU) specificall y for HGG (for use in relapsed or progressive disease). 
Although it is used in children based on adult efficacy  data, its benefit in children is considered 
modest at best. Overall, the treatment of children with HGG reflects a significant unmet need, 
with almost no improvement in survival outcomes in recent years (EMA 2011) .
The role of BRAF V600 mutation in the clinical behaviour of pediatric HGG has been studied 
in a large retrospective analysis of patients with available tumor tissue and known clinical 
course (Korsunov 2015 ).  Of the [ADDRESS_967429] a ‘low grade glioma’ 
methy lation signature [CONTACT_711335] (PFS, OS).  Seventeen of the 21 BRAF
V600 mutant tumors were also classified as ‘low grade glioma methy lation signature’ and thus 
associated with a more favourable prognosis. A univariate evaluation of the patient specific data 
from this report reveals no apparent 
difference in PFS for tumors with BRAF V600 mutation 
relative to BRAF wildty pe, while the OS of patients with the mutation appears favourable. The 
public data from this analy sis does not include information on response to standard treatment 
in the second line setting. Nonetheless, the data do suggest that pediatric patients with BRAF
V600 mutant HGG may be more likely  respond to conventional therap y in the second line 
setting, as their time to first progression is similar to patients with BRAF V600 wild type tumors, 
yet their OS is distinctly  longer. In a recent analysis of anaplastic ganglioglioma, a subty pe of 
HGG, in both pediatric and adult patients, the BRAF V600 mutation does not appear to have 
prognostic significance, while other histologic and molecular features were identified with 
potential prognostic significance (Zanello 2016). The BRAF V600 mutation was detected in 4 
of 5 (80%) of the pediatric tumor specimens and 9 of 18 adult t
umor specimens (50% ).  
This study  will evaluate the ORR (CR+PR) in patients with relapsed or refractory  BRAF V600 
mutant HGG .
[IP_ADDRESS] Low Grade Glioma
Unlike patients with HGG, patients with LGG t ypi[INVESTIGATOR_456124] a more protracted natural history .
  
For unselected pediatric patients with LGG who could not be cured by [CONTACT_711231] y, the 5 year PFS was 46% and OS was 89% 
(Gnekow 2017).   Treatment goals generall y are to prolong overall and progression free survival 
while minimizing morbidity  of treatment . Surgical removal, when practical, is often the 
treatment of choice. The extent of resection is predictive of progression free interval. Most 
patients will eventuall y experience progression of their disease and require post-surgical 
therap y.  Because of the typi[INVESTIGATOR_711170], and the potential for lon g 
term neurocognitive effects of radiotherap y, post -surgical therapy  often includes chemotherap y 

[COMPANY_001] Confidential Page 30
Protocol Amended Version 05 Protocol No. C DRB436G2201
with carb oplatin and vincristine.  I n one large study , the ORR (CR+PR) by  [CONTACT_510828] 
35% (Ater 2012 ) in unselected patients with LGG requiring post-operative systemic therapy 
with carboplatin and vincrist ine.
The BRAF V600 mutation is identified in about 17% of pediatric LGG tumors (Lassaletta 2017 ). 
The role of BRAF V600 mutation in the clinical course of pediatric LGG has recently  been 
described. First , patients with L GG who have progressed to secondary  HGG (sHGG) are more 
likely  to have had BRAF V600 mutation in their LGG at initial diagnosis (Mistry  2015), and 
thus suggestive of a poor prognosis.  More recentl y, the molecular profile of archived diagnostic 
tumor tissues has been coupled with clinical outcomes of patients treated with standard of care.  
This analy sis revealed that those patients whose tumor harbored the BRAF V600 mutation had 
worse PFS and OS (Lassaleta 2017) than those with tumors with wild type sequence at BRAF
V600. This research also revealed a lower ORR for these patients when treated with 
chemotherap y with apparent 11% PR+CR ra te.  In  both analy ses, there w as evidence of poorer 
outcomes when deletion of CDKN2A was coupled with the BRAF V600 mutation (Mistry  2015,
Lassaletta 2017, Jones 2017) ) .
Pediatric patient swith LGG harboring aBRAF V600 mutation have a poorer prognosis than 
those without this mutation, and require improved treatment options.
1.2 Introduction to investigat ional treatment(s) and other study  
treatment(s)
1.2.1 Overview  ofDabrafenib
Dabrafenib is a potent and selective inhibitor of BRAF kinase (a member of the RAF kinases) 
with a mode of action consistent with adenosine triphosphate- competitive inhibition. 
Dabrafe nibsuppresses ERK [pERK] that is downstream of BRAF in the MAPK pathway  and 
demonstrated anti-proliferative activity  against multiple BRAF V600 mutation -positive tumor 
cell lines, and tumor regression in BRAF mutation positive xenograft models, and has 
demonstrated significant anti-tumor efficacy  in BRAF V600 -mutation positive tumors, 
including melanoma, and non
-small cell lung cancer.
Dabrafenib (Tafinlar®) was first approved by [CONTACT_8956] 29 May 2013 as a single -agent oral 
treatment for unresectable or metastatic melanoma in adult patients with the BRAF V600E 
mutation. Tafinlar®is currentl y also approved in the, EU, Switzerland, Canada, Australia and 
multiple other countries for the treatment of adult patient s with unresectab le or metastatic 
melanoma with a BRAF V600 mutation. Prior to initiation of dabrafenib patients must have 
confirmation of tumor BRAF V600 mutation. These approvals include the following limitation 
of use: dabrafenib is not indicated for the treatment of wild-type BRAF melanoma. The 
recommended dose of dabrafenib is 150 mg (two 75 mg capsules) BID (corresponding to a total 
daily  dose of 300 mg). Dabrafenib in combination with trametinib is also approved in the US 
and EU for the treatment of patients with advanced non-small cell lung cancer (NSCL C) with 
a BRAF V600 mutation.
[IP_ADDRESS] Non
-clinical experience
The toxicologic effects following administration of dabrafenib to rats, mice and/or dogs were 
noted in skin, heart, vasculature, testes, epi[INVESTIGATOR_2130], hematologic/ly mphoid tissues, liver, 

[COMPANY_001] Confidential Page [ADDRESS_967430].  The principal dose-limiting toxicity  in animals was 
adverse gastrointestinal effects, which can be clinically  monitored.  Aside from mild to 
moderate increases in heart rate, there were no significant findings in safet y pharmacology 
studies in animals evaluating the cardiovascular and respi[INVESTIGATOR_711171] a general 
behavioral study  conducted with dabrafenib. In a dabrafenib and trametinib 4- week 
combination study  in dogs, 
there were no significant new findings or exacerbations of toxicities 
previously  observed with either agent alone. Details of non- clinical experience can be found in 
the [Dabrafenib Investigators Brochure ].
In support of clinical development in pediatric can cer patients, toxicity  studies in juvenile rats 
with dabrafenib were conducted. These studies included an oral tolerability /dose range juvenile 
toxicity  study, a GLP juvenile toxicity  study, and an oral investigative renal study . Key findings 
from these st udies are presented below. No further nonclinical studies are planned.
Renal Effects 
Renal toxicity  was observed primarily  in pre -weaning juvenile rats (PND 7 -21) which was not 
previously  observed in adult rats, dogs or mice. Renal findings were partially  reversible 
following a 6-week off-drug period and were consistent with an obstructive nephropath y 
characterised by [CONTACT_711232] s, increased incidence of cortical cysts and tubular basophilia 
with reversible increases in serum urea and/or creatinine concentrations. The renal tubular 
deposits were found to contain calcium, phosphate, potassium and lipi[INVESTIGATOR_805]; dabrafenib
-related 
material was not present in the deposits. These effects were seen in juvenile rats at a renal 
functional maturit y stage similar to a 6 to 12 month old human, suggesting a higher risk for 
tubular injury  for human infants <1 years of age. Monitoring for potential re nal effects will be 
performed in pediatric patient s by [CONTACT_711233].  
Patient s in clinical studies [BRF116013, CDRB436A2102] (Phase I/IIa) and [BRF116536, 
CDRB436G2201] (Phase II) must be ≥1 year old to particip ate.
Constitutional and Developmental Effects 
In juvenile rat toxicity  studies of dabrafenib monotherap y, there were dose-dependent decreases 
in body  weight and/or gain, food consumption and long bone growth. These changes in bone 
growth were likel y related to overall growth of the animal and not due to a bone specific effect 
of dabrafenib. Pediatric patient s will be monitored for potential effects on body  weight and 
growth through ph ysical examination including routine monitoring of height and weight.
Fertility  In testes 
Testicular toxicity  in the seminiferous tubules was observed with evidence of partial recover y 
after a 12-week recovery  period in rats, suggesting a potential human risk for impaired 
spermatogenesis, which may  be irreversible. 
Non
-clinic al pharmacokinetics and metabolism
Dabrafenib induces CYP3A4 -and CYP2C9 -mediated metabolism and may induce other 
enzy mes including CYP2B6, CYP2C8, CYP2C19 and UDP glucuronos yltransferases (UGT) . 
Dabrafenib may also induce transporters (e.g. P-glycoprotein (P-gp)). In human hepatocy tes, 
dabrafenib produced dose-dependent increases in CYP2B6 and CYP3A4 mRNA levels up to 

[COMPANY_001] Confidential Page [ADDRESS_967431] administration. No brain penetration of drug-related material was 
observed after a single dose in rats and pi[INVESTIGATOR_14107] (repeat dose studies were not conducted in these 
species); however, following repeat dosing in mice, low levels of dabra fenib may  reside in the 
cerebro spi[INVESTIGATOR_872].
For more details please refer to the latest [Dabrafenib I nvestigator Brochure ].
[IP_ADDRESS] Clinical experience
As of [ADDRESS_967432] received dabrafenib alone or in combination with trametinib across the clinical 
development program
. Cumulative postmarketing exposure to dabrafenib through 31 March 
2015 is estimated to be 3,546 .16patient -years. The estimated exposure from June 2015 to June 
2016 was approximately 5204.45 patient -years[Dabrafenib Investigator Brochure ].
Updated safet y data from an integrated safety  population (N=586) receiving 150 mg BID 
showed that 97% had experien ced AEs, the most common ( ≥20%) being hyperkeratosis, 
headache, pyrexia, arthralgia, fatigue, nausea, alopecia, skin papi[INVESTIGATOR_81875], and rash.  A total of 
174 (30%) patient s experienced serious adverse event s(SAE), and 114 (19%) patient s had 
treatment -related SAEs. The proportion of patient s who experienced AEs leading to 
discontinuation of study  treatment was low (3%).
In the pi[INVESTIGATOR_127817]  [BRF113683, BREAK -3, CDRB436A2301] , dabrafenib was 
associated with a 70% reduction in the risk of progression or death compared with dacarbazine 
with a hazard ratio (HR) of 0.30 (95% CI : 0.18, 0.51; p<0.0001) in patient s with BRAF V600E 
mutation positive melanoma and no brain metastases (Hauschild 2012) .Dabrafenib provided a 
clear and meaningful benefit in patient s with BRAF V600E mutation -positive melanoma with 
brain metastases as demonstrated by [CONTACT_711234] (OIRR) over 30% and 
median OS exceeding 7 months in study  [BRF113929, BREA K-MB] .  Patient s with BRAF
V600E mutation positive melanoma also benefit from dabrafenib treatment, with a confirmed 
response rate of 13% and the median duration of response of 5.3 months [BRF113710, BREAK-
2, CDRB436A2201] .For the latest summarized effica cy results for these studies, please refer 
to the Dabrafenib approved local prescribing information and [Dabrafenib Investigator 
Brochure] .
[IP_ADDRESS].1 Dabrafenib pediatric experience
A Phase I clinical trial of dabrafenib is ongoing in children with BRAF V600 mutant solid 
tumors [BRF116013, CDRB436A2102] .
Eight ypatients have been enrolled into study  [BRF116013 ,CDRB436A2102] beginning in 
April 2013 through the interim data cut off 12-Sept-2017; 27 into part 1 dose finding across 4 
dose levels, and 53into part 2 (disease specific cohort expansions) at the recommended phase 
2 dose.  Thirty -
two patients with relapsed refractory  LGG , 31with relapsed refractory  HGG , 

[COMPANY_001] Confidential Page 33
Protocol Amended Version 05 Protocol No. C DRB436G2201
13with advanced Langerhans Cell Histiocy tosis (LCH)and 4other solid tumor patients were
enrolled into the various parts of the stud y.
Part 1 patients had a median age of 8years, while part 2 patients had a median age of 11years.
All were previousl y treated for their tumor. Similar to the experience in adults, a maximall y 
tolerated dose was not identified in this study .  Based on the doses in part 1 that achieved target 
exposures (median AUCs 0-12 hours > 4000 ng*hr/mL , parent molecule) ,there are currentl y 
separate phase II dose recommendations for those under 12 years of age (5.25mg/kg/day ), and 
those 12 and older (4.5mg/kg/day ). 
At the time of i nterim data cutoff, 45 of the 80patients remained on study  (56%), with 35 still 
on protoco
l therap y(44%) .  
Efficacy  for glioma patients was determined using RANO criteria by [CONTACT_431], as well as 
by [CONTACT_711235] -radiologist. Independent expert histopathology  review of 
tumor specimens from the patients enrolled with presu med HGG was performed in all cases 
where tissue was available. Safet y monitoring included standard clinical trial methods, as well 
as routine echocardiograms and dermatologic exams.
Efficacy  Results
High Grade Glioma
Of the 31enrolled HGG patients, 10 (32%) had investigator confirmed responses (CR + PR)
following dabrafenib monotherapy . Independent radiologic determination of RANO response 
identified 14 patients (45%) with confirmed responses (CR+PR).  Median duration of treatment 
was 24 weeks, and median duration of response was 33 weeks.  Independent histopathology 
revealed that 7 of the 31patients (23%) had grade [ADDRESS_967433] sufficient tissue submitted to make any 
determination of glioma grade. The therapy  has been generall y well tolerated and adverse events 
easily  managed.  
Low Grade Glioma
At the time of interim analy sis, 32 pediatric patients with relapsed, refractory  or progressive 
LGG with BRAF V600 mutations were enrolled into[BRF116013 ,CDRB436A2102] . Of these ,
there was oneindependently  confirmed CR, and 13 PRs for an ORR of 14/32 or 44%.In 
addition, 11 patients had independentl y confirmed SD.  Median duration of treatment was 24 
months.  Median duration of independentl y confirmed response 
was 110 weeks .
Langerhans Cell Histiocytosis
At the time of interim analy sis, 13 pediatric patients with previously  treated severe LCH and 
BRAF V600 mutations were enrolled into [BRF116013 , CDRB436A2102] . Investigator 
assessed responses were 5 complete resolutions, and 5 regressions.  Median duration of 
treatment was 76 weeks.  Nine pa tients remain in response.
Other solid tumors
Four patients with other solid tumors and BRAF V600 mutations were enrolled; three 
discontinued within 16 weeks of enrollment (2 with Neuroblastoma , another with a sarcoma) .  

[COMPANY_001] Confidential Page [ADDRESS_967434] common AEs occurring in pediatric patients with advanced BRAF V600 mutation 
positive solid tumors treated with dabrafenib were pyrexia, vomiting, fatigue and rash. 
Serious A dverse Events 
As of the clinical cut-off date for [BRF116013, CDRB436A2102] , a single fatal SAE of 
depressed level of consciousness was reported in onesubject at 5.25 mg/kg /day dose in Part 1.
This event was associated with disease progression, and was considered not related to study  
drug.
At the time of the interim analy sis, 31of the 80enrolled patients (39%) were reported to have
SAEs. The most common SAEs were pyrexia (
11), pneumonia (4) and headache (4); all other 
SAEs occurred in one or two 
patient s.
Dose limiting toxicity
There was one patient with LGG (10 years old at 4.5 mg/kg/d dose) who experienced a dose 
limiting toxicity  (DLT) of Grade 3 maculopapular rash with onset on day 1 of dosing. After 
protocol specified dose interruption, the 
patient was able to resume treatment at 3.75 mg/kg/day 
and continues on treatment bey ond one y ear, with tolerab le skin toxicity  of grade ≤2. 
Dose modifications
Forty fourof the 80patients (55%) had at least one dose interruption due to AEs while on study .  
Discontinuations for toxicity
At the time of interim analy sis, 6 patients had been withdrawn from stud y for toxicity .  
Safety  Conclusions
Based on the interim analy sis of the dabrafenib monotherapy  study, the toxicity  profile observed 
in pediatric patient s is generall y similar to that observed in the adult patient experience. Both 
populations experienced frequent rash, pyrexia, fatigue, arthralgia and headache. The frequency 
of rash and related adverse events may be higher in this pediatric population than in adults.  
There were three patients (4%) with grade 3 rash in the pediatric study , while there were no 
patients with Grade ≥3 rash in the integrated safet y population (n=586) in adults.  Rash 
management guidelines suggested in the protocol were followed for patients with rash as they 
remained on therapy . There were no cases of cutaneous SCC observed in these pediatric patients .
The most common AEs according to the system organ class wasskin. Adequate exposures were 
obtained without reaching a maximally  tolerated dose. 

[COMPANY_001] Confidential Page 35
Protocol Amended Version 05 Protocol No. C DRB436G2201
[IP_ADDRESS] Pharmacokinetics -Dabrafenib
In adults following oral administration of dabrafenib HPMC capsules, the plasma 
concentrations of dabrafenib peaked approximately  [ADDRESS_967435] -dose and decreased thereafter 
following a bi-exponential decline. The terminal half-life (t1/2) is 8.4 hours , mainly due to a 
prolonged terminal phase after oral administration. The t1/2 following IV microdose is 2.6 
hours.
Increases in maximu m observed concentration (Cmax) and area under the concentration time 
curve (AUC) were generall y dose-proportional with single doses and less than dose 
proportional after repeat BID dosing. Following administration of 150 mg BID, the AUC on 
Day 18 was 27% lower than on Day 1. Following administration of 150 mg BID (HPMC 
capsules), the geometric mean Cmax, AUC(0 -τ) and predose concentration (Cτ) were 1478 
ng/mL, 4341 ng*hr/mL and 26.1 ng/mL, respectively . Interpatient variability  was 37 -38% for 
Cmax and AUC (0-τ) and 119% for Cτ. Administration of dabrafenib with food reduced the 
bioavailability  (Cmaxand AUC decreased by 51% and 31% respectively) and delay ed the 
absorption of dabrafenib capsules when compared to the fasted state. Dabrafenib should be 
taken either at least one hour before, or at least two hours after a meal .
The relative bioavailability  of single dose dabrafenib was slightl y lower (AUC decreased by 
20%) when administered as an oral suspension (dispersible tablets) compared to HPMC 
capsules. This difference inAUC is not considered clinicall y relevant based on the exposure -
response relationship in adult melanoma and therefore no dose adjustment will be made for the 
dispersible tablets in this study .
Results of a population pharmacokinetic analysisin adults indicated that body  weight is a 
significant predictor of oral clearance and apparent volume of distribution for dabrafenib, with 
higher weight being associated with higher clearance and lower plasma concentrations; 
however this does not appear to have a clinicall y relevant effect on exposure. The range of body 
weights of patient s included in the population PK analy sis was 36 to 150 kg. Dabrafenib 
apparent oral clearance and apparent volume of distribution were predicted in a typi[INVESTIGATOR_711172] (50 kg) or high (140 kg) bod y weight and were shown to be within 20% of the 
value of a t ypi[INVESTIGATOR_2855] 80 kg patient. This difference was not considered clinically  relevant.
Studies demonstrated that the oxidative metabolism of dabrafenib is primarily  mediated by 
[CONTACT_097]2C8 and CYP3A4. Dabrafenib is metabolized sequentiall y to three known metabolites: 
hydroxy-dabrafenib ([COMPANY_004]2285403, M7), carboxy -dabrafenib ([COMPANY_004]2298683, M4), and 
desmethy l-dabrafenib ([COMPANY_004]2167542, M8). Plasma concentrations of h ydroxy-dabrafenib peak 
at about [ADDRESS_967436]-dose, and exposure of the metabolite is similar to that of parent with a 
metabolite:parent AUC ratio of 0.9, with a similar half -life (9.7 hrs). Carboxy -and desmethy l-
dabrafenib accumulates with repeat dosing due to their long half -life (21 -22 hrs). Metabolite to 
parent AUC ratios after repeat -dose administration of dabrafenib [ADDRESS_967437] been characterized in multiple studies and compared to dabrafenib. Based on 
exposure, relative potency , and pharmacokinetic properties, both hydroxy -and desmethy l-
dabrafenib are likely to contribute to the clinical activity  of dabrafenib; while the activi ty of 
carbox y-dabrafenib is not likely  to be significant.

[COMPANY_001] Confidential Page 36
Protocol Amended Version 05 Protocol No. C DRB436G2201
Preliminary  pharmacokinetic results from study  BRF116013 (CDRB436A2102) in pediatric 
patients are summarized in 
Table 1-2 as doses of 3, 3.75, 4.5 and 5.25 mg/kg/day  (divided into 
two daily doses) based on the data cut- off date of 7 March 2015 .
Results from Table 1-2show that median plasma AUC achieved its target (between 95%CI: 
3599, 
5235 ng*h/mL, which is from the adult Phase III study  BRF113683) in older pediatric 
patients (> 12 years) at 4.5 mg/kg/day  dose level. In younger patients ( ≤ 12 years), target median 
was achieved at 5.25 mg/kg/day , while the median observed at 4.5 mg/kg/day  was be
low the 
target. These results were used to determine the recommended part 2 dose (s) in BRF116013.
Since Part 2 dose selection, an interim analy sis was performed based on a data cut-off of 01-
April -
2016. Results from Table 1-3 show that for patients 6 years and greater  after 
administration of the dosing regimen selected in Part 1: the geometric mean AUC(0 -tau) in Part 
2 are within the exposure range associated with efficacy  in adults when given as monoth erapy 
(BRF113683) and in combination therapy  with trametinib (BRF113220 and MEK115306). 
Table 1-2 Median Steady -State Dabrafenib A UC (ng*h/mL) (day  15) by  [CONTACT_711236] (total daily  dose)
3 mg/kg /day 3.75 mg/kg /day 4.5 mg/kg /day5.25 
mg/kg /day
All AUC, ng*h/mL (n) 2911 (3) 3389 (10) 3903 (9) 4384 (5)
≤ 12 years 2269 (2) 2928 (4) 3592 (6) 4384 (5)
>12 years 6604 (1) 3850 (6) 5285 (3) NA
Table 1-3 Geometric mean Steady -State Dabrafenib A UC(ng*h/mL) (day  15) by 
[CONTACT_711211] 2
Age Range Dose N AUC(0 -tau)* (ng*hr/mL)
12-17 years 4.5 mg/kg /day 15 3979
6-<12 years 5.25 mg/kg /day 8 3972
In study  [MEK116540, CTMT212X2101] , four pediatric patient s were dosed with the 
recommended dabrafenib doses from study  BRF116013 and the recommended dose for 
trametinib (from Part A MEK116540) in combination. Preliminary  PK was available in 3 
subjects; dabrafenib Day  15 AUC(0 -tau) values (3490, 4339, 3570 ng*hr/mL) were within the 
range observed in the pediatric patients from the dabrafenib monotherap y study  BRF116013.
1.2.2 Overview  of Trametinib
Trametinib ([COMPANY_004]1120 212/TMT212) is a MEK1 and MEK2 inhibitor with selective anti-
proliferative activity  towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer 
cells from acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) origins. 
Trametinib inhibi ted the proliferation of most BRAF mutant melanoma cell lines tested (22 of 
25) and it effectivel y inhibited the growth of BRAF mutant melanoma xenografts in vivo alone 
or in combination with dabrafenib. Trametinib inhibits ERK phosphory lation leading to G1 cell 
cycle arrest and tumor xenograft growth inhibition in vivo following oral dosing. The effects of 
trametinib in combination with dabrafenib and other anticancer agents have also been studied 
in a variet y of human cancer cell lines and in vivo models.

[COMPANY_001] Confidential Page 37
Protocol Amended Version 05 Protocol No. C DRB436G2201
Trametinib is being developed for the treatment of a variety  of cancers and is currently  approved :
In the [LOCATION_002], EU, and other countries as a monotherapy and in combination with 
dabrafenib for the treatment of subjects with unresectable or metast atic mel anoma with a 
BRAF V600 mutation 
In the [LOCATION_002] and other countries in combination with dabrafenib for the adjuvant 
treatment of patients with melanoma with a BRAF V600 mutation and involvement of 
lymph node(s), following complete resection
In the [LOCATION_002], and EU in combination with dabrafenib for the treatment of patients 
with advanced non -small cell lung cancer (NSCLC) with a BRAF V600 mutation 
In the [LOCATION_002] in combination with dabrafenib for the treatment of patients with 
locally advanced or metastatic anaplastic thy roid cancer with BRAF V600E mutation and 
with no satisfactory  locoregional treatment options
Please refer to local labeling for further details on approved indications.
[IP_ADDRESS] Non- clinical experience
The nonclinical toxico logy findings associated with trametinib administration to mice, rats and 
dogs are consistent with pharmacologicall y mediated changes as a result of MEK1/MEK2 
inhibition and disruption of mitogen- activated protein kin ase (MAPK) signaling pathway s. 
Trametin ib caused adverse effects in a variet y of tissues and systems (skin, gastrointestinal tract, 
phosphate homeostasis, liver, ovary , bone and hematological tissues). The majority  of the 
findings in mice and dogs appeared to be related to effects within the gastrointestinal tract. In 
rats, tolerability  was more dependent on changes occurring in skin over time and its effect on 
impaired barrier function. These findings may  be related to those seen in the clinic in the fo rm 
of skin rashes and diarrhea. Rats were more sensitive to trametinib, with liver, phosphate 
homeostasis, soft tissue mineralization, bone, hematopoietic and ovary  effects. In a dabrafenib 
and trametinib 
[ADDRESS_967438]-implantation 
loss, were ob served in rats and/or rabbits. 
The principal effects of trametinib in juvenile rats were on growth (body weight and long bone 
length) and in bone, phosphate homeostasis, eye, skin, liver, heart and female reproductive 
system effects, consisting of a delay  in a physical landmark of sexual maturity  and mammary 
gland development, lower corpora lutea and lower ovarian weights. With the exception of 
corneal mineralization/dy strophy  and increased heart weight, similar effects have been 
observed in a dult animals given trametinib. 
The genotoxicity  assessments conducted indicate that trametinib does not present a genotoxic 
hazard to humans.
Trametinib was phototoxic in the in vitro mouse fibroblast 3T3- Neutral Red Uptake (3T3 -NRU) 
assay  at significantl y higher concentra tions than clinical exposures.

[COMPANY_001] Confidential Page [ADDRESS_967439]  in cellular proliferation (Sebolt -Leopold 2000). In mice, rats and 
dogs, these effects generally  occurred at or below the exposures achieved at the oral therapeutic 
dose of 2 mg/day in cancer patients. Other findings include effect s on phosphate homeostasis 
and soft tissue mineralization, liver, bone, ovary  and the developi[INVESTIGATOR_584468].
[IP_ADDRESS] Clinical experience
As of 22-Jun- [ADDRESS_967440] been treate d with trametinib
monotherap y across 25 clinical studies.
Data from a Phase I, II and III studiesindicate substantial clinical activity  of trametinib in 
unresectable, BRAF mutation positive melanoma. Efficacy  results from the pi[INVESTIGATOR_711173]114267 (CTMT212A2301) (melanoma) study  and the supporting studies 
MEK113583 (melanoma), MEK111054 (solid tumors or lymphoma), and MEK114653 
(NSCL C) indicated:
Substantial evidence of effectiveness in unresectable BRAF V600 mutation positive 
melanoma as evidenced by [CONTACT_711237] -free survival (P FS) and overall 
survival (OS). Updated long term results from MEK114267 (CTMT212A2301) study  also 
consolidated the OS benefit of trametinib treatment over chemotherap y in this patient 
population.
The clinical activity  of trametinib observed in melanoma subjects whose tumors harbor 
BRAF V600K mutations is comparable to the activity  seen in BRAF V600E mutations. 
The efficacy  of trametinib in melanoma was evident across all demographic (i.e., age, 
gender) and prognostic factors (i.e., tumor stage, Eastern Cooperative Oncology  Group 
Performance Status [ECOG PS], lactate dehy drogenase (LDH) levels, history  of brain 
metastases).
In the 11 monotherapy  studies of trametinib for which data are available , 50% to 100% of all 
subjects in any  dose group had at least 1 AE, and 0% to 70% of all subjects in any  dose group 
had at least 1 serious adverse event (SAE). Of the studies with discontinuations or withdrawals, 
3% to 26% of subjects receiving trametinib permanently  discontinued study  treatment or 
withdrew due to AE s.
In the 2.[ADDRESS_967441] [T rametinib I nvestigator Brochure] .
[IP_ADDRESS].1 Trametinib pediatric experience
Study  [MEK116540, CTMT212X2101] is an ongoing study  of trametinib monotherapy, 
including dose finding, age specific cohort expansions, disease specific cohort expansions, as 

[COMPANY_001] Confidential Page 39
Protocol Amended Version 05 Protocol No. C DRB436G2201
well as combination dabrafenib and trametinib dose finding and disease specific cohort 
expansions .
The recommended phase 2 dose (RP2D) for trametinib monotherapy  is 0.025 mg/kg/day  (not 
to exceed a dult dose) for patients 6 y ears old and above and is equivalent to the 2 mg/day  dose 
for an average [ADDRESS_967442] tolerated dose tested in this age group , 
with 0.04mg/kg/day  dosing resulting in unacceptable skin toxicity across each age category .  
Twelve patients under 6 years of age were treated with an intermediate dose of 0.032 mg/kg/day 
to determine tolerability and in an effort to achieve suitable exposures in this age group.  
Preliminary  data are available.  During the 28 day dose limiting toxicity  (DLT)period, there 
were no DLTs, no dose adjustments, and no SAEs.  Interruption of dosing due to adverse events 
occurred in 2 patients, each after about 25 weeks of treatment. 
The RP2D for the combination of dabrafenib with trame tinib is 100% of dabrafenib with 100% 
of trametinib.  Evaluation of the combination in patients under 6 y ears of age (N=3, July  2018) 
reveals that 100% of each monotherapy dose is tolerated, with no DL Ts, dose adjustments, nor 
SAEs reported in this group .
Results from an interim analysis with data cutoff date of 19-Sept-[ADDRESS_967443] enrolled into this multipart study .Forty 
patients enrolled into part A across 4 trametinib monotherap y dose levels . Thirty  eight patients 
enrolled into part B disease specific cohorts (Part B1, Neuroblastoma; part B2, LGG with fusion; 
Part B3, NF1 
with plexiform neurofibromas (NF1 with PN); and part B4, solid tumors with 
BRAF V600 mutation –all of which had LGG ) and were treated with the RP2D of trametinib 
monotherap y.  In addition, 12 patients were enrolled into two dose level cohorts of combination 
therap y, dabrafenib (50% of RP2D (n=3) or 100% of RP2D (n=9)) combined with trametinib
(100% of RP2D) . Across parts A and B, there were [ADDRESS_967444] LGG with BRAF V600 mutation, 
and 9 with neuroblastoma .  All were previously  treated for their tumor. At the time of interim 
data cutoff, 55 of the 90 patients (61%) were still on protocol therap y .
Efficacy  for glioma patients was determined using RANO criteria by [CONTACT_431], as well as 
by [CONTACT_711235] -radiologist. Efficacy  for NF1 patients with PN was reported 
by [CONTACT_711238], the volumetric approach, or both. Independent determination of 
efficacy  using the volumetric approach was also reported. Safet y monitoring included standard 
clinical trial methods, as well as routine echocardiograms, ophthalmologic exams, and 
dermatologic exams.
Neurofibromatosis 1 with plexiform neurofibromas (NF1 with PN)
There were 26 patients with NF1 with PN enrolled into several dose levels in part A and at 
RP2D in part B. I ndependent response determination using the volumetric approa ch yielded 12 
partial responses (46%) ,9 SD and 1 PD, and 4 unknown or too soon to determine.   At the time 
of data cutoff, 20 of 27 patients remained on treatment with a median duration of 61 weeks . 
Low Grade Glioma with BRAF fusion
There were 23 patients with LGG and a known fusion involving the BRAF gene, across parts A 
and B. At data cutoff, 15 (65%) patients remained on treatment with minimum follow up of at 

[COMPANY_001] Confidential Page [ADDRESS_967445] one year.  Independent response determination was performed using RANO. One patient 
(4%) had confirmed PR as best response, 18 (78%) had stable disease and four were not 
evaluable.  None had a best response of progressive disease.  
Low Grade Glioma with BRAF V600 mutation
There were 12 patients with LGG and known BRAF V600 mutation, across parts A and B.  
Independent response determination was performed using RANO. Two patients (17%) had 
confirmed PR as best response, 6 (50%) had SD, while 4 (33%) had PD within 16 weeks’ time.
Neuroblastoma
There were 9 patients with neuroblastoma enrolled.  One has remained on treatment beyond 
one y ear; the others have withdrawn from treatment within three months’ time.
Trametinib monotherapy
Adverse event s occurring at the RP2D can be described among the 38 patients from part B 
disease cohort expansion. T he median duration of treatment is 55 weeks with 26 (68%) still on 
treatment.  The most common AEs experienced with trametinib monotherap y from part B on 
this study  have been diarrhea 53%, dry  skin 42%, pyrexia 40%, anemia (37%) , vomiti ng (34%), 
alopecia (32%), and parony chia (32%).  Treatment related AEs leading to discontinuation 
occurred in 5 (13%) patients; 14 (37%) patients required some dose adjustment or interruption 
for AEs.   Five patients experienced at least one treatment relat ed serious adverse event, with no 
event reported more than once.   There were no on- study  deaths .Adverse events of special 
interest were collected, regardless of study  drug relationship. Thirty -one (82%) patients had 
skin related toxicity , 20 (53%) had diarrhea, 15 (40%) had pyrexia, 13 (34%) had hepatic events, 
12 (32%) had h ypersensitivity , and 11 (29%) had bleeding events.  4 (11%) patients had ocular 
events. All 
but 2 events were grade 2 or less (one each of hepatic disorder, hy persensitivity ).
Safety  conclusions
The safet y of trametinib monotherap y has previously  been described in the adult population, 
and in pediatric patients in the ongoing stud y [MEK116540, CTMT212X2101] .  Most patients 
experienced skin related toxicity , as well as diarrhea, py rexia, anemia, vomiting, and alopecia.  
Thirty -seven percent required some form of dose adjustment or interruption due to toxicity .  
Most patients remain on treatment more than one year since starting therapy .  Treatment with 
trametinib monotherapy is manageable following protocol described treatment and dose 
modification for toxicity .
[IP_ADDRESS] Pharmacokinetics -Trametinib 
Trametinib pharmacokinetic (PK) parameters in adults were determined after single and repeat 
dose oral administration. Trametinib was absorbed rapi[INVESTIGATOR_2478] y, requiring 1.5 hr to reach the 
maximum concentration (Tmax) after single oral administration under fasting conditions
[MEK113709] . The absolute oral bioavailability  of a single trametinib 2 mg tablet is moderate 
to high (72%) relative to a co -administere d intravenous microdose [MEK116540, 
CTMT212X2101] . Single -dose administration of trametinib with a high -fat, high -calorie meal 
resulted in a 70% decrease in maximum observed concentration (Cmax) and a 10% decrease in 

[COMPANY_001] Confidential Page 41
Protocol Amended Version 05 Protocol No. C DRB436G2201
area under the concentration -time curve from time zero (pre-dose) extrapolated to infinity  
[AUC(0 -∞)]compared to fasted conditions [MEK113709] . 
Following repeat -dosing, the mean area under the concentration -time curve over the dosing 
interval (AUC0 -∞) and Cmax increased in a dose proportional manner. Trametinib accumulates 
with repeat dosing, with a mean accumulation ratio at the recommended dose of 2 mg once 
daily  of 5.97. Terminal half-life is 5.3 days, determined after single dose administration. Steady  
state is achieved by  [CONTACT_2006]  15, with lit tle difference in pre -dose (trough) concentration at the end 
of the dosing interval (Cτ), Cmax andAUC from time zero (pre-dose) to 24 hr AUC(0 -24h)
between Day 15 and Day 21. In adults receiving trametinib 2 mg daily  for 15 days (n=13) the 
geometric mean AUC(0 -24h) (coefficient of variation [CV] %) was 370 (22%) ng*hr/mL, 
Cmax 22.2 (28%) ng/mL , Tmax 1.75 hr (range 1-3 hr ), and Cτ12 .1 (19%) ng/mL (Infante, 2012) .
The oral liquid formulation (0.05 mg/mL) had similar bioavailability  to the trametinib tablet 
formulation. Single dose administration of trametinib as a 2 mg oral solution compared to the 
oral tablet resulted in a 12%, 10 % and 71% increase in AUC(0 -∞), AUC([ADDRESS_967446]) and Cmax, 
respectivel y.
A popula tion PK model was developed with data (n=493) combined from the 
FTIH study  
[MEK111054] , and the Phase II and III studies in subjects with BRAF V600 mutation positive 
melanoma [MEK113583] and [MEK114267, CTMT212A2301] . Trametinib CL/F was 
estimated as 5.07 L/hr and was dependent on gender and weight. Although smaller female 
subjects will tend to have higher exposure than heavier male subjects, no dosage adjustment is 
warranted in this population.
In adults ,administration of trametinib and dabrafenib in comb ination had no clinically relevant 
effect on the exposure of trametinib or of dabrafenib relative to single agent administration.
Preliminary  trametinib PKresults for the selected dose of 0.025 mg/kg /day from study 
[MEK116540, CTMT212X2101] are summarized in Table 1-4. The summary includes 6
patient s with available Day 15 PK who received the combination treatment. For patients aged 
6 to 17 years ,themedian trametinib average concentration (Cavg) 
value was similar to that 
achieved in adults with melanoma that were treated with 150 mg dabrafenib BID in combination 
with trametinib 2mg QD (BRF113220 median= 13.4 ng/ml). Median Ctrough was also 
consistent between patients aged 6 to 17 years and adults in [
BRF113220] (10.1 ng/mL). In 
study  [BRF113220 ], an increase in confirmed response rate was noted in subjects that received 
dabrafenib in combination with 2mg trametinib as compared to combination with 1 mg
trametinib. 
Preliminary  trametinib PK results for the selected dose of 0.032 mg/kg/day for subjects less 
than 6 years old from study  [MEK116540, CTMT212X2101] are summarized in Table 1-4. The 
summary  includes 3 patients with available Day 15 PK who received the combination treatment. 
Cavg for this age group was similar to that achieved in adults with melanoma at the 
recommended combination regimen [BRF113220].
Table 1
-4 Median trametinib PK (day  15) by  [CONTACT_711239]
(mg/kg
/day)NCtrough 
(ng/mL)Cavg 
(ng/mL)
12-17 years 0.025 14 9.9 13.5

[COMPANY_001] Confidential Page 42
Protocol Amended Version 05 Protocol No. C DRB436G2201
Age RangeDose
(mg/kg/day )NCtrough 
(ng/mL)Cavg 
(ng/mL)
6-<12 years 0.025 16 12.0 16.3
6-17 years 0.025 30 11.7 16.3
< [ADDRESS_967447] common adverse reactions (>20%) for dabrafenib and trametinib 
combination therap y include pyrexia, fatigue, nausea, headache, chills, diarrh ea, rash, arthralgia, 
hypertension, vomiting and cough. Increased risks of intracranial and gastrointestinal 
hemorrhage are notable concerns for the combination treatment compared to dabrafenib 
monotherap y; confounding 
factors in these cases include brain metastasis and anticoagulant 
therap y.The safet y profile of the combination of dabrafenib and trametinib in adults generall y 
reflects the safet y profiles of the individual agents, with adverse events that are manageable 
with appropriate intervention. Pyrexia remains the most common AE for the combination and 
hyperproliferativ e skin lesions including cuSCC are reduced for the combination when 
compared to dabrafenib monotherap y. 
Based on efficacy  data for adults with BRAF V600 mutant metastatic melanoma or BRAF V600 
mutant NSCLC, the concomitant and more complete inhibition of the MAPK pathway  at the 
level of the BRAF -and MEK- kinases provides greater anti -tumor effect than administration of 
dabrafenib alone. Additionally  the combination prevents the paradoxical activation of the 
MAPK pathway  in BRAF wild-type cells resulting i n lower incidence of cuSCC.
Preliminary  data from [MEK116540, CTMT212X2101] are available for pediatric patients
treated with the combination of dabrafenib and trametinib.  The combination was tolerated when 
dosed at 100% of recommend ed pediatric phase 2 d ose of each agent.
[IP_ADDRESS] Safety ofdabrafenib with trametinib
Twelve patients were treated in part C dose exploration for combination therapy  of dabrafenib 
with trametinib, 3 at 50% dabrafenib, and 9 at full dose dabrafenib.  Each received full dose 
trametinib.
All twelve patients had BRAF V600 mutant LGG.  Two (17%) had independently  confirmed 
PR as best response, 8 (67%) had SD, and 2 (17% )had PD as best response. Eight (67%) remain 
on treatment, with median treatment duration at [ADDRESS_967448] common AEs reported, regardless of causal relationship were rash (67%), pyrexia 
(58%), diarrhea, fatigue, headache, and vomiting (each 42%). Two patients had a total of 5 
possibly  related SAEs, both with ejection fraction decrease (17%) and one each with nausea, 
vomiting, and pyrexia (8%).  Dose interruptions for toxicity  were required for 8 (67%) patients.   
There have been no deaths in this group.
No dose limiting toxicities were observed.  Evaluation of combinati on therapy  in patients under 
6 years of age also demonstrates tolerability  at the 100% dose of trametinib (0.032 mg/kg/day ) 
together with 100% dabrafenib dose (5.25 mg/kg/day  divided into two equal doses per day ).

[COMPANY_001] Confidential Page [ADDRESS_967449] of care treatment in several large studies ( Ater 2012, Gnekow 2017 ).
There are multiple treatment schedules or regimens for administering carboplatin with 
vincristine in this setting of first systemic thera py for patients with LGG.  The most widel y 
utilized are those employed in the COGA9952 protocol (Ater 2012 ) and the SIOP-LGG -2004 
protocol (Gnekow 2017). For CDRB436G2201, the treatment regimen from COGA9952 will 
be used for those patients assigned to chemotherapy  treatment in the LGG cohort.
The treatment regimen is described in detail in Section 
6.1.2, and consists of 10 weeks of 
induction therap y, followed by 8 cy cles of maintenance therapy . 
2 Rationale
2.1 Stud y rationale and purpose
The RAS/RAF/MEK/ERK pathway  is a critical proliferation pathway  in many  human cancers. 
This pathway  can be constitutively  activated by [CONTACT_681835], including BRAF , 
which phosphory
lates MEK on two regulatory  serine residues . 
Dabrafenib is a potent and selective inhibitor of BRAF kinase activit y. Excluding RAF enzy mes, 
dabrafenib demonstrated IC50 values <[ADDRESS_967450] only 8 kinases from ~300 protein and 
lipid kinases tested.  In addition, dabrafenib suppresses phosphory lated ERK [pERK]) that is 
downstream of BRAF in the MAPK pathway  anddemonstrated anti-proliferative activit y 
against multiple BRAF mutation positive tumor cell lines, and tumor regression in BRAF
mutation positive xenograft mod els.
When present, the BRAF V600 mutation appears to result in constitutive activation of the BRAF
enzy me in cancer cells regardless of tumor context, and as s uch, BRAF V600 mutations may  be 
relevant drivers of tumor progression in other settings, including childhood cancers.  Reports 
citing the frequencies of BRAF mutations in childhood cancers are currently  limited in the 
scientific literature . However, to dat e, BRAF V600E mutations have been positively  identified 
in >10% of patients with certain types of gliomas (both low -and high-grade tumors) (Doughert y 
2010; MacConaill 2009 ; Schiffman 2010 ; Janeway  2013 ; Jones 2012).
Relapsed, refractory  or resist ant pediatri c HGG lacks a standard of care. BRAF V600 mutant, 
recurrent or refractory , pediatric HGG is a rare tumor type with a dismal prognosis. Multiple 
chemotherapi[INVESTIGATOR_711174] . Temozolomide has demonstrated poor expected ORR in this 
setting. The most relevant historical efficacy  data for pediatric patients with relapsed, refractory , 
or progressed HGG may come from the literature (Lashford 2002 ). The observed response rate 
of 12% (4 PRs in 33 temozolomide treated pediatric patients) is
 low and is generall y consistent 
with other similar studies. A more recent study  of bevacizumab and irinotecan, conducted based
on demonstrated efficacy  in treating adults with recurrent HGG, failed to show efficacy  in 
pediatric patients with second line HGG (Gururangan 2010) . Other targeted agents have also 
been studied in thisdisease setting buthave shown a lack of efficacy  
(Jones 2012).  P reliminary 

[COMPANY_001] Confidential Page 44
Protocol Amended Version 05 Protocol No. C DRB436G2201
results from [BRF116013 , CDRB436A2102] showed that 6of 19patients (31.5%) with
relapsed or refractory BRAF V600 mutant HGG and measurable disease had investigator 
confirmed responses (CRs+ PRs)following dabrafenib monotherap y
.These results indicate that 
dabrafenib may  offer improvement in treatment outcome for these patients.
The prognostic role of BRAF V600 mutation in pedia tric HGG is unclear , but available data 
suggest that BRAF V600 mutation may  be prognostically favourable in pediatric HGG. For this 
reason, the historical RR in BRAF V600 mutant pediatric relapsed refractory  HGG may be 
higher than that observed in unselect ed populations ,where the RR is less than 12%. The 
combination of dabrafenib with trametinib in adults with BRAF V600 mutant melanoma ,
NSCL C and other tumors have resulted in improved efficacy  over dabrafenib monotherap y and  
suggests that greater efficacy  may also be seen in the pediatric setting such as patients with 
relapsed refractory  BRAF V600 mutant HGG. Given the high unmet medical need in pediatric 
HGG, the encouraging efficacy  of dabrafenib monotherapy  in pediatric patients with BRAF
V600 mutant HGG, and the improved efficacy seen in adult cancer studies upon the addition of 
trametinib to dabrafenib, the HGG cohort portion of this study  aims to demonstrate the 
effectiveness of dabrafenib with trametinib in pediatric patients with BRAF V600 mutant 
relapsed refractory  HGG. 
Recent analy sis of tumor tissue and clinical outcomes has revealed that patients with BRAF
V600 mutant LGG represent a subgroup of patients with L GG who have a significantl y worse 
prognosis, with lower ORR , shorter PFS and shorter OS (Lassaletta 2017).  While unselected 
patients with LGG requiring systemic therap y typi[INVESTIGATOR_711175] y treated with standard of 
care chemotherap y, this group of patients with BRAF V600 mutant LGG has a need for 
improved treatment options over standard cytotoxic chemotherap y. The observed activity  of 
dabrafenib monotherapy in patients with BRAF V600 mutant LGG that had failed their first 
systemic anticancer therapy  (CR+PR 44%) [BRF11603 ,CDRB436A2102 ]exceeds historical 
expectations (11% ) (Lassaletta 2017) for this subgroup of patients, and suggests a role for 
dabrafenib treatment in this disease. 
The LGG cohort portion of this trial will compare the relative clinical benefit of combination 
targeted therap y of dabrafenib and trametinib to carboplatin with vincristine chemotherap y. 
The decision to use systemic therap y for pediatric patients with LGG can be complex.  
Treatment is reserv ed for those patients who are deemed to require therapy  for their disease, 
having had optimal surgical resection, where further surgical treatment would result in 
unacceptable neurologic toxicity  and who will have further neurologic deterioration due to their 
disease.
Carboplatin with vincristine chemotherap y has been employ ed in the systemic treatment of 
pediatric patients with LGG for several decades, and has served as the standard of care treatment 
in several large studies. Toxicity  in treatment with carboplatin and vincristine includes 
hematologic suppression, peripheral neurotoxicity , and significa nt hypersensitivity  reactions. 
Median progression free survival in unselected patients undergoing their first systemic 
chemotherap y with carboplatin with vincristine was about 5 years (Ater 2012). Response rate 
(CR+PR) at the end of chemotherap y was 35% in this study .

[COMPANY_001] Confidential Page [ADDRESS_967451] local and centrall y confirmed measurable 
disease for enrolment, and efficacy will be determined using the RANO criteria by [CONTACT_711240] -radiologists. After discontinuation of the study  treatment, patient s will 
remain on the study  for follow -up assessments and collection of information on subsequent anti-
cancer treatments and survival. 
A single arm design is used in th e HGG cohort for the following reasons:
1. T here is no standard of care comparator available in this patient population. 
2. T here is no non- standard therap y available that would offer equipoise to dabrafenib or 
dabrafenib in combination with trametinib in this setting.
3. A non- randomized approach is suitable as the study  aims to demonstrate a large treatment 
effect. 
4.
It is infeasible to conduct a larger statistically  robust randomized controlled tria l in such a 
rare tumor population.
Eligible patients must have tumors harboring the BRAF V600 mutation, as the antitumor effect 
of dabrafenib is limited to tumors with this mutation. Approximately  10% of pediatric HGGs 
will have this mutation. This enrichment of the trial population limits the participation of 
patients with BRAF V600 wild type tumors who would not be expected to respond to dabrafenib 
therap yand thus allow sthose patients to promptly seek alternative treatments that might be 
more beneficial to them.
Tumor response is the primary  endpoint, represent ingan objective measurement of clinically 
relevant antitumor effect that can be ascertained in a uniform and reliable fashion. Response 
assessment will be performed using the RANO crit eria. ORR is a direct measure of therapeutic 
effect and is not affected by [CONTACT_711241] . ORR can also be determined relativel y 
rapi[INVESTIGATOR_711176]. There are extensive historical ORR data for a variety of 
salvage therapi[INVESTIGATOR_711177], including cytotoxic chemotherapi[INVESTIGATOR_711178]. These studies can serve as indirect comparators for the proposed study . 
BRAF V600 mutation status, tumor histo pathology and grade III/IV will be centrall y confirmed 
for allenrolled patients. ORR will be determined by  [CONTACT_711242]. Independent assessment of ORR will be the primary  endpoint .
Central review of tumor histo patho
logy is intended to assure consistent applicat ion of the WHO
[ADDRESS_967452] locally  
determined BRAF V600 mutant LGG with both local and centrall y confirmed measurable 
disease .Approximately  102 patients will be randomized in a 2:[ADDRESS_967453] historical 
datasets upon which to compare. For example, the assumptions of relative clinical efficacy  used 
to design the LGG cohort of this study  are taken from a relatively  small number of patients with 
molecularl y selected tumors who were treated with targeted therapy  for the experimental arm, 
and taken from a retrospective analysis of clinical outcomes 
database where there was also 
sufficient clinical tumor material available to allow molecular profiling ( Lassaletta 2017) for 
the chemotherap y arm. While the data are encouraging and supportive of further e
xploration of 
targeted therapy  in this patient subset, the data may not besufficient to establish future treatment 
recommendations for this and closely  related patient populations.  Through the use of a 
randomized comparison, the L GG cohort portion of this trial aims to prove t he relative clinical 
benefit of combination targeted therapy  of dabrafenib with trametinib as compared to standard 
of care cy totoxic chemotherap y. 
The primary  endpoint for the LGG cohort of this study  is ORR by [CONTACT_711243]. This independent 
reviewer will not have access to clinical data prior to making radiologic determination of 
response. This approach reduces the potential for bias regarding the treatment assignment t o 
interfere with objective determination of response.
To avoid introduction of bias into the determination of progression free survival, frequent tumor 
assessments are scheduled during the first [ADDRESS_967454] chemotherapeutic arm under the assumptions of this trial 
using the response rate (CR+P R) as the primary endpoint . Additionally , the study  design will 
allow for a description of the important endpoint of progression free survival in this indolent 
disease at a later time point, to supplement the ORR results. Randomization will be in a 2:[ADDRESS_967455] 
in the route of administration, the schedule for administration, and the clinically  obvious 
toxicity  profiles. The necessary  supportive care will also vary depending on treatment 
assignment.
2.3 Rationale for dose and regimen selection
The combination dose regimen rationale for this study  was based on safet y, tolerability and PK.
In Study  [BRF116013, CDRB436A2102 ]the recommended dabrafenib monotherap y doses 
were determined based on PK as an MTD was not determined. Dabrafenib exposure associated 
with efficacy  in adult studies has been well demonstrated, while anMTD has not been 
determined .The geometric mean (95% CI) dabrafenib AUC(0 -12) after administration of 150
mg BID in the Phase III study  [BRF113683, CDRB436A2301] (patients with BRAF mutant 
metastatic melanoma) was 4341 (3599, 5 235) ng*h/mL .Therefore the exposure target range of 
~4000-5500 ng*h/mL  was applied in the dose-escalation part of the pediatric Phase I study 
[BRF116013, CDRB436A2102] . 
Based on the preliminary PK data, the following doses were determined:
<12 years old patients: 5.25 mg/kg/day  dabrafenib administered orall y, divided into two 
equal doses
≥12 years old 
patient s: 4.5 mg/kg/day  dabrafenib administered orall y, divided into two 
equal doses
In Study  [MEK116540, CTMT212X2101] , three dose levels were initially tested for trametinib: 
0.0125, 0.025 and 0.04 mg/kg /day. Since the dose regimen of 0.04 mg/kg /day resulted in dose 
limiting toxicities, 0.025 mg/kg /day was selected as the recommended trametinib dose for 
patients 6 years of age and older, based on safet y and tolerability .An intermediate dose of 0.032 
mg/kg/day  trametinib was studied in patients under 6 years of age and was well tolerated and is 
the recommended trametinib dose for patients under 6 years of age.   
In Part C of MEK114560 the combination regimen was tested using a dose escalation scheme 
for dabrafenib: trametinib 0.025 mg/kg /day with half the recommended dabrafenib dose from 
study  [BRF116013 , CDRB436A2102] (dose level 1) and with 100% of the recommended 
dabrafenib dose from [BRF116013, CDRB436 A2102](dose level 2). The combination regimen 
was safe and tolerated at both dose levels.  Forpatients under 6 years of age a higher dose of 
0.032 mg/kg /day for trametinib in combination with 5.25 mg/kg/day  dabrafenib was evaluated 
with the aim of achiev ing higher exposure levels than those observed at the trametinib 0.025 
mg/kg/day dose in this age group. This higher dose was safe and tolerated based on data from
three patients in Part C that received the combination regimen. 

[COMPANY_001] Confidential Page 48
Protocol Amended Version 05 Protocol No. C DRB436G2201
Based on PK data from [BRF116013 , CDRB436A21 02]and [MEK116540 , CTMT212X2101]
at the recommended dabrafenib doses for patients ≥6 years; dabrafenib AUC(0 -tau) on Day  15 
was within the exposure values associated with efficacy  in adults ( Section [IP_ADDRESS]). 
Based on preliminary  PK data from [MEK116540, 
CTMT212X2101] at the recommended
trametinib dose (0.025 mg/kg /day)for patients ≥ 6 years: the trametinib Cavg was greater than
10 ng/mL  for 90% of patients and at the recommended dose (0.032 mg/kg/day ) for patients < 6
years: the trametinib Cavg was greater than 10 ng/mL  for 2 out of 3 patients (Section [IP_ADDRESS] ). 
This target concentration hasbeen associated with higher response rate in adults receiving 
combination therap y.
Overall the PK of dabrafenib and trametinib are within the exposure ranges associated with 
efficacy  in adults and the combination regimen has a manageable safety  profile. Collectivel y 
these data support the selected dabrafenib and trametinib dose(s) for children and adolescents. 
The recommended combination dosing regimen for children and adolescents are:
Trametinib
< 6 y ears old: 0.032 mg/kg/day
≥6 years old: 0.025 mg/kg/day
Dabrafenib
< 12 years old: 5.25 mg/kg/day , divided into two equal doses
≥12 y ears old: 4.5 mg/kg/day , divided into two equal doses
Patients enrolled in this study will receive dabrafenib twice daily and trametinib once daily . The 
total daily  dose of dabrafenib will not e xceed 300 mg (150 mg BID) and for trametinib will not 
exceed [ADDRESS_967456] of care treatment 
in several large studies (Ater 2012, Gnekow 2017 )
There are multiple treatment schedules or regimens for administering carboplatin with 
vincristine in this setting of first systemic therapy  for patients with LGG.  The most widel y 
utilized are those employed in the COGA9952 protocol (Ater 2012) and the SIOP-LGG -2004 
protocol (Gnekow 2017). For this current study , the treatment regimen from COGA9952 will 
be used for those patients assigned to chemotherapy in the LGG cohort. The treatment regimen 
includes [ADDRESS_967457] been no randomized comparisons of these regimens, but they are considered 
comparable in overall outcomes.  The chosen regimen is slightl y shorter in duration. This 
schedule was selected with guidan ce from the protocol steering committee as one that is well 
recognized and has a good benefit risk profile for this patient population.

[COMPANY_001] Confidential Page 49
Protocol Amended Version 05 Protocol No. C DRB436G2201
2.6 Risks and benefits 
Potential Risks
Based onthe interim analy sisof the 65 pediatric patients enrolled across four dose levels
[BRF113773, CDRB436A2101] , the toxicity  profile of dabrafenib is generally  similar to that 
observed in the adult patient experience. Both populations experienced frequent rash, pyrexia, 
fatigue, arthralgia and headache. The frequency  of rash and similar adverse events may be 
higher in this pediatric population than in adults. In contrast, there were no cases of cutaneous 
SCC observed in these pediatric patient s. The most common adverse event s (AEs) were in the 
Skin body  system. Adequate exposures were obtained without reaching a maximally  tolerated 
dose. 
Results from the ongoing [MEK116540, CTMT212X2101] study  are preliminary .  Dose 
limiting toxicity  was predominantly  skin toxicity  (rash, folliculitis). In adults in the 2.[ADDRESS_967458] common AEs were rash, 
diarrhea, fatigue, edema peripheral, nausea, dermatitis acneiform, vomiting, constipation, 
anemia, pruritus, alopecia, hy pertension, decreased appetite, dy spnea and dry  skin.
The combination treatment of pediatric patients at full recommended monotherap y dose of 
dabrafenib and trametinib was tested in a small (less than 10) number of patients. No DLTs 
were observed.  In adults, the safet y of dabrafenib and trametinib combination therap y has been 
evaluated in multiple studies of adults treated with dabrafenib [ADDRESS_967459] common adverse reactions (>20%) for dabrafenib 
and trametinib combination therap y include pyrexia, fatigue, nausea, headache, chills, diarrhoea, 
rash, arthralgia, hypertension, vomiting and cough. The safet y profile of the combination of 
dabrafenib and trametinib in adults generall y reflects the safet y profiles of the individual agents, 
with adverse events that are manageable with appropriate intervention. Pyrexia remains the 
most common AE for the combination and hyperproliferative skin lesions including cuSCC are 
reduced for the combination therap ywhen compared to dabrafenib monotherap y. 
The safet y experience in the pediatric population is described in more detail in the latest 
[Investigator Brochure].
Potential Benefits
Relapsed or refractory  pediatric HGG is associated with very unfortunate outcomes using 
conventional therap y, with expectations of less than 12% RR and a median survival of 5 months
for unselected patients . Interim analy sisof[BRF116013, CDRB436A2102
]includes
independentl y confirmed response rate of 45% ( 10/22 ) and manageable safety  profile for 
dabrafenib monotherap y. The combination of dabrafenib with trametinib has been studied in 
adult patients with BRAF V600 mutant metastatic melanoma or NSCLC and has shown greater 
efficacy  than with dabrafenib alone.  
Pediatric patients with BRAF V600 mutant LGG who progress following optimal surgical 
resection often require systemic treatment. The standard of care in this setting has been a 
regimen of carboplatin and vincristine.  Recent analysis of paired tumor molecular profiles and 
patient outcomes reveals that this standard of care may not be as effective as previously  noted
in patients whose tumor carries the BRAF V600 mutation, with lower response rate, PFS and 

[COMPANY_001] Confidential Page [ADDRESS_967460] failed prior s ystemic chemotherap y, independentl y confirmed response rate (RANO, 
CR+PR) of dabrafenib monotherap y (44%) [ BFR116013, C DRB436A2102 ]exceeds historical 
expectations (11%) ( Lassaletta 2017) for this subgroup of patients. Thus, it is possible that this 
apparent improved outcome in relapsed or refractory  LGG may also be seen in patients with 
BRAF V600 mutant LGG experiencing their first post-surgical progression . For the reasons 
stated previous ly, the addition of trametinib to dabrafenib is predicted to further improve the 
outcomes forLGG patie nts. Patients randomized to the chemotherap ytreatment arm of the LGG 
cohort will benefit from the treatment approach that has been utilized for many  years, but will 
also have the opportunity to cross over to the experimental therap y upon reaching the centrall y 
confirmed progression of disease endpoint. Patients with LGG often receive substantial benefit 
from subsequent treatments
, suggesting that those patients who do cross over as part of their 
study  treatment, may experience benefit from that therapy . 
Overall Conclusion 
Overall, these results suggest that dabrafenib monotherap y represents a potentially  favorable 
benefit risk t o pediatric patients with BRAF V600 mutant relapsed refractory  or progressive 
HGG and LGG , and that the addition of trametinib to this treatment may  result in even greater 
response rates, with possible longer duration of responses, while maintaining a tolerable risk 
profile .For patients in the LGG cohort, a recognized standard of care treatment regimen of 
carboplatin and vincristine (Ater, 2012 ) will be utilized, together with the option to cross over 
totreatment with dabrafenib plus trametinib at the time of centrall y confirmed disease 
progression on study . The study  is designed in such a way  as to reduce the overall sample size, 
including the number of patients randomized into the chemotherap ytreatmen t arm of the LGG 
cohort, while providing a reasonable expectation of meaningful results to guide future treatment 
decisions in this molecularly selected patient populations.  Risks will also be minimized by 
[CONTACT_711244], 
and interim analysis to determine early stoppi[INVESTIGATOR_711179] .An independent Data Monitoring Committee (DMC) will be 
constituted and will be responsible for monitoring and reviewing clinical data for safet y durin g 
the study . Recommended guidelines for proph ylactic or supportive management of study drug 
induced adverse events are provided in Section 6.3. There may be unforeseen risks which could 
be serious. Refer to the latest [Investigator's Brochure] .
3 Objectives and endpoints
Objectives and related endpoints are described in Table 3
-1below.

[COMPANY_001] Confidential Page 51
Protocol Amended Version 05 Protocol No. C DRB436G2201
Table 3-1 Objectives and related endpoints
Objective Endpoint Anal ysis
Primary Refer to Section 10.4
HGG Cohort:
Evaluate the anti -tumor activity of dabrafenib in combination with 
trametinib, as measured by [CONTACT_34426] (ORR) by 
[CONTACT_711212].ORR, proportion of patients with a best overall confirmed Complete 
Response (CR) or Partial Response (PR) by [CONTACT_711245].
LGG Cohort:
Compare the anti -tumor activity of dabrafenib in combinati on 
with trametinib versus carboplatin with vincristine , as measured 
by [CONTACT_34426] (ORR) by [CONTACT_711246].ORR, proportion of patients with a best overall confirmed Complete 
Response (CR) or Partial Response (PR) by [CONTACT_711247].
Secondary Refer to Section 10.5.1
HGG Cohort:
1.Evaluate ORR by [CONTACT_3138]   
2.Evaluate duration of response (DOR) by [CONTACT_711248]
3.Evaluate progression free survival (PFS) by [CONTACT_711248]
4.Evaluate time to response (TTR) by [CONTACT_711215]
5.Evaluate clinical benefit rate (CBR) by [CONTACT_711248]
6.Evaluate overall survival (OS)
7.Evaluate the safety and tolerability profile of dabrafenib in 
combination with trametinib in children and adolescents
8.Evaluate the palatability of dabrafenib oral suspension and 
trametinib oral solution
9.Characteriz e the pharmacokinetics of dabrafenib, its 
metabolites and trametinib in the study population 1.ORR by [CONTACT_711249]
2.DOR, calculated as the time from the date of the first 
documented confirmed response (CR or PR) to the first 
docu mented progression or death due to any cause, as 
assessed separately by [CONTACT_711250].
3.PFS, defined as time from first dose of study treatment to 
progression or death due to any cause, as assessed separatel y 
by [CONTACT_711251] 
4.TTR, calculated as the time from the start date of study 
treatment to first documented confirmed response CR or PR 
(which must be confirmed subsequently) as assessed 
separately by [CONTACT_711252]
5.CBR is the proportion of patients with a best overall response of 
CR or PR, or an overall lesion response of SD which lasts for a 
minimum time duration of at least [ADDRESS_967461] dose of study treatment to 
death due to any cause
7.Incidence of adverse events and serious adverse events, 
changes in laboratory results, vital signs, ECG and ECHO .
8.Palatability questionnaire data
9.Plasma concentration -time profiles of dabrafenib, its 
metabolites and trametinib and PK parameters
Secondary  Refer to Section 10.5.1
LGG Cohort:
10.Evaluate ORR of dabrafenib in combination with trametinib 
versus carboplatin with vincristine, as measured by 
[CONTACT_3138] .   
11.Evaluate the DOR of dabrafenib in combination with 
trametinib versus carboplatin with vincristine by [CONTACT_711253] .
12.Evaluate PFS of dabrafenib in combination with trametinib 
versus carboplatin with vincristine, as measured by [CONTACT_711253] .
13.Evaluate TTR of dabrafenib in combination with trametinib 
versus car boplatin withvincristine, as measured by [CONTACT_711253] .
14.Evaluate CBR of dabrafenib in combination with trametinib 
versus carboplatin withvincristine, as measured by [CONTACT_711253]
15.Evaluate OSof dabrafenib in combinati on with trametinib 
versus carboplatin withvincristine .
16.Evaluate 2 -year OS estimate of dabrafenib in combination 
with trametinib versus carboplatin with vincristine.
17.Evaluate the safety and tolerability of d abrafenib in 
combination with trametinib versus carboplatin with 
vincristine =.
18.Evaluate the palatability of dabrafenib and trametinib 
19.Characterize the pharmacokinetics of dabrafenib, its 
metabolites and trametinib in the study population10.ORR by [CONTACT_711249].
11.DOR, calculated as the time from the date of the first 
documented confirmed response (CR or PR) to the firs t 
documented progression or death due to any cause, as 
assessed separately by [CONTACT_711250].
12.PFS, defined as time from date of randomization to progression 
or death due to any cause, as assessed separately by [CONTACT_711254]
13.TTR, calculated as the time from the date of randomization to 
first documented confirmed response CR or PR (which must be 
confirmed subsequently) as assessed separately by 
[CONTACT_711255]
14.CBR is the proportion of patients with a best overall response of 
CR or PR, or an overall lesion response of SD which lasts for a 
minimum time duration of at least 24 weeks, as assessed 
separately by [CONTACT_711256].
15.OS, defined as the time from date of randomization to death 
due to any cause.
16.2-year OS estimate
17.Incidence of adverse events and serious adverse events, 
changes in laboratory results, vital signs, ECG and ECHO .
18.Palatability questionnaire data

[COMPANY_001] Confidential Page 53
Protocol Amended Version 05 Protocol No. C DRB436G2201
Objective Endpoint Anal ysis
20.Assess patient reported outcomes of dabrafenib in 
combinat ion with trametinib versus c arboplatin with 
vincristine19.Plasma concentration -time profiles of dabrafenib, its 
metabolites and trametinib and PK parameters
20.Change from baseline in PROMIS Parent Proxy scale -Global 
Health 7+2

[COMPANY_001] Confidential Page 54
Protocol Amended Version 05 Protocol No. CDRB436G2201
4 Study  design
4.1 Description of study  design
High Grade Glioma (HGG) Cohort
The HGG cohort is a multi -center, single arm, open -label part of this phase II study  conducted 
in children and adolescent patients with BRAF mutation positive, refractory orrelapsed HGG 
tumors after having received at least one previous standard therap y. 
Approximately  40patients will be enrolled to receive dabrafenib and trametinib . 
The primary  objective is to evaluate the 
anti-tumor activity  of dabrafenib in combination with 
trametinib, as measured by [CONTACT_711257] (FAS)population .ORR as assessed by [CONTACT_1697] , 
DOR, PFS, TTR, and CBR assessed by [CONTACT_711258], OS, 
palatability  and the safety  and tolerabilit y profile of dabrafenib and trametinib are secondary 
endpoints. 
A Steering Committee (SC) will be established, composed of investigators and [COMPANY_001] 
personnel participating in the trial, to ensure transparent management of the study according to 
the protocol through recommending and ap proving modifications as outlined in Section 8.7.
A Data Monitoring Committee (DMC) will also be established for the study . The DMC will 
function independently  of all other individuals associated with the conduct of this clinical trial, 
including the site investigators participating in the study . The DMC will be responsible to 
review study  data from the HGG and LGG cohorts approximate ly every [ADDRESS_967462] of the stud y as outlined in Section 8.6. 
Patients in the HGG cohort may continue to receive the 
assigned study  treatment until disease 
progression by [CONTACT_711259] , 
unacceptable toxicity , start of a new anti -neoplastic therap y
, discontinuation at the discretion of 
the investigator or patient/ legal guardian ,lost to follow -up, death, or study  terminat ionby [CONTACT_103].
HGG p atients who have disease progression by [CONTACT_711260], continuing study  treatment may be in the best interest for the patient ,and the 
patient /legal guardian is willing to continue on study  treatment and sign the Informed Consent 
for treatment beyond progression. The decision to continue study  treatment after PD must be 
documented in the patient records and eCRF after every  tumor evaluation .In this case, the 
patient will continue assessments as defined in Section 7. An End of Treatment visit will be 
performed when patients permanentl y discontinue study  treatment. 
Patients who discontinue the study  treatment without disease progression by [CONTACT_711261] -up 
outlined in Section 
7,until central independently  confirmed disease progression by [CONTACT_711262] -neoplastic therap y. 

[COMPANY_001] Confidential Page [ADDRESS_967463] study
treatment (except if consent is withdrawn, death, or patient is lost to follow -up or study  
discontinuation). 
An interim analy sis for futility  will be implemented to allow possible termination of recruitment 
of the HGG cohort in the event that there is insufficient efficacy . The patients for inclusion in 
the formal interim analysis for futility  will be determined shortly  after [ADDRESS_967464] withdrawn early . If the observed ORR in the HGG cohort assessed by [CONTACT_711263] ≤ 25%, there may be aconsideration to stop the HGG cohort due to 
insufficient efficacy . The final decision on whether to stop enrollment in theHGG cohort will 
take intoaccount all available study  information at the IA cut-off including safet y data and all
efficacy  endpoints .Any decision to halt further enrollment into the HGG cohort will not impact 
the treatment options for patients alread y enrolled into this cohort. HGG patien ts deriving 
benefit as per investigator discretion may continue receiving dabrafenib plus trametinib 
treatment on study .
The primary  analysisof the HGG cohort will be conducted based on the all treated patients 
when allHGG patients have either completed at least 32weeks of treatment or have 
discontinued earlier. In order toevaluate response against the efficacy  seen in existing Standard 
of Care (SOC )and to provide evidence that trametinib contributes to the effect of the 
combination therapy for the HGG cohort , the point estimate and exact binomial confidence 
interval s(CIs) of ORR will be provided. The lower bound of the CIs will be used to provide 
evidence that the true ORR is greater than a certain specific response rate.
Figure 4-1 Study  Design for HGG Cohort

[COMPANY_001] Confidential Page 56
Protocol Amended Version 05 Protocol No. CDRB436G2201
Low Grade Glioma (LGG) Cohort
The LGG cohort is a multi -center, randomized, open- label part of this phase II study  conducted 
in children and adolescent patients with BRAF mutation positive , with progressing LGG whose 
tumor is unresectable and who require treatment.
Approximately  102 patients will be randomized in a 2:1 ratio to either dabrafenib plus
trametinib or carboplatin with vincristine .
The primary  objective is to compare the anti -tumor activity  of dabrafenib in combination with 
trametinib versus carboplatin with vincristine, as measured by [CONTACT_711264] (FAS) populati on. Secondary 
endpoints include ORR as assessed through investigator assessment , DOR, PFS, TTR, and CBR
assessed by [CONTACT_711265]. Patient reported outcomes 
from the PROMI S questionnaire , palatabilit y, and the safet y and tolerability  profile of 
dabrafenib and trametinib are additional secondary endpoints. 
A Steering Committee (SC) composed of investigators and [COMPANY_001] person nel participating in 
the trial will ensure transparent management of the study  according to the protocol through 
recommending and approving modifications as outlined in Section 8.7.
A Data Monitoring Committee (DMC) will be established forthe study . The DMC will function 
independentl y of all other individuals associated with the conduct of this clinical trial, including 
the site investigators participating in the study . The DMC will be responsible to review data
from the HGG and LGG cohorts approximately  every [ADDRESS_967465] of the study 
as outlined in 
Section 8.6.
LGG patients receiving carboplatin with vincristine treatment will follow the regimen in 
Section 
6.1.2 in conjunction with institutional practice. Duration of treatment should continue 
for the prescribed number of cyclesas tolerated, or until unacceptable toxicity , start of a new 
anti-neoplastic therapy , discontinuation at the discretion of the investigat or or patient/legal 
guardian, lost to follow -up, death, study  termination by [CONTACT_456] ,or until disease progression. 
See Section [IP_ADDRESS] for dose modifications and management guidelines or carboplatin with 
vincristine. Patients randomized to the carboplatin with vincristine treatment arm will only be 
allowed to cross over to receive dabrafenib in combination with trametinib after centrally 
confirmed RANO -defined disease progression. Crossover will be allowed during the treatment 
period or the post -treatment period.
LGG patients on dabrafenib with trametinib treatment may continue to receive the assigned 
study  treatment until disease progression by [CONTACT_711266], unacceptable toxicity , start of a new anti-neoplastic therap y, 
discontinuation at the discretion of the investigator or patient/legal guardian, lost to follow -up, 
death, or study  termination by [CONTACT_456].  
LGG patients receiving dabrafenib with trametinib who have disease progression by [CONTACT_711267], continuing study  treatment may be in the best 
interest for the patient, and the patient/legal guardian is willing to continue on study  treatment 
and sign the Informed Consent for treatment beyond progression. The decision to continue study  
treatment after PD must be documented in the patient records and eCRF after every  tumor 

[COMPANY_001] Confidential Page [ADDRESS_967466] study  
treatment (except if consent is withdrawn, death, or patient is lost to follo w
-up or study  
discontinuation). 
No formal interim anal ysis is planned for the LGG cohort.
The primary  analysis will be conducted based on all treated patients when all patients have 
either completed at least [ADDRESS_967467] be reviewed by [CONTACT_15009]/her designee prior to 
enrollment of each patient into the study  to ensure all criteria have been met.  

[COMPANY_001] Confidential Page 58
Protocol Amended Version 05 Protocol No. CDRB436G2201
Eligible patients may only be included in the study  after the patient or parental/legal guardian 
provides written (witnessed, where required by [CONTACT_6617]) inform edconsent. In cases 
where the patient’s representative gives consent, the patient should be informed about the study 
to the extent possible given his/her understanding. If the patient is capable of doing so, he/she 
should indicate assent b y personall y signing and dating the written informed consent document 
or a separate assent form. 
As part of the screening, all patients must have available tumor samples (either formalin -fixed, 
paraffin-embedded [ FFPE ]blocks or slides) for central confirmation of BRAF V600 mutation 
(HGG and LGG), and for patients enrolled into the HGG cohort, for independent confirmation 
of HGG histopathology by [CONTACT_711268]. The sample should be the best 
representation of the tumor and submitted for central confirma tion approximately  within one 
month of enrollment onto the study . Eligibility  will be assessed based on local results of 
histology  and BRAF V600 mutation. 
Central confirmation of baseline measurable disease by [CONTACT_711269] b efore enrollment. 
Following thecompletion of screening procedures and verify ing patient eligibility  based on 
assessments, the patient will be enrolled via the Interactive Response Technology  (IRT) system. 
Please refer to and comply  with detailed guidelines in the IRT manual. IRT systems will confirm 
the inclusion of eligible patients. 
4.1.[ADDRESS_967468] administration of study  treatment .In 
the HGG cohort, all patients will receive dabrafenib in combinatio n with trametinib. In the LGG 
cohort, patients will be randomized 2:1 to receive dabrafenib in combination with trametinib or 
carboplatin with vincristine. 
All patients who receive dabrafenib with trametinib will take dabrafenib twice daily and 
trametinib once daily until no longer receiving clinical benefit as determined by [CONTACT_093], 
disease progression, death, unacceptable toxicity  that precludes further treatment, start of new 
anticancer therap y, or study is terminated by [CONTACT_2728]. 
Patients enro lled into the LGG cohort and randomized in the control arm will be administered 
carboplatin with vincristine, according to the regimen defined in Section 6.1.2. T reatment 
should continue for the prescrib ed number of cycles, as tolerated, or until unacceptable toxicity , 
start of a new anti-neoplastic therap y
, discontinuation at the discretion of the investigator or 
patient/legal guardian, lost to follow -up, death, study  is terminated by [CONTACT_711270]. Patients randomized to the control arm are expected to follow protocol 
specified evaluations according to Table 7 -
3, including efficacy  and safet y assessments. 
Patients inboth cohorts will be assessed at screening ( within 28 day s before initiation of study  
treatment) and every  [ADDRESS_967469]
been met. 
Safety  assessments (collection of AEs, concomitant medications, laboratory  parameters, 
dermatologic skin evaluations, and ophthalmologic exams) will be conducted on a continuous 
basis during the treatment phase according to Table 7 -1,Table 7 - 2 for LGG crossover patients
or Table 7-3.  
 
[IP_ADDRESS] Treatment after Progression of Disease
Patients receiving dabrafenib with trametinib arepermitted to continue treatment beyond 
investigator -
assessed, RANO- defined PD, as long as they  meet the following criteria:
Investigator assessed clear evidence of clinical benefit 
Tolerance of stud y treatment
Continuation of study  treatment is in the best interest of the patient as determined by  [CONTACT_3786]
Patient /legal guardian is willing to continue on the study and sign Informed Consent for 
treatment bey ond progression
If the Principal Investigator [INVESTIGATOR_711180], the patient may continue 
dabrafenib with trametinib treatment on study  and follow all study  related procedures, including 
tumor assessments ,as scheduled in Table 7-1. After each tumor assessment, the Principal 
investigator [INVESTIGATOR_711181] , and doc ument 
this in patient medical records and the eCRF .
[IP_ADDRESS] Crossover and Continuation of Treatment (LGG Cohort)
For the LGG cohort, patients randomized to the carboplatin with vincristine treatment arm will 
be allowed to crossover to receive dabrafenib in combina tion with trametinib treatment after 
centrall y confirmed and RANO -defined disease progression. Patients who cross over are 
expected to continue to undergo protocol specified evaluations according to Table [ADDRESS_967470] 
Treatment Follow Up phase. 
Tumor evaluations during this period will continue as per Table 7-1, Table 7-2or Table 7-3
until central independently confirmed disease progression by [CONTACT_28843], withdrawal of 
consent by [CONTACT_426569] a parental/legal guardian to tumor status follow -
up, or lost to follow -up. 
Patient swho start a new anti-cancer therapy  prior to disease progression will continue tumor 
evaluations following the same above schedule until radiographic evidence of disease 
progression is centrally  confirmed .
Skin examinations should be performed at [ADDRESS_967471] dose of stud y 
treatment
or until thestart of anew anti-cancer therapy .Safety  assessments including physical exams and 
growth/developmental follow up will continue according to Table 7-1, Table 7-2or Table 7-[ADDRESS_967472] to 
follow -up, the patient /legal guardian withdraws consent or study  discontinuation . 
4.[ADDRESS_967473] withdrawn earl y. If 
the observed ORR assessed by [CONTACT_711271] ≤ 25%,there may bea 
consideration tostop the HGG cohort due to insufficient efficacy . 
The final decision on whether 
to stop the HGG cohort will also take intoaccount allavailable study information at the IA cut -
off including safet y data and allefficacy  endpoints .If enrollment into the HGG cohort is 
stopped early , patients on study continuing to derive benefit from dabrafenib plus trametinib 

[COMPANY_001] Confidential Page [ADDRESS_967474] received dabrafeni band trametinib may be assessed in 
a separate protocol.  
4.4 Early study  termination
The study  can be terminated at any  time for any  reason by  [CONTACT_5343]. Should this be necessary, 
the patient sshould be seen as soon as possible and the same assessments should be performed 
as described in Section 7.1.4 and Section 7.1.5 for a discontinued or withdrawn patient. The 
investigator may be informed of additional procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the patient’s interests. The investigator will 
be responsible for informing IRBs and/or ECs of the earl y termination of the trial.
If the study  is terminated early for any reason, patients continuing to derive benefit from 
dabrafenib plus trametinib treatment may be transferred to another stud y wh ere study drug will 
be provided. 
5 Population
5.1 Patient population
This study  will b e conducted in two cohorts :HGG and LGG pediatric patient cohorts . 
For the HGG cohort, the patient population is children and adolescent patients with BRAF V600 
mutation positive, refractory orrelapsed HGG tumors after having received at least one previous 
standard therap y.
For the LGG cohort, the patient population is children and adolescent patients with BRAF V600 
mutant LGG with progressive disease following surgical excision, or non-surgic al candidates 
with 
necessity  to begin first systemic treatment because of a risk of neurologi cal impairment 
with progression
Patients enrolled in this study  are not permitted to participate in additional parallel 
investigational drug or device studies. 

[COMPANY_001] Confidential Page [ADDRESS_967475] to meet all of the following criteria:
1.Male or female between ≥12 months and <[ADDRESS_967476] 10 k g at the time of enrollment.
2.For HGG cohort only: Relapsed, progressed, or failed to respond to frontline therap y. 
Frontline therap y is presumed to be optimal surgical approach (biops y or resection) with 
radiation and/or chemotherap y.
For LGG cohort only: Patients with progressive disease following surgical excision, or 
non-surgical candidates with necessity  to begin first sy stemic treatment because of a risk 
of neurologi cal impairment with progression. 
3.Locally  determined HGG or LGG as defined by  [CONTACT_711272], 
revised 2016 ( Appendix 4 ). For HGG cohort only: Locally confirmed histologic 
diagnosis of High Grade Glioma (Grade III or IV glioma ), including a naplastic 
pleomorphic xanthoastrocy toma ( aPXA) andanaplastic gangliogliomas .
For LGG cohort only : Locally  confirmed histologic diagnosis of Low Grade Glioma 
(Grade I or II)
4.Locally  determined and c entrally  confirmed m easurable disease with minimal bi -
perpendicular diameter t hat must be at least twice the imaging slice thickness to be used 
forefficacy  assessments . (Both local and c entrally  confirmed results must show 
measurable disease to meet eligibility )
5.BRAF V600 mutation- positive tumor asassessed locally ,or at a [COMPANY_001] designated 
central reference laboratory  if local BRAF V600 testing is unavailable .
6.Tumor tissue must be available and subsequently  provided to [COMPANY_001] for central 
confirmatory  testing of BRAF mutational status (HGG and LGG cohort) , and forHGG 
histopathology  (HGG cohort) .
7.Performance score of ≥50% according to the Karnofsky /Lansky  performance status scale.
8.Females of child -bearing potential must be willing to practice acceptable methods of birth 
control.  Additionally , females of childbe aring potential must have a negative serum 
pregnancy  test wi thin 28days prior to day  1.
9.Must have adequate bone marrow function per central or local lab in the absence of 
growth factor support and is defined as:
Absolute neutrophil count (ANC) ≥1000/µL ;
Platelets ≥75,000/µL  and transfusion independent, defined as not receiving platelet 
transfusions within a
7day period prior to meeting thisenrollment criteria . Note f or 
LGG patients only, platelets ≥ 100,000/ µLprior to Day  1 dosing.
Hemoglobin ≥8.0 g/dL (may  receive red blood cell transfusions)
10.Adequate renal function defined as:
Calculated eG FR (Schwartz formula ) or radioisotope GFR ≥90 mL/min/1.73 m2; or

[COMPANY_001] Confidential Page 63
Protocol Amended Version 05 Protocol No. CDRB436G2201
A serum creatinine within the testing lab reference range (for age/gender, if available)
11.Adequate li ver function defined as:
Total Bilirubin (sum of direct and indirect) ≤ 1.5 x upper limit of normal (ULN) for 
ageexcept for subjects with Gilbertsy ndrome who may  only be included if the total 
bilirubin is ≤3.[ADDRESS_967477] bilirubin ≤1.[ADDRESS_967478]
AST a nd ALT ≤ 2.[ADDRESS_967479]
12.Adequate cardiac function defined as:
LVEF greater than or equal to institutional LLN by [CONTACT_18585] (while not receiving 
medications for cardiac function)
Corrected QT (QTc F) interval ≤[ADDRESS_967480] dose of study  treatment . 
14.
Written informed consent/assent must be obtained prior to an y protocol specific screening 
procedures being performed.
5.[ADDRESS_967481] not meet anyof the following criteria:
1.Malignancy  OTHER than BRAF V600 mutant HGG or LGG .
2.Previous treatment with dabrafenib or another RAF inhibitor, trametinib or a nother MEK 
inhibitor , or ERK inhibitor .
3.HGG patien ts: Cancer therap y (chemotherap y with delay ed toxicity , immunotherap y, 
biologic therap y, vaccine therap y) or investigational drugs within [ADDRESS_967482] dose of study  treatment.  LGG patients: Any systemic anticancer therapy  
(chemotherap y, imm unotherap y, biologic therap y, or vaccine therap y)or investigational 
drugs prior to enrollment .
4.HGG patients: Radiotherapy  to CNS glioma lesions within [ADDRESS_967483] dose of 
study  treatment , unless there is clear evidence of radiologic progressio n outside of the 
field of radiation. LGG patients: Radiotherap y to CNS glioma lesions at any point prior to 
enrollment. 
5.History  of malignancy  with confirmed activating RAS mutation or with BRAF fusion such 
as BRF -KIAA1549 or with known diagnosis of NF1. N ote:Prospective RAS testing is not 
required. However, if the results of previous RAS testing are known, they  must be used in 
assessing eligibility . 
6.Current use of a prohibited medication or herbal preparation or requires any of these 
medications during t he study . See 
Section 6.4 for details. 
7.Unresolved toxicity  greater than NCI CTCAE v 4.03 grade 2 from previous anti- cancer 
therap y, including major surgery, except those that in the opi[INVESTIGATOR_711182] y/toxicity  profile of the study  treatment (e.g., 
alopecia and/or peripheral neuropath y related to platinum or vinca alkaloid based 
chemotherap y).
8.History  of allergic reactions attributed to compounds of similar chemical or biologic 
composition to dabrafenib , trametinib and their excipi[INVESTIGATOR_840]. For LGG patients only:history  

[COMPANY_001] Confidential Page 64
Protocol Amended Version 05 Protocol No. CDRB436G2201
of allergic reactions or contraindications to the use of carboplatin or vincristine (refer to 
local product label or SmPC). 
9. Autologous or allogeneic stem cell transplant within [ADDRESS_967484] dose of 
study  treatment [NOTE:  
patient s with evidence of active gra ft versus host disease are 
excluded regardless of elapsed time].
10.History  or current diagnosis of cardiac disease indicating significant risk of safet y for 
patients participating in the study  such as uncontrolled or significant cardiac disease, 
including an y of the following:
recent m yocardial infarction (within last 6 months), 
uncontrolled congestive heart failure, 
unstable angina (within last 6 months),
clinically  significant (symptomatic) or known, uncontrolled cardiac arrhy thmias (e.g., 
sustained ventr icular tachy cardia, and clinicall y significant second or third degree AV 
block without a pacemaker) except sinus arrhy thmia within the past [ADDRESS_967485] dose of study  treatment 
coronary  angioplasty  or stenting (within last 6 months)
intra-cardiac defibrillators
abnormal cardiac valve morphology  (≥grade 2) documented b y echocardiogram 
(patients with grade 1 abnormalities [i.e. mild regurgitation/stenosis] can be enrolled 
on study .  Patients with moderate valvular thickening should NOT be enr olled.
11.Uncontrolled medical conditions (e.g., diabetes mellitus, hy pertension, liver disease or 
uncontrolled infection), psy chological, familial, sociological, or geographical conditions 
that do not permit compliance with the protocol; or unwillingness or inability  to follow the 
procedures required in the protocol
12. Presence of active GI disease or other condition (e.g., small bowel or large bowel 
resection) that will interfere significantl ywith the absorption of drugs.
13.A history  of Hepatitis B Virus, or Hepatitis C Virus infection ( patie nts with laboratory  
evidence of cleared Hepatitis B Virus and/or Hepatitis C Virus may  be enrolled )
.
14.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant (e.g. are menstruating), unless they are using highl y effective methods 
of contraception during dosing of stud y treatment and for 16 weeks after stoppi[INVESTIGATOR_711183], 
and 2weeks after stoppi[INVESTIGATOR_711184] , whichever is longer . 
Effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
patient . Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post- ovulation 
methods) and withdrawal are not acceptable methods of contraception 
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total hy stere ctom y,or bilateral tubal ligation or tubal occlusion at least 
six weeks before taking study  treatment. In case of oophorectom y alone, only when 
the reproductive status of the woman has been confirmed by  [CONTACT_5347].

[COMPANY_001] Confidential Page 65
Protocol Amended Version 05 Protocol No. CDRB436G2201
Male sterilization (at least 6 months prior to screening). For female patient s on the 
study , the vasectomized male partner should be the sole partner for that patient.
Placement of a hormonal or non-hormonal intrauterine device (IUD) or intrauterine 
system (IUS) with a documented failure rate of less than 1% per y ear.
Note: Oral contraceptives are not permitted as a method of contraception due to potential drug-
drug interactions with dabrafenib
.  
15.Pregnant females as determined by  [CONTACT_483030] (hCG) test at 
screening or prior to dosing .
16.Lactating females who are activel y breast feeding .
17.Sexually  active males (including those that have had a vasectomy )unless they  use a 
condom during intercourse while on study  and for 16 weeks after stoppi[INVESTIGATOR_577461], and agree not to father a child during this period.
18.A history  or current evidence of retina vein occlusion (RVO) or central serous retinopathy .
6 Treatment
6.1 Stud y treatment
In this study , the term “study  treatment or drug” refers to [COMPANY_001] study  drugdabrafenib 
(DRB436) with trametinib (TMT212) or carboplatin and vincristine . 
Refer to Section [IP_ADDRESS] for dabrafenib (DRB436) and trametinib (TMT212) dosing instructions.
Refer to Section 6.1.[ADDRESS_967486] eCRF.
6.1.1 Dabrafenib and Trametinib Dosing regimen
Dabrafenib (DRB436) will be administered orally, twice daily  based on weight, age and the 
appropriate dose level. Trametinib (TMT212) will be administered orally , once daily  in 
combination with the first daily  doseof dabrafenib based on weight .A dosing nomogram based 
on weight and /orage will be used to prescribe dabrafenib (DRB436) and trametinib (TMT212)
to minimize inter-patient dosing variability . Dabrafenib is available as capsules and as 
dispersible tablets for oral suspension 
(Table 6-1, Table 6-2, Table 6-3and Table 6-4) and 
trametinib is available as tablets and as a powder in bottle for oral solution (Table 6 -
5, Table 6 -
6, Table 6-7 and Table 6 - 8).
Dabrafenib Dosing Tables 
Patients <12 y
ears old and ≥16 kg may  be administered either the dabrafenib capsules 
(Table 6 -1) or dabrafenib dispersible tablets for oral suspension ( Table 6-3 )
Patients ≥12 years old and ≥19 kg may  be administered either the dabrafenib capsules 
(Table 6 -2) or dabrafenib dispersible tablets for oral suspension ( Table 6-4 )
Patients <12 y ears old and <[ADDRESS_967487] be administered dabrafenib dispersible tablets for 
oral suspension ( Table 6 -3)

[COMPANY_001] Confidential Page 66
Protocol Amended Version 05 Protocol No. CDRB436G2201
Patients ≥12 years old and <[ADDRESS_967488] be administered dabrafenib dispersible tablets for 
oral suspension ( Table 6 -4)
Table 6
-1 Dose and treatment schedule for dabrafenib (DRB436) capsules for 
patients less than 12 years of age (5.25 mg/kg/day )
Table 6-2 Dose and treatment schedule for dabrafenib (DRB436) capsules for 
patients greater or equal 12 years of age (4.5 mg/kg/day )
Table 6-3 Dose and treatment schedule for dabrafenib (DRB436) dispersible 
tablet sfor patients less than 12 y ears of age (5.25mg/kg/day )Weight DoseFrequency  and/or 
Regimen Total Daily  DosePharmaceutical form and route of 
admi nistration
16-23.5 kg 50 mg b.i.d 100 mg Capsules for oral administration
23.6-33.5kg 75 mg b.i.d 150 mg Capsules for oral administration
33.6-42.5kg 100 mg b.i.d 200 mg Capsules for oral administration
42.6-52.5kg 125 mg b.i.d 250 mg Capsules for oral administration
≥52.6kg 150 mg b.i.d 300 mg Capsules for oral administration
Weight DoseFrequency  and/or 
RegimenTotal Daily  
DosePharmaceutical form and route of 
administration
19-27.5 kg 50 mg b.i.d 100 mg Capsules  for oral administration
27.6-38.5kg 75 mg b.i.d 150 mg Capsules  for oral administration
38.6-50.5kg 100 mg b.i.d 200 mg Capsules  for oral administration
50.6-61.5kg 125 mg b.i.d 250 mg Capsules  for oral administration
≥61.6kg 150 mg b.i.d 300 mg Capsules  for oral administration
Weight (kg) DoseFrequency  
and/or 
Regimen Total Daily  DosePharmaceutical form and route of 
administration
7-9.5 20 mg b.i.d 40 mg Dispersible tablet for oral suspension
9.6-13.5 30 mg b.i.d 60 mg Dispersible tablet for oral suspension
13.6-17.5 40 mg b.i.d 80 mg Dispersible tablet for oral suspension
17.6-20.5 50 mg b.i.d 100 mg Dispersible tablet for oral suspension
20.6-24.5 60 mg b.i.d 120 mg Dispersible tablet for oral suspension
24.6-28.5 70 mg b.i.d 140 mg Dispersible tablet for oral suspension
28.6-32.5 80 mg b.i.d 160 mg Dispersible tablet for oral suspension
32.6-36.5 90 mg b.i.d 180 mg Dispersible tablet for oral suspension
36.6-40.5 100 mg b.i.d. 200 mg Dispersible tablet for oral suspension
40.6-43.5 110 mg b.i.d 220 mg Dispersible tablet for oral suspension
43.6-47.5 120 mg b.i.d 240 mg Dispersible tablet for oral suspension
47.6-51.5 130 mg b.i.d 260 mg Dispersible tablet for oral suspension
51.6-55.5 140 mg b.i.d. 280 mg Dispersible tablet for oral suspension
≥55.6 kg 150 mg b.i.d 300 mg Dispersible tablet for oral suspension

[COMPANY_001] Confidential Page 67
Protocol Amended Version 05 Protocol No. CDRB436G2201
Table 6-4 Dose and treatment schedule for dabrafenib (DRB436) dispersible 
tablet for patients greater than or equal 12 y ears of age (4.5 
mg/kg/day )
Trametinib Dosing Tables
Patients <6 y ears old and <[ADDRESS_967489] be administered the trametinib oral soluti on (Table 
6-5)
Patients <6 y earsold and ≥26 kg may  be admin istered either the trametinib oral solution 
(Table 6
-5) or trametinib tablets ( Table 6-7 )
Patients ≥6 years old and ≥10 kg < [ADDRESS_967490] be administered the trametinib oral 
solution ( Table 6-6)
Patients ≥6 years old and ≥33 kg may  be administered either the trametinib oral solution 
(Table 6-6 ) or the trametinib tablets ( Table 6-8)
Table 6-5 Dose and treatment schedule for trametinib (TMT212) oral solution for 
patients less than 6 y ears old (0.032 mg/kg/day )Weight (kg) DoseFrequency  
and/or 
Regimen Total Daily  DosePharmaceutical form and route of 
administration
10-11.5 20 mg b.i.d 40 mg Dispersible tablet for oral suspension
11.6-17.5 30 mg b.i.d 60 mg Dispersible tablet for oral suspension
17.6-20.5 40mg b.i.d 80 mg Dispersible tablet for oral suspension
20.6-24.5 50 mg b.i.d 100  mg Dispersible tablet for oral suspension
24.6-28.5 60 mg b.i.d 120 mg Dispersible tablet for oral suspension
28.6-32.5 70 mg b.i.d 140 mg Dispersible tablet for oral suspension
32.6-36.5 80 mg b.i.d 160 mg Dispersible tablet for oral suspension
36.6-40.5 90 mg b.i.d 180 mg Dispersible tablet for oral suspension
40.6-43.5 100 mg b.i.d 200 mg Dispersible tablet for oral suspension
43.6-47.5 110  mg b.i.d 220 mg Dispersible tablet for oral suspension
47.6-51.5 120 mg b.i.d 240 mg Dispersible tablet for oral suspension
51.6-55.5 130 mg b.i.d 260 mg Dispersible tablet for oral suspension
55.6-64.5 140 mg b.i.d 280 mg Dispersible tablet for oral suspension
≥64.6 150 mg b.i.d 300 mg Dispersible tablet for oral suspension
Weight
(kg) DoseFrequency  and/or 
RegimenTotal Daily  
DosePharmaceutical form and route 
of administration
mL mg
7-9.9 5 0.25 q.d 0.25 Solution  for oral administration
10-12.5 7.5 0.375 q.d 0.375 Solution  for oral administration
12.6-16.5 10 0.5 q.d 0.5 Solution  for oral administration
16.6-24.5 12.5 0.625 q.d 0.625 Solution  for oral administration
24.6-35 17.5 0.875 q.d 0.875 Solution  for oral administration
35.1-45 25 1.25 q.d 1.25 Solution  for oral administration
45.1-55 30 1.5 q.d 1.5 Solution  for oral administration
≥55.1 40 2 q.d 2 Solution  for oral administration

[COMPANY_001] Confidential Page 68
Protocol Amended Version 05 Protocol No. CDRB436G2201
Table 6-6 Dose and treatment schedule for trametinib (TMT212) oral solution for 
patients greater or equal to 6 y ears old (0.025 mg/kg/day )
Table 6-7 Dose and treatment schedule for trametinib (TMT212) tablets for 
patients less than 6 y ears and weight greater or equal 26kg (0.032 
mg/kg/day )
Table 6-8 Dose and treatment schedule for trametinib (TMT212) tablets for
patients greater or equal to 6 and weight greater or equal 33kg (0.025 
mg/kg/day )
The investigator or responsible site personnel should instruct the patient and guardians to take 
the study  drug as per protocol (promote compliance).
If a patient’s weight changes by [CONTACT_711273] (or 10% if no 
institutional standard), the patient’s administered dose may be adjusted based on the current 
weight of the patient using protocol Table [ADDRESS_967491] ered, the protocol 
dosing Table 6-1through Table 6-8should be consulted to determine if a higher dose should 
be given.  Otherwise, it is optional to consider if a higher dose should be administered.
If the patient has decreased in weight, they  may  continue on th e current administered dose if it 
is tolerated. However, if the current administered dose is not tolerated, then the protocol dosing 
Table 6-1 through Table 6 -8should be consulted to determine if a lower dose should be given.  
Otherwise, it is optional to consider if a lower dose should be administered.Weight
(kg) DoseFrequency  and/or 
RegimenTotal Daily  
DosePharmaceutical form and route of 
administration
mL mg
10-12.5 5 0.25 q.d 0.25 Solution  for oral administration
12.6-16.5 7.5 0.375 q.d 0.375 Solution  for oral administration
16.6-24.5 10 0.5 q.d 0.5 Solution  for oral administration
24.6-35 15 0.75 q.d 0.75 Solution  for oral administration
35.1-45 20 1.0 q.d 1.0 Solution  for oral administration
45.1-55 25 1.25 q.d 1.25 Solution  for oral administration
55.1-68 30 1.5 q.d 1.5 Solution  for oral administration
68.1-72 35 1.75 q.d 1.75 Solution  for oral administration
>72 40 2 q.d 2 Solution  for oral administration
Weight DoseFrequency  
and/or RegimenTotal Daily  
DosePharmaceutical form and route of 
administration
26-39.5 2 X 0.5 mg q.d 1 mg Tablets  for oral administration
39.6-54.5 kg 3 X 0.5 mg q.d 1.5 mg Tablets  for oral administration
≥54.6 kg 1 X 2 mg q.d 2 mg Tablets  for oral administration
Weight DoseFrequency  
and/or RegimenTotal Daily  
DosePharmaceutical form and route of 
administration
33-49.5 kg 2 X 0.5 mg q.d 1 mg Tablets  for oral administration
49.6-69.5 kg 3 X 0.5 mg q.d 1.5 mg Tablets  for oral administration
≥69.6 kg 1 X 2 mg q.d 2 mg Tablets  for oral administration

[COMPANY_001] Confidential Page 69
Protocol Amended Version 05 Protocol No. CDRB436G2201
If a patient’s weight should fall below the lowest weight specified in Table 6-1through Table 
6-8, and per investigator the patient requires a lower administered dose (i.e., not tolerating 
current dose) then the dose specified in dose modification Table 6-12 through Table 6-15should 
be utilized.
[IP_ADDRESS] Dabrafenib (DRB436) and trametinib (TMT212) dosing
Study  medications should be taken as follows:
Dabrafenib will be administered twice daily  per the dosing regimen shown in Table 6-1 , 
Table 6-2, Table 6 -3and Table 6-4.
Trametinib will be administered once daily  per the dosing regimen shown in Table 6- 5, 
Table 6-6, Table 6 -7and Table 6-8.
Trametinib should be taken in combination with dabrafenib once daily , preferabl y in the 
morning. 
Dabrafenib capsules and trametinib tablets should be taken with approximately  120-240 
mL of water .
Trametinib pediatric oral solution formulation will be administered with a graduated 
syringe . Please refer t o the trametinib oral solution Instructions for Us e. 
Dabrafenib pediatric oral suspension formulation administration will be administered 
using dosing cup and/or graduated s yringe. Please refer to dabrafenib oral suspension 
Instructions for U se.
Refer to the dabrafenib and trametinib Instructions for Use documents if enteral feeding 
tubes are required for administering pediatric oral solutions . 
Patients less than [ADDRESS_967492] be administered the
dabrafenib dispersible tablets for oral suspension.
Patients equal to or gr eater than [ADDRESS_967493] be 
administered the dabrafenib dispersible tablets for oral suspension. 
Patients less than [ADDRESS_967494] be administered the 
trametinib oral solution.
Patients older than [ADDRESS_967495] 33 kg to be administered the trametinib 
tablets. 
Patients should be encouraged to take dabrafenib at approximately  12 hour intervals and at 
similar times each day .
Study  treatment should be administered under fasting conditions, at least 1 hour before or 
2 hours after a meal.
If it is not possible for a patient to tolerate the fasting conditions noted above, study  
treatment may  be administered with a small non-fat meal (e.g. small amount of apple 
juice/sauce, a pi[INVESTIGATOR_13959] o f dry  toast).  Patients and their guardians should be advised to avoid 
administering stud y drug with milk or high -fat, high -calorie foods.  
Patients who are being breastfed may  continue to be breastfed on demand. If the patient is 
breastfed during collection of PK samples the time of breastfeeding should be recorded as 
a meal . 

[COMPANY_001] Confidential Page 70
Protocol Amended Version 05 Protocol No. CDRB436G2201
If a patient vomits after taking study drug, the patient should be instructed not to retake the 
dose and wait for the next scheduled dose.  
If a patient misses a dabrafenib dose, t hey should be instructed not to double the next 
regularl y scheduled dose.  However, patients may take the missed dose immediately  if the 
next scheduled dose is at least 6 hours later. Patients may then take the next dose at the 
scheduled time. 
If a patient misses a trametinib dose, they  should be instructed not to double the next 
regularl y scheduled dose. However, patients may take the missed dose immediatel y if the 
next scheduled dose is at least 12 hours later. Patients may  then take the next dose at the
scheduled time.
The total daily  dose of dabrafenib will not exceed 300 mg (150 mg BID).
The total daily  dose of trametinib will not exceed 2 mg. 
[IP_ADDRESS] Additional dosing guidelines for pharmacokinetic sampling/chemistry  
panel collection
PK samples will be collected on all HGG patients and LGG patients randomized to receive 
dabrafenib with trametinib treatment. PK samples will not be collected from theLGG patients 
randomized to receive carboplatin with vincristine , even after crossover from carboplatin with
vincristine to dabrafenib plus trametinib. 
On day s with PK, the following additional guidelines must be followed:
On protocol visit dayswhen PK blood collection is scheduled at the clinic, patients must 
take study  treatment in the clinic under the supervision of the Investigator or designee.  On 
all other day s, patients may  take dabrafenib and trametinib at home.
Post-dose PK samples should be collected after dosing of the stud y treatment in the 
morning (AM). PK sample collection will be performed a ccording to Table 7 -5and Table 
7-6.
6.1.2 Carboplatin and Vincristine Dosing Regimen
Carboplatin and vincristine will be supplied locally  as commerciall y available and labelled 
accordingl y to comply  with legal requirements of each country . Carboplatin and vincristine will 
be administered as one course of induction ([ADDRESS_967496]), 
followed by [ADDRESS_967497] labels and institutional standards for duration of 
infusion and flush requirements when administering carboplatin and vincristine. 
Local safet y laboratory  testing to confirm hematologic parameters may be conducted per 
institutional practice during induction and maintenance phases of chemotherapy prior to dosing
when central labs are not scheduled per protocol or when central lab results will not be available 
prior to dosing . Results will be collected in the eCRF. 

[COMPANY_001] Confidential Page 71
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Induction Therapy
Prior to induction, central or local lab results must be assessed to confirm ANC ≥1000/ µL and 
platelet count ≥100,000/µL.
Induction will consist of 10 weeks of therapy  followed by 2 weeks without chemotherap y.  
Induction should only be interrupted in the event of grade 3 neurotoxicity , grade 2 
nephro toxicity , grade 4 hematologic toxicity , or disease progression. See Section [IP_ADDRESS] for 
dose modification guidelines. 
Carboplatin (CBDCA): 175 mg/m2 as weekly  IV infusion ove r 60 minutes on weeks 1 to 4, and 
onweeks 7 to 10 , on the same day  as VCR dosing
Vincristine (VCR): 1.5 mg/m2as weekl y IV bolus infusion (0.05 mg/kg if child is <12 kg) 
(maximum dose of 2.0 mg) for [ADDRESS_967498]
[IP_ADDRESS] Maintenance Therapy 
Following induction therapy  and two weeks of rest, maintenance therapy  should begin if 
periphera l counts recover to ANC ≥1,000/ µL and platelet count ≥100,000/ µL. Repeat blood 
counts every  [ADDRESS_967499]. Maintenance will continue for a total of 8 cycles. 
See Section [IP_ADDRESS] for dose modification guidelines. 
Carboplatin (CBDCA): 175 mg/m2 as weekl y IV infusion over 60 minutes onweeks 1 to 4of 
each cy cle.
Vincristine (VCR): 
1.5 mg/m2as weekl y IV bolus infusion (0.05 mg/kg if child is <12 kg) 
(maximum dose of 2.0 mg) on weeks [ADDRESS_967500]
6.1.3 Ancillary  treatments 
Not applicable

[COMPANY_001] Confidential Page 72
Protocol Amended Version 05 Protocol No. CDRB436G2201
6.1.4 Rescue medication 
Not applicable
6.1.5 Guidelines for continuation of treatment 
For guidelines for continuation of treatment, refer to Section 6.3.
6.1.6 Treatment duration
Dabrafenib with trametinib:
Patients will receive dabrafenib in combination with trametinib until disease progression or loss 
of clinical benefit as determined by [CONTACT_093] , death, unacceptable toxicity , withdrawal 
of consent or if the investigator judges that further therap y is no longer in the best interest of 
the patient, or earl y termination of the study b y the sponsor. 
Patients who have disease progression (as defined by [CONTACT_95733]) may continue on study  treatment 
if the investigator determines that the patient has clear evidence of clinical benefit 
from study 
treatment, continuing study  drug may be in the best interest for the patient, and the patient /legal 
guardian is willing to continue on study  drug and sign Informed Consent for treatment bey ond 
progression. If the patient is continuing on study treatment , then all study procedures including 
tumor assessments must be followed as scheduled (Table 7-1or Table 7-2). In addition, after 
each tumor assessment, the investigator must confirm and docume
nt in patient medical records 
and the eCRF that the patient is still benefitting from study  treatment and therefore can continue 
receiving stud y treatment. 
Carboplatin wi th vincristine for LGG Cohort only:
Duration of treatment should continue for the prescribed number of cy cles, as tolerated or until 
unacceptable toxicity , start of a new anti -neoplastic therap y, discontinuation at the discretion of 
the investigator or patient/legal guardian, lost to follow -up, death, study  is terminated by [CONTACT_711274]. 
Carboplatin should alway s be given in a setting with rapid access to pediatric advanced life-
supporting support capability . See Section [IP_ADDRESS].[ADDRESS_967501] ing management and dose reduction for adverse events that are 
considered by [CONTACT_711275] 6-11.These guidelines are intended primarily  for toxicities 
not easily  managed with routine supportive care. For example, alopecia is not an indication for 
dose modification, nor is grade 2 nausea and vomiting that can be easily managed with anti-
emetics. Refe r to Section [IP_ADDRESS] for general guidelines for dose modifications for carboplatin 
and vincristine.
Table 6-11 General g uidelines for dose modification for adverse events 
considered related to dabrafenib and trametinib combination 
treatment
GradeRecommended adverse event 
management guidelinesMandatory  dose modification 
requirements
Grade 1 or Grade 2 
tolerableMonitor closely.
Provide supportive care according 
to institutional standards.Continue dabrafenib and trametinib at 
the same dose level.
Grade 2 intolerable or
Grade 3Monitor closely.
Provide supportive care according 
to institutional standards.Interrupt dabrafenib and trametinib 
(except for cuSCC, keratoacanthoma, 
new primary melanoma, and basal cell 
carcinoma) .
-When toxicity resolves to ≤ Grade 
1 or baseline, restart dabrafenib 
and trametinib reduced by [CONTACT_23615].
If the Grade 2 (intolerable) or Grade 3 
toxicity recurs, interrupt dabrafenib 
and trametinib.
-When toxicity resolves to Grade 1 
or baseline, restart dabrafenib 
and trametinib reduced by 
[CONTACT_182466]. Re-escalation 
of the patient ’s dose is 
recommended if criteria in 
Section 6.3.1 are met.
Grade 4 Monitor closely.
Provide supportive care according 
to institutional standards.Interrupt dabrafenib and trametinib.
Restart with dabrafenib and trametinib 
reduced by [CONTACT_711276] ≤ Grade [ADDRESS_967502] preceding toxicit y 
using Common Terminology  Criteria for Adverse Events (CTCAE) Version v4.03.
If treatment related toxicities occur that are specific to combination treatment of dabrafenib and 
trametinib, then both treatments should be simultaneously  dose reduced, interrupted or 
discontinued with the exception shown below:
Exception where dose modifications are necessary  for only dabrafenib :
Uncomplicated pyrexia ( Table 6
-16 )
Uveitis ( Table 6-21)
Exception where dose modifications are necessary  for only trametinib :
Retinal vein occlusions (RVO) ( Table 6 -19) and retinal pi[INVESTIGATOR_6678] 
(RPED) 
Table 6-20 )
Left ventricular ejection fraction (LVEF) reduction ( Table 6-23 )
If the patient requires a dose interruption of > 28 days (greater than 6 weeks for uveitis, iritis, 
see Table 6-21) from the previous dose for persistent grade 2 or greater dabrafenib and/or 
trametinib treatment related toxicity , then the patient must be discontinued from study  treatment. 
Up to two dose reductions will be allowed.
Dose reductions will occur in increments of 50 mg from the total daily  dose for dabrafenib 
capsules and in increments of 0.5 mg from the total daily  dose for trametinib tablets
.If a patient 
is receiving trametinib 0.05 mg/mL  oral solution, dose modification guidelines in Table 6-[ADDRESS_967503] eCRF.
Table 6-12 Dose Modification for trametinib (TMT212) oral solution for pati ents 
greater or equal to 6 y ears old
Dose: 0.025 mg/kg/day
Dose Level 1: ~30% reduction
Dose Level 2: ~30% reductionWeight
(kg) DoseDose Reduction 
Level 1Dose reduction
Level 2
mL mg mL mg mL mg
10-12.5 5 0.25 3.5 0.175 2.5 0.1225
12.6-16.5 7.5 0.375 5 0.25 3.5 0.175
16.6-24.5 10 0.5 7 0.35 5 0.25
24.6-35 15 0.75 10 0.5 7 0.35
35.1-45 20 1.0 14 0.7 10 0.5
45.1-55 25 1.25 17.5 0.875 12 0.6
55.1-68 30 1.5 20 1 14 0.7
68.1-72 35 1.75 25 1.25 17.5 0.875
>72 40 2 28 1. 4 20 1

[COMPANY_001] Confidential Page 75
Protocol Amended Version 05 Protocol No. CDRB436G2201
Table 6-13 Dose Modification for trametinib (TMT212) for oral solution for 
patients less than 6 y ears old
Dose: 0.032 mg/kg/day
Dose Level 1: ~0.025 mg/kg/day
Dose Level 2: ~ 30% reduction
Table 6-14 Dose Modification for dabrafenib (DRB436) dispersible tablet for 
patients less than 12 years of age
Weight (kg) Dose (b.i.d)Dose Reduction Level 1
(b.i.d) Dose Reduction Level 2 (b.i.d)
7-9.5 20 mg 10 mg 0 mg
9.6-13.5 30 mg 20 mg 10 mg
13.6-17.5 40 mg 30 mg 20 mg
17.6-20.5 50 mg 40 mg 30 mg
20.6-24.5 60 mg 50 mg 40 mg
24.6-28.5 70 mg 60 mg 50 mg
28.6-32.5 80 mg 70 mg 60 mg
32.6-36.5 90 mg 80 mg 70 mg
36.6-40.5 100 mg 90 mg 80 mg
40.6-43.5 110 mg 100 mg 90 mg
43.6-47.5 120 mg 110  mg 100  mg
47.6-51.5 130 mg 120 mg 110 mg
51.6-55.5 140 mg 130 mg 120 mg
≥55.6 kg 150 mg 140 mg 130 mg
Dose: 5.25 mg/kg/day
Dose level 1: 4.5 mg/kg/day
Dose level 2: 3.75 mg/kg/day
Table 6-15 Dose Modification for dabrafenib (DRB436) dispersible table tfor 
patients greater or equal 12 y ears of ageWeight
(kg) DoseDose Reduction 
Level 1Dose reduction
Level 2
mL mg mL mg mL mg
7-9.9 5 0.25 3.5 0.175 2.5 0.1225
10-12.5 7.5 0.375 5 0.25 3.5 0.175
12.6-16.5 10 0.5 7.5 0.375 5 0.25
16.6-24.5 12.5 0.625 10 0.5 7 0.35
24.6-35 17.5 0.875 15 0.75 10 0.5
35.1-45 25 1.25 20 1 14 0.7
45.1-55 30 1.5 25 1.25 17.5 0.875
≥55.1 40 2 30 1.5 20 1
Weight Dose (b.i.d)Dose Reduction Level 1 
(b.i.d) Dose Reduction Level 2 (b.i.d)
10-11.5 20 mg 10 mg 0 mg
11.6-17.5 30 mg 20 mg 10 mg
17.6-20.5 40 mg 30 mg 20 mg
20.6-24.5 50 mg 40 mg 30mg

[COMPANY_001] Confidential Page 76
Protocol Amended Version 05 Protocol No. CDRB436G2201
If a patient’s dose of dabrafenib and trametinib has been reduced per the dose modification 
instructions, dose re-escalation may be considered provided the following criteria are met:
A period of [ADDRESS_967504] passed since restarting dosing at the lower dose 
level and treatment has been well tolerated
Patient is deriving clinical benefit
Dose re -escalation follows the same dosing steps as de- escalation , in increments of 50 mg 
from the total daily  dose for dabrafenib capsules and in increments of 0.5 mg from the total 
daily  dose for trametinib tablets. Patients receiving trametinib 0.05 mg/mL oral solution are to 
follow Table 6-[ADDRESS_967505] not exceed 150 mg twice daily  (300 mg total dail y dose). The trametinib 
dose must not exceed 2 mg once dail y. 
The following sections address the specific instructions for mandatory  dose modifications and 
recommended management for AEs considered suspected to be related to study  treatment. 
[IP_ADDRESS] Pyrexia
Epi[INVESTIGATOR_711185] s receiving dabrafenib 
monotherap yor in combination with trametinib. The pyrexia sy ndrome is defined as treatment -
related fever (≥38°C) or chills/rigors/night sweats or flu -like sy mptoms .In a minority  of cases 
pyrexia was accompa nied by [CONTACT_483020]/rigors, dehy dration, and 
hypotension, dizziness or weakness and required hospi[INVESTIGATOR_059]. The incidence and severit y of 
pyrexia syndrome are increased when dabrafenib is used in combination with trametinib 
compared to dabrafenib monotherap y. 
Patients and guardians must be instructed on the importance of immediately  reporting febrile 
epi[INVESTIGATOR_1841]. Dabrafenib and trametinib must be interrupted promptly and anti-pyretics
(acetominophen, ibuprofen, similar) started at the very first symptom of pyrexia or its associate d 
prodrome (chills or rigors or night sweats or flu
-like symptoms) .Adequate hydration status 
should be maintained.  Dabrafenib and trametinib should be restarted upon improvement of 
symptoms of at least 24 hours, and at the same dose .24.6-28.5 60 mg 50 mg 40 mg
28.6-32.5 70 mg 60 mg 50 mg
32.6-36.5 80 mg 70 mg 50 mg
36.6-40.5 90 mg 80 mg 60 mg
40.6-43.5 100 mg 90 mg 60 mg
43.6-47.5 110  mg 100 mg 70mg
47.6-51.5 120 mg 110 mg 80 mg
51.6-55.5 130 mg 120 mg 80 mg
55.6-64.5 140 mg 130 mg 100 mg
≥64.6 150 mg 140 mg 110 mg
Dose: 4.5 mg/kg/day
Dose level 1: 3.75 mg/kg/day
Dose level 2: 3.00 mg/kg/day

[COMPANY_001] Confidential Page 77
Protocol Amended Version 05 Protocol No. CDRB436G2201
In the event ofrecurring pyrexia events despi[INVESTIGATOR_711186],
the use of oral corticosteroids may be considered when restarting dabrafenib and trametinib. In 
patients experiencing p yrexia associated with rigors, severe chills, deh ydration or hypotension, 
serum creatinine increase and other evidence of renal function decrease should be monitored 
carefully  during and following severe events of pyrexia.
Pyrexia accompanied by [CONTACT_27913], dehydration requiring intravenous fluids, renal 
insufficiency  and/or severe (≥ Grade 3) rigors/chills in the absence of anobvious infectious 
cause are to be reported as a SAE.
Guidel ines for dose modification and management for pyrexia syndrome considered to be 
related to dabrafenib are provided in Table 6-16
.
Table 6-16 Mandatory  dose modification and recommend ed clinical management 
for py rexia syndrome suspected to be related to dabrafenib and/or 
trametinib treatment
Pyrexia
Occurrence Recommended adverse event management
guidelinesMandatory  dose modification 
requirements
1stoccurrence and 
subsequent 
occurrencesRe-educate patient /family about pyrexia 
syndrome and immediately interrupt 
dabrafenib and trametinib at the very first 
symptom of pyrexia or its associated 
prodrome (chills or rigors or night sweats 
or flu -like symptoms).
Clinical evaluation for infection and 
hypersensitivitya
Laboratory work -upa
Administer anti -pyretic treatment with non -
steroidal anti -inflam matory drugs (NSAID) 
and/or paracetamolb
Oral hydration should be encouraged in 
patients without evidence of dehydration .  
Intravenous hydration is recommended in 
patients exp eriencing pyrexia complicated 
by [CONTACT_114475]/hypotension.
For recurring pyrexia events despi[INVESTIGATOR_711187] -pyretics and dose interruption, 
consider oral corticosteroids (i.e. 
prednisone 10mg or pediatric equivalent , 
or more ) for at least 5 days or as clinically 
indicated.  
Optimize oral corticosteroid dose as 
clinically indicated for recalcitrant pyrexiaDabrafenib and trametinib must 
be interrupted promptly at the 
very first symptom of pyrexia or its 
associated prodrome (chills, 
rigors, night sweats or flu -like 
symptoms )Adequate hydration 
status should be maintained.  
Dabrafenib and trametinib should 
be restarted upon improvement of 
symptoms of at least 24 hours , at 
the same dose
If pyrexia cannot be managed 
with interruption, dose reduction 
must be considered if clinically 
indicated.
a.For patients experiencing pyrexia, a clinical evaluation and laborato ry work -up is mandatory for each 
event; t horough clinical examination for signs and symptoms of infection or hypersensitivity is required; 
laboratory work -up should include full -blood -count, electrolytes, creatinine, blood urea nitrogen (BUN), C -
reactive p rotein (CRP), liver transaminases , blood culture, and urine culture.
b.Anti-pyretic treatment should be started immediately at the first occurrence and prophylactic anti -pyretic 
treatment is recommended. Anti -pyretic treatment may include acetaminophen, ibuprofen, or suitable anti -
pyretic medication according to institutional standards. Prophylactic anti -pyretic treatment is recommended 
to be discontinued after three days in the absence of pyrexia.

[COMPANY_001] Confidential Page 78
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Renal Insufficiency
Cases of renal insufficiency  have occurred in adult patients receiving dabrafenib and the 
combination of dabrafenib and trametinib. Prior to start of study  treatment, concomitant 
medications must be reviewed for the potential risk of inducing nephrotoxicity  and concomitant 
medications may be modified if clinically  possible. 
Guidelines regarding management and dose reduction for renal insufficiency  considered to be 
related to stud y treatment by [CONTACT_711277] 6
-17 .
Table 6-17 Mandatory  dosemodifications and recommended clinical 
management guidelines for renal function alterations
NCI-CTCAE v4.03
Grade Recommended adverse event 
management guidelinesMandatory  dose modification 
requirements
Grade 1 (Creatinine > ULN to 
≤ 1.5× ULN)Monitor creatinine weekly
If creatinine return to baseline 
resume routine creatinine 
monitoring per protocol
Promote hydration and cessation 
of nephrotoxic drugs.Continue dabrafenib and 
trametinib at the same dose.
Grade 2 (Creatinine > 1.5× to 
≤ 3× ULNMonitor creatinine every 2 to 3 
days
Consult with specialist and 
consider renal biopsy 
Promote hydration and cessation 
of nephrotoxic drugs.1stoccurrence
Interrupt dabrafenib and 
trametinib until ≤ Grade 1 or 
basel ine and then reinstate 
dabrafenib and trametinib at the 
same dose.
2ndoccurrence:
Interrupt dabrafenib and 
trametinib until ≤ Grade 1 or 
baseline. Once recovered, reduce 
dabrafenib and trame tinib to the 
next dose level. Re-escalation of 
the patient ’s dose is 
recommended if criteria in Section 
6.3.1 are met.
3rdoccurrence:
Interrupt dabrafenib and 
trametinib until ≤ Grade 1 or 
baseline. Once recovered, reduce 
dabrafenib and trametinib to the 
next dose le vel.Re-escalation of 
the patient ’s dose is 
recommended if criteria in Section 
6.3.1 are met.
4thoccurrence
Permanently discontinue 
dabrafenib and trametinib.
Grade 3 (Creatinine > 3.0 to < 
6×ULN)Monitor creatinine every 1 to 2 
days.
Consult with nephrologist. 
Promote hydration and cessation 
of nephrotoxic drugs.1stoccurrence:
Interrupt dabrafenib and 
trametinib until ≤ Grade 1 or 
baseline and then reduce 
dabrafenib and trametinib to the 
next lo wer. Re -escalation of the 

[COMPANY_001] Confidential Page 79
Protocol Amended Version 05 Protocol No. CDRB436G2201
NCI-CTCAE v4.03
Grade Recommended adverse event 
management guidelinesMandatory  dose modification 
requirements
patient ’s dose is recommended if 
criteria in Section 6.3.1 are met.
2ndoccurrence:
Interrupt dabrafenib and 
trametinib until ≤ Grade [ADDRESS_967506]’s dose is 
recommended if criteria in Section 
6.3.1 are met.
3rdoccurrence:
Interrupt dabrafenib and 
trametinib until ≤ Grade 1 or 
baseli ne and then reduce 
dabrafenib and trametinib to the 
next lower dose , if available as 
dose level -2.If already at dose 
level -2 at time of occurrence, 
permanently discontinue 
dabrafenib and trametinib. Re-
escalation of the patient ’s dose is 
recommended if criteria in Section 
6.3.1 are met.
4thoccurrence:
Permanently discontinue 
dabrafenib and trametinib.
Grade 4: Creatinine > 6× ULN Monitor creatinine daily.
Consult with specialist and 
recommend renal biopsy. 
Promote hydration and cessation 
of nephrotoxic drugs.Permanently discontinue 
dabrafenib and trametinib.
[IP_ADDRESS] Pneumonitis
Pneumonitis has been observed in patients receiving trametinib in combination with dabrafenib. 
Guidelines for dose modification and management of pneumonitis considered to be related to 
study  treatment by  [CONTACT_301178] 6-18.

[COMPANY_001] Confidential Page 80
Protocol Amended Version 05 Protocol No. CDRB436G2201
Table 6-18 Mandatory  dose modifications and recommended clinical 
management guid elines for pneumonitis
Pneumonitis (NCI-CTCAE v4.03)
Grade Recommended adverse event 
management guidelinesMandatory  dose modification 
requirements
Grade 1: Radiographic 
changes only -
AsymptomaticCT scan (high -resolution with 
lung windows) recommended, 
with serial imaging to monitor for 
resolution or progression -re-
image at least every 3 weeks
Monitor for symptoms every 2 -3 
days -Clinical evaluation and 
laboratory work -up for infection
Monitoring of oxygenation via 
pulse oximetry recommended
Consultation of pulmonologist 
recommended.Continue dabrafenib and trametinib 
at the same dose.
Grade 2 : Symptomatic
medical intervention 
indicated; limits 
instrumental Activities of 
Daily Living ( ADLs )CT scan (high -resolution with 
lung windows)
Monitor symptoms daily, 
consider hospi[INVESTIGATOR_059]
Clinical evaluation and 
laboratory work up for infection
Consult pulmonologist
Pulmonary function tests if 
normal at baseline, repeat every 
8 weeks
Bronchoscopy with biopsy 
and/or bronchoscopic alveolar 
lavage ( BAL)recommended
Symptomatic therapy including 
corticosteroids if clinically 
indicated (systemic 
corticosteroids at a dose of 1 to 
2 mg/kg/day prednisone or 
equivalent as clinically 
indicated).1stoccurrence:
Interrupt trametinib until recovery to 
≤ Grade 1 or baseline. Dabrafenib 
may continue at the same dose.
Once recovered, reduce 
trametinib to the next lower 
dose. Re-escalation of the 
patient ’s dose is recommended 
if criteria in Section 6.3.1 are 
met.
If no recovery to ≤ Grade 1 
within 4 weeks, permanently 
discontinue trametinib. 
Dabrafenib may continue.
If worsens treat as Grade 3 or 
4.
Grade 3: Severe 
symptoms; limits self -care 
ADLs; oxygen indicatedCT scan (high -resolution with 
lung windows)
Clinical evaluation and 
laboratory work -up for infection
Consult pulmonologist
Pulmonary function tests -if < 
normal, repeat every 8 weeks 
until ≥ normal
Bronchoscopy with biopsy 
and/or BAL if possible
Treat with intravenous steroids 
(methylprednisolone 125 mg or 
equivalent ) as indicated. W hen 
symptoms improve to ≤ Grade 
1, a high dos e oral steroid 
(prednisone 1 to 2 mg/kg /day or 
dexamethasone 4 mg every 4 
hours or equivalent ).Interrupt trametinib until recovery to 
Grade ≤1 or baseline. Dabrafenib 
may continue.
Once recovered, trametinib 
may be re started at the next 
lower dose .Re-escalation of 
the patient ’s dose is 
recommended if criteria in 
Section 6.3.1 are met.
If no recovery to Grade ≤ 1 or 
baseline within 4 weeks, 
permanently discontinue 
trametinib. Dabrafenib may 
continue.

[COMPANY_001] Confidential Page 81
Protocol Amended Version 05 Protocol No. CDRB436G2201
Pneumonitis (NCI-CTCAE v4.03)
Grade Recommended adverse event 
management guidelinesMandatory  dose modification 
requirements
If IV steroids followed by [CONTACT_711278] 
48 to 72 hours, consider non -
corticosteroid 
immunosuppressive medicat ion 
Grade 4: Life -threatening 
respi[INVESTIGATOR_7798]Same as Grade 3 Same as Grade 3
[IP_ADDRESS] Dose modification and management guideline for visual changes
suspected to be related to dabrafenib and/or trametinib treatment
Epi[INVESTIGATOR_711188] s receiving trametinib, dabrafenib, and 
combination therap y. An ophthalmologi st is tobe consulted if changes in vision develop.  
However, if the visual changes are clearl y unrelated to study  treatment (e.g., allergic 
conjunctivitis), then monitor closely  as it may  be reasonable to defer ophthalmic examination.
Special attention should be given to retinal findings (e.g., retinal pi[INVESTIGATOR_6678] 
(RPED) or retinovascular abnormalities (i.e., branch or central retinal vein occlusions (RVO). 
Treatment emergent cases of RVO and RPED are to be reported as SAEs. 
Guidelines for dose modifications and management for visual changes and/or ophthalmic 
examination findings considered to be related to study  treatment are provided in Table 6-19 and
Table 6
-20.
Treatment with dabrafenib has been associated with the development of uveitis, including iritis.  
Monitor patients for visual signs and symptoms (such as, change in vision, photophobia and 
eye pain) during therapy . Guideline s for dose modifications and management for uveitis, 
including iritis considered to be related to stud y treatment are provided in Table 6-21.
Table 6-19 Mandatory  dose modification and recommended clinical management 
for visual changes and/or ophthalmic examination findings suspected 
to be related to trametinib treatment 
Visual changes (Ey e disorders – Other, CTCAE Version 4.03, retinal, and similar )
Grade Recommended a dverse event 
management guidelinesMandatory  dose modification requirements
Grade 1
If visual changes 
are clearly 
unrelated to study 
treatment (e.g. 
allergic 
conjunctivitis), 
monitor closely but 
ophthalmic 
examination is not 
required Initiate local therapy and c onsult 
ophthalmologist within 7 days of 
onset.Ifdilated fundus examination cannot be 
performed within [ADDRESS_967507]/ ophthalmologist. 
Continue dabrafenib .
If RPED and RVO excluded, continue (or restart) 
trametinib at same d ose level
If RPED suspected or diagnosed: see RPED 
dose modification Table 6 -20; report as SAE 
if diagnosed.
If RVO diagnosed: Permanently discontinue 
trametinib and report as SAE.

[COMPANY_001] Confidential Page 82
Protocol Amended Version 05 Protocol No. CDRB436G2201
Visual changes (Ey e disorders – Other, CTCAE Version 4.03, retinal, and similar )
Grade Recommended a dverse event 
management guidelinesMandatory  dose modification requirements
Grade 2 and Grade 
3Initiate local therapy and consult 
ophthalmologist immediatelyInterrupt trametinib. Dabrafenib may be continued 
at the current dose.
If RPED and RVO excluded, restart trametinib 
at same dose level. 
If RPED diagnosed, see RPED dose 
modification in Table 6 -20; report as SAE.
If RVO diagnosed: Permanently discontinue 
trametinib and report as SAE .
Grade 4 Initiate local therapy and consult 
ophthalmologist immediatelyInterrupt trametinib. Dabrafenib may be 
continued at the same dose .
If RPED and RVO excluded ,consider 
restart ingtrametinib at the same or reduced 
dose level. 
If RVO diagnosed, permanently  
discontinue trametinib and report as SAE.
Table 6-20 Mandatory  dose modification and r ecommended clinical management 
for retinal pi[INVESTIGATOR_70341] (RPED) suspected to be 
related to trametinib treatment
Retinal pi[INVESTIGATOR_70341] (RPED)
Grade Recommended adverse event 
management guidelinesMandatory  dose modification 
requirements
Grade 1 (Asymptomatic; 
clinical or diagnostic 
observations only)If RPED worsens follow 
instructions below.Continue treatment with retinal 
evaluation monthly until 
resolution.
Grade 2 -3 RPED 
(Symptomatic with mild to 
moderate decrease in 
visual acuity).Retinal evaluation monthly. Interrupt trametinib.
If improved to ≤ Grade 1, restart 
trametinib at a lower dose.
Table 6-[ADDRESS_967508] immediatelyContinue dabrafenib and trametinib
If no response to local treatment within 7 days, 
interrupt dabrafenib.  Once uveitis resolves, 
restart dabrafenib
Continue trametinib
Grade [ADDRESS_967509] immediately Interrupt dabrafenib
If ≥ grade 2 uveitis (including iritis and iridocylitis)
lasts >6 weeks on local treatment and 
dabrafenib has not been restarted, permanently 
discontinue dabrafenib
Continue trametinib 

[COMPANY_001] Confidential Page 83
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Dose modification and management guideline for new malignancies
suspected to be related to dabrafenib and/or trametinib treatment
New Malignancies: Cutaneous and Non -cutaneous
[IP_ADDRESS].1 Cutaneous malignancies
Cutaneous squamous cell carcinoma (CuSCC), keratoacanthomas (KA) and new primary 
melanomas have been observed in patient s treated with dabrafenib and dabrafenib/trametinib 
combination therap y. These treatment -related lesions should be surgically  removed according 
to institutional practices. Dose modification or interruption of study  treatment is not required 
for cuSCC, KA, or new primary  melanoma, however cuSCC and new primary  melanoma are 
to be reported as a SAE. In addition, a biops y of the lesion should be taken, where possible, and 
submitted for further analy ses and a summary  of the results submitted to [COMPANY_001]. Patients 
should be instructed to immediately  inform their physician if new lesions develop. Skin 
examination sare tobe performed prior to initiation of study  treatment and throughout therap y 
as detailed inthe Visit Evaluation Schedule (Table 7-1, Table 7-2for LGG crossover patients
or Table 7-3) .Monitoring will occur at 3 and6 months following discontinuation of study 
treatment or until initiation of another anti-neoplastic therapy . Monitoring of the skin can be 
performed by a qualified local physician at the discretion of the investigator during non-clinic 
visits. If possible, the same local phy sician should perform each exam throughout the study  to 
ensure consistency  between evaluations. 
[IP_ADDRESS].[ADDRESS_967510] 
been seen with BRAF inhibitors.  Consider the benefits and risks 
before continuing treatment with dabrafenib in patients with a non-cutaneous malignancy  that 
has a RAS mutation. No dose modification of trametinib is required when taken in combination 
with dabrafenib.
New non -cutaneous malignancies are to be reported as a SAE. A biopsy  of the new malignancy 
should be taken, where possible, and submitted for further analysesincluding RAS mutation 
status with the results provided to [COMPANY_001].  
 
 
Patients 
should be monitored for secondary  malignancy  as clinicall y appropriate. This may 
include review of signs and symptoms and physical exam.  If there is clinical concern or 
possible incre ased risk for the development of an occult secondary  malignancy , additional 
imaging such as whole- body  MRI may be appropriate. Following discontinuation of dabrafenib , 
monitoring for non-cutaneous secondary /recurrent malignancies should continue for up to 6 
months or until initiation of another anti -neoplastic therap y.

[COMPANY_001] Confidential Page 84
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Dose modification and management guideline for hy perglycemia
Hypergl ycemia requiring an increase in the dose of, or initiation of insulin or oral therapy  can 
occur with dabrafenib. Monitor se rum glucose levels as clinically appropriate during treatment 
with dabrafenib in patients with pre- existing diabetes or hy pergl ycemia.
Advise patient s to report symptoms of severe hypergly cemia such as excessive thirst or any 
increase in the volume or freq uency  of urination.
[IP_ADDRESS] Guidelines for prolonged QTc
Guidelines for dose modification and stoppi[INVESTIGATOR_711189]-prolongation are provided in 
Table 6-22.
If ECG results demonstrate a prolonged QT interval (QTcF ≥501 msec) , obtain two or more 
additional ECGs over a brief period, and then use the average QTc values of the three ECGs to 
determine if study  treatment should be interrupted or discontinued. If the QTc prolongation 
resolves to Grade [ADDRESS_967511] be 
documented b y the investigator in the patient’s medical record.
Table 6
-22 Withholding and Stoppi[INVESTIGATOR_482935] -Prolongation
QTc Prolongation Action and Dose Modifications
QTcF ≥501 msec
Based on average QTc value of 
triplicate ECGsAsses s the quality of the ECG recording and the QT value and repeat 
if needed
Interrupt dabrafenib and trametinib (study treatments) until QTcF 
prolongation resolves to Grade 1 or baseline
Test serum potassium, calcium, phosphorus and magnesium. If 
abnormal, correct per routine clinical practice to within normal limits.
Review concomitant medication associated with QT prolongation, 
including drugs with a “known”, “possible” or “conditional risk of 
Torsade de pointes” and drugs with the potential to increase th e risk of 
study drug exposure related to QT prolongation
If event resolves to grade 1 or baseline, patient may restart study 
treatments at current dose level if patient may benefit from further 
treatment 
If event does not resolve within [ADDRESS_967512].
If event recurs, permanently discontinue study treatment s.  Consider 
evaluation with cardiologist.
Abbreviations:  ECG = electrocardiogram; msec = milliseconds; QTcF = QT du ration corrected for heart rate by 
[CONTACT_711279].
[IP_ADDRESS] Left Ventricular Ejection Fraction Stoppi[INVESTIGATOR_711190]-ventricular -ejection -fraction (LVEF) have been observed in patient s
receiving trametinib monotherap y and in combination with dabrafenib. Therefore, ECHOs must 
be performed to assess cardiac ejection fraction in regular intervals asoutlined inthe Visit 
Evaluation Schedule (Table 7-1, Table 7-2for LGG crossover patients , Table 7-3). Dose 
modification guidance andstoppi[INVESTIGATOR_711191] 6-23. 
ECHO to be performed at baseline and at follow up visit(s).

[COMPANY_001] Confidential Page 85
Protocol Amended Version 05 Protocol No. CDRB436G2201
Table 6-23 Mandatory  dose modification and recommended clinical management 
forLVEF suspected to be related to dabrafenib and/or trametinib 
treatment
Left Ventricular Ejection Fraction decrease (NCI-CTCAE v4.03)
LVEF -drop (% ) &
clinical sy mptomsRecommended adverse event 
management guidelinesMandatory  dose modification 
requirements
Asymptomatic:
Absolute decrease of >10% in 
LVEF compared to baseline 
andejection fraction below 
the institution’s LLNClosely monitoring LVEF via 
ECHO, repeat ECHO within 2 
weeks*.
If the LVEF recovers within 4 
weeks (defined as LVEF ≥LLN 
andabsolute decrease ≤10% 
compared to baseline)
Repeat ECHO 2, 4, 8 and 12 
weeks after re -start; continue 
in intervals of 12 weeks 
thereafter.
If repeat LVEF does not recover 
within 4 weeks.
Consult with cardiologist
Repeat ECHO after 2, 4, 8, 
12, and 16 weeks or until 
resolutionRepo rt as SAE.
Interrupt trametinib.
If the LVEF recovers, restart 
trametinib reduced by [CONTACT_711280].
More than two occurrence, 
permanently discontinue 
trametinib.
Permanently discontinue 
trametinib if repeat LVEF does 
not recover within 4 weeks.
Symptomatic:
Resting LVEF 39 -20%
or >20% absolute reduction 
from baseline
resting LVEF <20%Consult with cardiologist.
Repeat ECHO after 2, 4, 8, 12, 
and 16 weeks or until resolution.Report as SAE.
Permanently discontinue 
trametinib.
Interrupt dabrafenib
Restart dabrafenib if LVEF 
recovers including resolution of 
symptoms.
* If ECHO does not show LVEF recovery after 2 weeks, repeat ECHO 2 weeks later.
[IP_ADDRESS] Cardiac valvular toxicity  stoppi[INVESTIGATOR_602471] 2:Patients who have an asymptomatic, moderate regurgitation or stenosis by [CONTACT_18585] 
(Grade 2 mitral/tricuspid/aortic valvular toxicity ) should temporarily  discontinue dabrafenib 
and trametinib and have a repeat evaluation by [CONTACT_301174] 1 week. ECHO should be repeated 
every  1-2 weeks for 4 weeks or until valve recovery  to baseline.
If the valve recovers to baseline an y time during the next 4 weeks, the 
patient may be 
restarted at a reduced dose(s). For such patients, monitoring of the valve via ECHO will 
then be performed 2 and 4 weeks after re- challenge, and every  4 weeks thereafter for 12 
weeks and then per protocol.
If repeat ECHO does not reveal valve recovery  to baseline within 4 weeks, then the patient 
should permanentl y discontinue dabrafenib and trametini b.  The valve should continue to 
be monitored via ECHO every  4 weeks for 16 weeks or until resolution.
Grade 3: Patients with a Grade 3 valvular toxicity (symptomatic, severe regurgitation/stenosis 
by [CONTACT_9661], with symptoms controlled by [CONTACT_711281]) must discontinue dabrafenib
and trametinib . Valvular toxicity  should continue to be monitored every  4 weeks for 16weeks 
or until resolution. If recovery  occurs (return to baseline via imaging AND symptom resolution) 
within 4 weeks and the patient is receiving unequivocal clinical benefit from the study  treatment 

[COMPANY_001] Confidential Page 86
Protocol Amended Version 05 Protocol No. CDRB436G2201
as per documented investigator assessment , the patient may restart dabrafenib and trametinib at 
a reduced dose.
Grade 4:Patients with a Grade 4 valvular toxicity  [life-threatening consequences; urgent 
intervention indicated (e.g., valve replacement, valvuloplasty )
]must permanently discontinue
dabrafenib and trametinib .
[IP_ADDRESS] Dose modification and management guideline for skin rash
Guidelines for dose modification and management of skin rash considered to be related to study 
treatment b y the investigator are provided in Table 6 -
24.
Table 6
-24 Mandatory  dose modifications and recommended clinical 
management guidelines for rash
Rash Events (NCI -CTCAE v4.03)
Grade Recommended adverse event 
management guidelinesMandatory  dose modification 
requirements
Grade 1: Rash covering < 
10% body surface areaInitiate prophylactic and symptomatic 
treatment measures.
Consider use of topi[INVESTIGATOR_711192] 
(hydrocortisone 2.5% cream or 
fluticasone propi[INVESTIGATOR_16847] 0.5% cream)
Reassess after 2 weeksContinue dabrafenib and 
trametinib at the same dose.
Grade 2: 10 -30% of body 
surface areaIf tolerable, as per Grade 1
If intolerable, initiate systemic steroids 
(0.5 to 1 mg/k g/day prednisone or 
equivalents)
If symptoms persist or recur consider 
skin biopsy.If tolerable, continue 
dabrafenib and trametinib at 
the same dose.
If intolerable:
1stoccurrence
Interrupt dabrafenib and 
trametinib until ≤ Grade 1, and 
reduce dabrafenib and 
trametinib to the next dose 
level. Re-escalation of the 
patient ’s dose is 
recommended if criteria in
Section 6.3.1 are met.
Grade 3: More than 30% of 
body surface areaObtain a skin biopsy and dermatology 
consult.
Initiate therapy with high dose steroid s 
(1 to 2 mg/kg/d ayprednisone or 
equivalents)1stoccurrence
Interrupt dabrafenib and 
trametinib until ≤ Grade 1, and 
reduce dabrafenib and 
trametinib to the next dose 
level. Re -escalation of the 
patient ’s dose is 
recommended if criteria in
Section 6.3.1 are met.
2ndoccurrence
Interrupt dabrafenib and 
trametinib until ≤ Grade 1 or 
baseline. Once recovered, 
reduce dabrafenib and 
trametinib to the next dose 
level. Re-escalation of the 

[COMPANY_001] Confidential Page 87
Protocol Amended Version 05 Protocol No. CDRB436G2201
Rash Events (NCI -CTCAE v4.03)
Grade Recommended adverse event 
management guidelinesMandatory  dose modification 
requirements
patient ’s dose is 
recommended if criteria in 
Section 6.3.1 are met.
3rdoccurrence
Interrupt dabrafenib and 
trametinib until ≤ Grade 1 or 
baseline. Once recovered, 
reduce dabrafenib and 
trametinib to the next d ose 
level, if available as dose level 
-2. If already at dose level -2 at 
time of occurrence, 
permanently discontinue 
dabrafenib and trametinib . Re-
escalation of the patient ’s dose 
is recommended if criteria in 
Section 6.3.1 are met.
4thoccurrence
Permanently discontinue 
dabrafenib and trametinib.
Grade 4: Life -threatening Same as Grade 3 Permanently discontinue 
dabrafenib and trametinib.
[IP_ADDRESS] Management of Severe cutaneous adverse reactions (SCA R)
Cases of severe cutaneous adverse reactions (SCARs), including Stevens -Johnson syndrome, 
and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-
threatening or fatal, have been reported during treatment with dabrafenib in combination with 
trametinib. Before initiating treatment, patients should be advised of the signs and symptoms 
and monitored closel y for skin reactions. If signs and symptoms suggestive of SCARs appear, 
dabrafenib and trametinib should be permanentl y discontinued..
[IP_ADDRESS] Mana gement Guidelines for A dditional A Es
Palmar Plantar Ery throd ysesthesia (PPES) – Measures for PPES should include:
Lifesty le modification:  avoidance of hot water, traumatic activity , constrictive 
footwear, or excessive friction on the skin and the use of t hick cotton socks and 
gloves, and shoes with padded insoles
Symptomatic treatments:  apply  moisturizing creams frequentl y, topi[INVESTIGATOR_477365] 
(e.g. urea 20- 40 % cream, salicy lic acid 6%, tazarotene 0.1% cream, fluorouracil 5% 
cream), clobetasol propi[INVESTIGATOR_16865] e 0.05% ointment for erythematous areas, topi[INVESTIGATOR_558825] 2%, and / or systemic pain medication such as nonsteroidal anti -
inflammatory  drugs, codeine, and pregabalin for pain.
Dose modification may  also be required (refer to Table 6-9)
Pancreatitis – In the event of abdominal pain or suspected pancreatitis, amylase and 
lipase laboratory  samples should be collected for confirmation of the diagnosis. If 
pancreatitis is suspected, dabrafenib should be held until recovery .  Trametinib dosing 

[COMPANY_001] Confidential Page 88
Protocol Amended Version 05 Protocol No. CDRB436G2201
may continue.  Patients should be closely  monitored when re -starting dabrafenib after an 
epi[INVESTIGATOR_28547]
[IP_ADDRESS] Dose modification and management guideline for hy pertension
suspected to be related to dabrafenib and/or tra metinib treatment
Increases in blood pressu re have been observed in patient s receiving trametinib. For adequate 
monitoring and management of hypertension, all blood pressure assessments should be 
performed under the following optimal conditions:
the patient has been seated with back support, ensuring that legs are uncrossed and flat on 
the floor
the patient is relaxed comfortably  for at least 5 minutes
restrictive clothing has been removed from the cuff area and the right cuff size has been 
selected
the patient ’s arm is supported so that the middle of the cuff is at heart level
the patient remains quiet during the measurement.
In patien ts with an initial blood pressure reading within the hypertensive range, a second reading 
should be taken at least 1 minu te later, with the 2 readings averaged to obtain a final blood 
pressure measurement. The averaged value should be recorded in the eCRF.
Persistent hypertension is defined as an increase of systolic or diastolic blood pressure (SBP , 
DBP ) > 95th percentile for agein three consecutive visits with blood pressure assessments from 
two readings collected as described above. Visits to monitor increased blood pressure can be 
scheduled independentl y from the protocol visits outlined in Table 7-1, Table 7-2for LGG 
crossover patients or Table 7-3. Ideally , subsequent blood pressure assessments should be 
performe d within one week.
Asymptomatic hypertension 
is defined as an increase of SBP or DBP >95thpercentile in the 
absence of headache, light-headedness, vertigo, tinnitus, epi[INVESTIGATOR_711193] h ypertension.
For patients experienc ing an increase in systolic and/or diastolic blood pressure that is persistent 
and may be associated with the study  treatment, recommendations for dose modifications and 
management of h ypertension are described below in Table 6-25 .
Table 6-25 Mandatory  dose modification and recommended clinical management 
for hy pertension
Hypertension (NCI -CTCAE 4.03)
Severit y Recommended adverse event 
management guidelinesMandatory  dose modification 
requirements
(Scenario A)
Asymptomatic and 
persistentaincrease of 
SBP or DBP >95th
percentile 
Clinically significant 
increase in DBP of 20 
mmHg (but still below 100 
mmHg).Adjust current or initiate new 
antihypertensive medication.
Titrate antihypertensive 
medication(s) during the next 2 
weeks as indicated to achieve well -
controlledbBP
If BP is not well controlled within [ADDRESS_967513] and go to scenario (B).Continue dabrafenib and 
trametinib at the same dose.

[COMPANY_001] Confidential Page 89
Protocol Amended Version 05 Protocol No. CDRB436G2201
Hypertension (NCI -CTCAE 4.03)
Severit y Recommended adverse event 
management guidelinesMandatory  dose modification 
requirements
(Scenario B)
Asymptomatic increase of 
SBP or DBP >99th
percentile , or
Failure to achieve well -
controlled BP within 2 weeks 
in Scenario AAdjust current or initiate new 
antihypertensive medication(s).
Titrate antihypertensive 
medication(s) during the next 2 
weeks as indicated to achieve well -
controlled BP.Interrupt dabrafenib and 
trametinib if clinically 
indicated.
Once BP is well controlled, 
restart dabrafenib and 
tramet inib reduced by [CONTACT_23615] .
Symptomaticc
hypertension or
Persistent increase in 
SBP or DBP >99th
percentile, despi[INVESTIGATOR_31900].Adjust current or initiate new 
antihypertensive medication(s)
Titrate antihypertensive medication 
during the next 2 weeks as 
indicated to achieve well -controlled 
BP.
Referral to a specialist for further 
evaluation and follow -up is 
recommended .Interrupt dabrafenib and 
trametinib.
Once BP is well controlled, 
restart dabrafenib and 
trametinib reduced by [INVESTIGATOR_2394] e 
dose level.
Refractory hypertension 
unresponsive to above 
interventions or 
hypertensive crisis.Continue follow -up per protocol. Permanently discontinue 
dabrafenib and trametinib.
a.Hypertension detected in two separate readings during up to three consecutive visits.
b.Well-controlled blood pressure defined as SBP and DBP ≤95thpercentile in two separate readings during 
up to three consecutive visits.
c.Symptomatic hypertension defined as hypertension aggravated by [CONTACT_23805] (e.g., headache, light -
heade dness, vertigo, tinnitus, epi[INVESTIGATOR_31901]) that resolve after the blood pressure is controlled within 
the normal range.
[IP_ADDRESS] Dose modification and management guideline for hemorrhage
Hemorrhage, including major hemorrhage defined as s ymptomatic bleeding in a critical area or 
organ, can occur when dabrafenib is administered with trametinib. Permanently  discontinue 
dabrafenib and trametinib for all Grade 4 hemorrhagic events and for any persistent Grade 3 
hemorrhagic events. Withhold dabrafenib and trametini b for Grade 3 hemorrhagic events; if 
improved, resume at the next lower dose level. 
[IP_ADDRESS] Dose modification and management guideline for thromboembolic 
events
Advise patients to immediatel y seek medical care if they develop symptoms of DVT or 
pulmonary  embolism (PE), such as shortness of breath, chest pain, or arm or leg swelling. If 
any signs or symptoms of venous thromboembolism are present, the patient will undergo 
specific laboratory  and medic al imaging assessments to confirm . The medical imaging 
assessment( s)selected will depend on the anatomic site or organ of involvement . If the 
diagnosis is confirmed, appropriate medical care according to standard local clinical practice 
should be initiated immediately . 
Permanently  discontinue trametinib for life threatening PE. Withhold trametinib for 
uncomplicated venous thromboembolism for up to 3 weeks; if improved, trametinib may be 
resumed at a lower dose level .  Dabrafenib dosing may continue.

[COMPANY_001] Confidential Page 90
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Dose modification and management guidelines for carboplatin with 
vincristine treatment
The induction cycle should only be interrupted in the event of grade 3 neurotoxicity , grade 2 
nephro toxicity , grade 4 hematologic toxicity , or disease progression.
[IP_ADDRESS].1 Myelosuppression
To begin induction or each cy cle of maintenance chemo therap y:
ANC should be ≥1000/µL and platelet count ≥100,000/µ L
If ANC <1,000/µL or platelet count <100,000/µ L:
hold administration and repeat counts every  [ADDRESS_967514] been required because of my elosuppression during the previous two successive cy cles. If 
this has occurred, then begin the next cy cle with 75% of full dose carboplatin.
During induction or maintenance:
If ANC falls <500/ µL and/or platelet count <50,000 /µL, hold chemotherapy administration 
and repeat counts every  7 days until they recover to an ANC of ≥1000/ µL and platelet count 
of ≥100,000/ µL.
Resume at 75% of full dose carboplatin when these levels are reached. The 75% reduced 
dose should continue for the remainder of Induction or Maintenance.
However, if a patient is dose reduced during Induction, they canstart the first maintenance cycle 
at 100% dosing. Those patients who are dose reduced during maintenance, should continue at 
the dose reduction thro ughout the remainder of all maintenance cy cles.
Once induction or maintenance has started, vincristine should not be held due to 
Myelosuppression.
[IP_ADDRESS].2 Nephrotoxicity
If creatinine is greater than upper limit of normal for the patient’s age, a creatinine cleara nce or 
GFR must be determined.  If the creatinine clearance is <75% of normal for the patient’s age, 
then the carboplatin dose should be held until creatinine clearance recovers to 75% of normal. 
Carboplatin dose should then be reduced b y 25%. 
[IP_ADDRESS].3 Hepatotoxic ity
If Grade 3-4 hepato toxicity  develops during maintenance , hold chemotherapy  until toxicity  is 
less than Grade 2.  If the etiology  of the toxicity  is unexplained, then the dose of vincristine and 
carboplatin should be reduced b y 25%. 

[COMPANY_001] Confidential Page 91
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS].4 Neurotoxicity
Seizu res
For seizure due to vincristine, hold one dose, then resume at 1.0 mg/m2 (1.5 mg max) while on 
anticonvulsants. If seizures do not recur, escalate to full dose. For seizures not associated with 
vincristine, place patient on anticonvulsants after appropr iate neurological evaluations, and 
proceed with chemotherapy  at full doses.
Encephalopathy
Neither carboplatin nor vincristine commonl y cause encephalopathy . Therefore the patient must 
be carefull y assessed for other causes including hydrocephalus, shunt malfunction, over-
hydration, too rapid withdrawal of steroids, syndrome of inappropriate antidiuretic hormone 
secretion (SIADH ), hypothalamic dysfunction, hemorrhage, anticonvulsant toxicity , etc. If a 
correctable cause cannot be identified, delay  therapy  up to 2 weeks and proceed onl y if patient 
has improved substantially.  Proceed with 20% reduction of both carboplatin and vincristine.
Peripheral neuropathy
For peripheral neuropathy  from vincristine including weakness, paresthesia, ileus requiring IV 
thera py, stridor or ptosis or visual change, hold vincristine until symptoms are markedl y 
improved. Resume at 66% dose or 1.0 mg/m2 (1.5 mg max). Escalate to full dose as tolerated. 
For jaw pain, constipation, mild foot drop, do not modify  dose unless causing significant patient 
discomfort. Then the vincristine may  be reduced to 80% or 1.2 mg/m2 (1.5 m2) and escalate as 
tolerated. 
[IP_ADDRESS].5 Allergic reactions
Allergic reactions may occur in 10 to 30% of children receiving frequent carboplatin. These 
reactions can include facial flushing, urticaria, agitation, abdominal pain, edema, and 
sometimes bronchospasm leading to h ypoxia and even respi[INVESTIGATOR_4047].  
Patients receiving carboplatin should be monitored by [CONTACT_711282] [ADDRESS_967515] s be given in a setting with rapid access to pediatric advanced life-
supporting support capability .  
Consideration should be given to provide effective measures to prevent any recurrences of 
allergic reactions.  

[COMPANY_001] Confidential Page 92
Protocol Amended Version 05 Protocol No. CDRB436G2201
The following are offered as a supplement to institutional practice.  If an allergic reaction occurs 
it should be treated as for any  other drug reactions as follows:
1.Stop the carboplatin infusion
2.Rapid assessment and management of the airway
3.If airway  compromise or acute bronchospasm, give Epi[INVESTIGATOR_238] 0.01 ml/kg (maximum 
0.5 mL ) of 1:1000 solution SQ and repeat in 20 minutes if necessary .
4. Albuterol inhaled can be used to treat resistant bronchospasm.
5.Diphenhy dramine 1-2 mg/kg slow IV will help shorten the d uration of the reaction, but 
does not have an immediate effect.
6.Glucocorticoids may  have no effect for 6 to 12 hours, but may  help prevent relapse of 
severe reactions. 
7.
Patients with mild to moderate reactions (urticaria or mild bronchospasm) should be 
observed for a minimum of [ADDRESS_967516] overnight. 
8.Prevention of recurrence:
a.Children with respi[INVESTIGATOR_711194] .
b.Children with mild or questionable reactions can continue carboplatin with close 
monitoring and pre- treatment with steroids and diphenhy dramine. For optimal effect, 
give Prednisone 1 mg/kg q6 hours PO or Prednisolone 1 mg/kg IV q6 hours for [ADDRESS_967517] dose one hour before carboplatin. Also give 
diphenhy dramine 1 mg/kg IV or PO one hour before carboplatin. All carboplatin 
should be given in a monitored setting with resuscitation drugs and equipme nt readil y 
available. A guideline for desensitization and continuation of treatment if a patient’s 
tumor is responding well to carboplatin treatment has been published ( Broom 1996).
[IP_ADDRESS] Follow up on potential drug -induced liver injury (DILI) cases
Patients with transaminase increase combined with total bilirubin (TBIL )increase may be 
indicative of potential DILI, and have to be considered as clinically  important events. 
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:
For patients with normal AL T andAST and TBIL value at baseline: AST or AL T > 3.[ADDRESS_967518] combined with TBIL > 2.0 x UL N 
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T > 2 x 
baseline AND > 3.[ADDRESS_967519]] OR [AST or ALT > 8.[ADDRESS_967520]], combined with [TBIL > 2 x 
baseline (if elevated at baseline) AND > 2.[ADDRESS_967521]]
Medical review needs to ensure that liver test elevations are not caused by  [CONTACT_15014], defined 
as ALP elevation > 2.[ADDRESS_967522] with R value < 2 in patients without bone metastasis, or elevation 
of AL P liver fraction in patients with bone metastasis.

[COMPANY_001] Confidential Page 93
Protocol Amended Version 05 Protocol No. CDRB436G2201
Note: (The R value is calculated by  [CONTACT_5358], using multiples of the ULN 
for both values. It denotes the relative pattern of ALT and/or ALP elevation is due to cholestatic
(R ≤ 2),hepatocellular (R ≥5), or mixed (R > 2 and < 5) liver i njury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferabl y within 48 hours from the 
awareness of the abnormal results. The evaluation should include laboratory tests, detailed 
history , physical assessment and thepossibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc. 
Laboratory tests should include ALT, AST, albumin, 
creatine kinase, total bilirubin, direct 
and indi rect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase. 
A detailed histo ry, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history of any  pre-existing liver 
conditions or risk factors, should be collected.
Further testing for acute hepatitis A, B, C or E infection and liver imaging (e .g.biliary  
tract) may be warranted. 
Obtain PK sample, as close as poss ible to last dose of study  drug .
Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), 
autoimmune hepatitis or liver biopsy  may  be considered as clinically  indicated or after 
consultation with specialist/hepatologist. 
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medicall y 
significant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the term 
“potential drug-induced liver injury ”. All events should be followed up with the outcome 
clearl y
documented.
6.[ADDRESS_967523] treatment follow up. Any concomitant medication(s), 
including dietary  supplements, taken during the study  will be recorded in the Concomitant 
Medications eCRF. The minimum requirement is that drug name, dose, and the dates of 
administration are to be recorded. Additionally , a complete list of all prior surgical procedures 
will be recorded onthe Medical History  eCRF.  
Patients should receive full supportive care during the study , including transfusions of blood 
and blood products, and treatment with antibiotics, 
anti-emetics, anti -diarrheals, and analgesics, 
and other care as deemed appropriate, and in accordance with their institutional guidelines. Use 
of anticoagulants such as warfarin is permitted, however, caution should be exercised and 
additional I nternational Normalized Ratio (I NR) monitoring is recommended when dabrafenib 
is used concomitantly  with warfarin. 

[COMPANY_001] Confidential Page 94
Protocol Amended Version 05 Protocol No. CDRB436G2201
6.4.2 Permitted concomitant therapy  requiring caution and/or action 
The following medications should be used wit h caution as their concentrations may  be altered 
by [CONTACT_711283]:
Drugs that are moderate inhibitors or inducers of CYP3A and CYP2C8 as they  may  alter 
concentrations of dabrafenib.
Dabrafenib has been shown to induce CYP3A4 and CYP2C9 in vivo using midazolam 
(CYP3A4 substrate) and S -warfarin (CYP2C9 substrate).  Dabrafenib is an in vitro 
inducer of CYP2B6 and other enzy mes such as CYP2C8, CYP2C19, UDP -glucuron yl 
transferases. Transporters may  also be affected.  Co- administration of dabrafenib and 
medications which are affected b y the induction of these enz ymes (including warfarin) 
and transporters may  result in loss of efficacy .  If co -administration of these medications 
is necessary ,investigators should monitor patient s for loss of efficacy or consider 
substitutions of these medications. A partial list of these medications is provided in 
Appendix 1 .
Warfarin exposure has been shown to decrease (37% decrease) due to dabrafenib-
mediated enzy me induction. Conversel y, if dabrafenib dosing is reduced, interrupted, or 
discontinued, warfarin exposure may  be increased. Thus, warfarin dosing may  need to be 
adjusted based on PT/INR during and after treatment with dabrafenib. Prophy lactic low 
dose warfarin may be given to maintain central catheter patency . 
The renal effects of nephrotoxic compounds (e.g. aminogl ycosides) may  be potentiated by  
[CONTACT_711284].
[IP_ADDRESS] Anti-cancer Surgery
For patients enrolled in the HGG cohort, a nti-cancer surgery  is allowed for patients enrolled on 
the study  after at least 8months on treatment or after radiologic progression of disease has been 
confirmed by [CONTACT_1697] . Study  treatment may be taken up to two daysprior to surgery  as 
deemed appropriate by [CONTACT_093]. If the investigator determines that further treatment 
with dabrafenib and trametinib may be clinicall y beneficial to the patient, study  treatment may 
be resumed when the surgical wound is stable, the patient is able to take oral medications and 
at least [ADDRESS_967524]. Elective anti-cancer surgery  prior 
to documented radiologic progression does not qualify  a patient for cross over therapy  within 
this protocol.  Study treatment may be taken up to one day prior to surgery  as deemed 
appropriate by [CONTACT_093]. If the investigator determines that further treatment with 
dabrafenib and trametinib may be clinicall y beneficial to the patient, study treatment may be 
resumed when the patient has recovered sufficiently to consume a semi -solid diet. Prior to anti -
cancer surgery , investigators are required to complete a RANO evaluation.

[COMPANY_001] Confidential Page 95
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Radi otherapy
Radiation skin injury  has been reported with concurrent use of dabrafenib and radiation. To 
reduce this risk, it is recommended that dabrafenib be held for at least [ADDRESS_967525] 1 day before and after stereostatic radiotherap y (Anker 
2016) .These recommendations can be modified based on the physician’s assessment of the risk 
of radiation skin injury .Prior to starting radiotherapy , investigators are required to complete a 
RANO evaluation.
Elective anti-cancer radiotherapy  should not be performed prior to the either documented 
radiologic progression of disease or at least a total of [ADDRESS_967526].  Elective anti-cancer radiotherap y prior to documented radiologic 
progression does not qualify a patient for cross over therap y(LGG cohort) within this protocol.
6.4.[ADDRESS_967527] dose of study  drug and for the duration of the study  will not be allowed. 
The following medications or non- drug therapi[INVESTIGATOR_482970] :
Other anti -
cancer therapi[INVESTIGATOR_014] (except for anti- cancer surgery  according to Section [IP_ADDRESS]
and radiotherap y in Section [IP_ADDRESS] );
Other investigational drugs;
Antiretroviral drugs;
Herbal remedies (e.g., St. John’s wort);
Dabrafenib is metabolized primarily  by [CONTACT_13439] P450 (CYP) 2C8 and CYP3A4.  Co -
administration of dabrafenib with ketoconazole, a CYP3A4 inhibitor, or with gemfibrozil, 
a CYP2C8 inhibitor, resulted in increases in dabrafenib AUC of 71% and 47%, 
respectivel y. Drugs that are strong inhibitors or inducers of CYP3A and CYP2C8 
(Appendix 1 ) may  only be us ed under special circumstances (e.g. as a single use for a 
procedure) w hile treatment with study  drug is interrupted as they  may  alter dabrafenib 
concentrations; consider therapeutic substitutions for these medications. The list may  be 
modified based on em erging data. 
Vincristine is a substrate for CYP3A. Drugs that are strong inhibitors or inducers of 
CYP3A ( Appendix 1 ) may  only be used under special circumstances (e.g. as a single use 
for a procedure) while treatment with study  drug is interrupted,
consider therapeutic 
substitutions for these medications.
Vincristine is also a substrate for P -glycoprotein (P -gp). The concomitant use of potent P -
pg inhibitors or inducers should be avoided.  
Simultaneous administration of phen ytoin and vincristine have been reported to reduce 
blood levels of phen ytoin and to increase seizure activity .

[COMPANY_001] Confidential Page [ADDRESS_967528] Number (Subject No.), that is assigned when 
the patient is first enrolled for screening and is retained as the primary  identifier for the patient 
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Cen ter No.) (as assigned by [CONTACT_5359]) with a sequential patient 
number suffixed to it, so that each patient is numbered uniquel y across the entire database. Upon 
signing the informed consent form, the patient is assigned to the next sequential Subject No. 
available to the investigator through the Oracle Clinical RDC interface.
The investigator or designated staff will contact [CONTACT_64081].Once assigned, the Subject No. must 
not be reused for an y other patient and the Subject No. for that individual must not be changed, 
even if the patient is re-screened. If the patient fails to start treatment or is not randomized (LGG 
cohort) for any  reason, th e reason will be entered into the Screening Disposition page.
IRT must be notified within 2 days that the patient did not receive study  drug or was not 
randomized (for LGG cohort).
6.5.2 Treatment assignment or randomization
HGG Cohort
All patients will receive the same treatment in the HGG cohort . 
LGG Cohort
Patients in the LGG cohort will be randomized in a 2:[ADDRESS_967529] will be produced by [CONTACT_15017]  (IRT) provider 
using a validated system that automates the random assignment of patient numbers to 
randomization numbers. These randomization numbers are linked to the different treatment 
arms, which in turn are linked to medication numbers.
The investigator or his/her delegate will log on to the IRT and confirm that the LGG patien t 
fulfills all the inclusion/exclusion criteria. The IRT will assign a randomization number to the 
LGG patient, which will be used to link the patient to a treatment arm and will specify a unique 
medication number for the first package of stud y treatment t o be dispensed to the patient. 
6.5.3 Treatment blinding
All patients in the HGG cohort receive the same treatment therefore blinding is not applicable.
The LGG cohort is open label. Sponsor statisticians and statistical programmers will remain 
blinded to the identity  of the treatment from the time of randomization until database lock for 
the LGG cohort only.Dummy  randomization codes will be employ ed, with the actual 

[COMPANY_001] Confidential Page 97
Protocol Amended Version 05 Protocol No. CDRB436G2201
randomization codes kept strictly  confidential until the time of database lock and treatment 
unblinding. However, independent statistician ( s)and programmer (s)who will perform analyses 
for the DMC will have access to the randomization codes.
6.6 Stud y drug preparation and dispensation
Patients and/or caregivers will be provided with an adequate suppl y ofstudy  drugs for self-
administration at home, including instructions for administration, until at least their next 
scheduled stud y visit.
The investigator or responsible site personnel must instruct the patient or caregiver to take the 
study  drugs as per protocol. The s tudy drug swill be dispensed to the patient by  [CONTACT_5361]. All dosages prescribed to the patient and all dose changes during the study  must 
be recorded on the Dosage Administration Record eCRF.
Drug accountability  must b e performed on a regular basis. Patients will be instructed to return 
unused study  drugs to the site at each visit. The site personnel will ensure that the appropriate 
dose of each study drug is provided at each visit. 
Responsible site personnel will identify  the study  treatment package(s) to dispense by [CONTACT_711285](s) assigned by [CONTACT_711286]. Site personnel will add the patient number on 
the label. If the label has 2-parts (base plus tear-off label), immediately  before dispensing the 
package to the patient, site personnel will detach the outer part of the label from the package 
and affix it to the patient’s source document.
6.6.1 Study treatment packaging and labeling
Study  treatment, dabrafenib (DRB436 ) and trametinib (TMT212), will be provided asglobal 
clinical open -labelled supply or commercially  sourced suppl y. Global supplies will be packed 
and labeled under the responsibility  of [COMPANY_001] Drug Supply  Management . Commerciall y 
sourced supplies will be packed and labeled as per local regulations.
Dabrafenib and trametinib in different formulations and strengths can be used once a protocol 
amendment with additional formulation description is approved.
Study  treatment labels will comply  with the legal requirements of each country  and will include 
storage conditions, and [COMPANY_001] Drug Supply  Management supplied treatment will also contain 
aunique medication number (corresponding to study  treatment and st rength ).  
Table 6-[ADDRESS_967530]
TMT212 PIB 5mg Powder in bottle TMT212 PIB 5mg FMI
Carboplatin 175 mg/m2Refer to local product information Refer to local product information
Vincristine 1.5 mg/m2Refer to local product information Refer to local product information

[COMPANY_001] Confidential Page [ADDRESS_967531] access. Upon receipt, the study treatment should be stored according to the 
instructions specified on the drug labels a nd in the [Investigator’s Brochure ]. 
6.6.3 Study drug compliance and accountability
[IP_ADDRESS] Study drug compliance
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each patient visit and 
information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each patient 
visit.
On PK sampling days, compliance will be assured by [CONTACT_711287]/her designee, and will be verified by [CONTACT_711288].
[IP_ADDRESS] Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by [CONTACT_5364]. Patients will be asked to return all 
unused study  treatment and packaging on a regular basis, at the end of the study  or at th e time 
of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountability  logto the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site.
[IP_ADDRESS] Handling of other study  treatment
Not applicable.
6.6.[ADDRESS_967532] all 
of the assessments and indicates with an “X”, the visits when they are performed. All data 
obtained from these assessments must be supported in the p atient’s source documentation. The 
table indicates which assessments produce data to be entered into the database (D) or remain in 
source documents only  (S) (“Category ” column).
Screening assessments must occur within 28 days of Week 1 (Day  1), as per Table 7-1.  A urine 
pregnancy  test must be completed on Day  1and confirmed negative prior to dosing.
For Visits on Weeks 1 through 5, there is a general ±2 day  visit window.  For all subsequent 
visits, there is a general ±[ADDRESS_967533]- treatment follow which is 
every  16 weeks with 
±[ADDRESS_967534] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery 8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day  visit 
window
End of treatment (EoT)
Within [ADDRESS_967535] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 5672, 
88-n
Obtain Informed 
Consent/AssentD 7.1.2 X
Obtain Informed 
Consent/Assent for 
post-progression 
treatment on 
dabrafenib with 
trametinibD [IP_ADDRESS] X –at the time of Treatment after Progression of Disease
Local determination 
of BRAF V600  D 5.2,7.1.2 X
Tumor tissue for 
histopathology (HGG 
only) and BRAF
central test 
confirmation (both 
HGG and LGG, 
paraffin block or 
slides)D 7.2.4 X
IRT Registration 
(after ICF signature)S [IP_ADDRESS] X

[COMPANY_001] Confidential Page [ADDRESS_967536] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery 8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day  visit 
window
End of treatment (EoT)
Within [ADDRESS_967537] Treatment Follow up
Every 16 weeks ±[ADDRESS_967538] 
(within IRT)S [IP_ADDRESS] X
IRT Randomization 
(LGG cohort only)D 6.5.2 X
Patient History
Demography D [IP_ADDRESS] X
Inclusion/exclusion 
criteriaD 5.2, 5.3 X
Medical History D [IP_ADDRESS] X
Seizure history D [IP_ADDRESS] X
Diagnosis and extent 
of cancerD [IP_ADDRESS] X
Prior antineoplastic 
therapyD [IP_ADDRESS] X
Prior/concomitant 
medications and non -
drug therapi[INVESTIGATOR_565266] [IP_ADDRESS] X X –Continuous
Prior surgical 
proceduresD [IP_ADDRESS] X
Physical exam
Physical examination S [IP_ADDRESS] X X X X X X X X X X X X X X X X

[COMPANY_001] Confidential Page [ADDRESS_967539] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery 8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day  visit 
window
End of treatment (EoT)
Within [ADDRESS_967540] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 5672, 
88-n
Performance status 
(Karnofsky/Lansky)D [IP_ADDRESS] X X X X X X X X X X X X X
Height D [IP_ADDRESS] X X X X X X X X X X X X
Weight D [IP_ADDRESS] X X X X X X X X X X X X X
Vital signs D [IP_ADDRESS] X X X X X X X X X X X X X X X X
Laboratory  assessments
Hematology D [IP_ADDRESS].1 X X X X X X X X X X X X X X X
Chemistry D [IP_ADDRESS].2 X X X X X X X X X X X X X X X
Hepatitis testing for 
clearance (only for 
positive history)D [IP_ADDRESS].5 X
Urinalysis D [IP_ADDRESS].[ADDRESS_967541], 
serum (as applicable)D [IP_ADDRESS].[ADDRESS_967542], urine 
(as applicable)D [IP_ADDRESS].4 X –Day [ADDRESS_967543] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery 8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day  visit 
window
End of treatment (EoT)
Within [ADDRESS_967544] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 5672, 
88-n
Imaging
Tumor evaluation D 7.2.1 X X X X X X X X X X X -until PD 
or off 
study.
Treatment after 
Progression of 
Disease on 
dabrafenib with 
trametinibD [IP_ADDRESS] X -See Section [IP_ADDRESS] for details
Safety
Adverse events 
 D 8.1 X –Continuous
Dermatological 
Evaluation D [IP_ADDRESS] X XX - Monthly (local qualified physician assessment for 
non-clinic visits)X  –At EOT, [ADDRESS_967545] dose of 
study treatment or until start 
of new antineoplastic 
therapy initiated 
ECG D [IP_ADDRESS].[ADDRESS_967546] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery 8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day  visit 
window
End of treatment (EoT)
Within [ADDRESS_967547] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 5672, 
88-n
Cardiac imaging/ 
ECHOD [IP_ADDRESS].2 X X X X X X X
Ophthalmic 
examinationD [IP_ADDRESS] X X X X X X X
Study  drug administration
DRB436 
administrationD 6.1 X -Continuous b.i.d daily dosing
TMT212 
administrationD 6.1 X –Continuous q.d. daily dosing
Pharmacokinetics
Full PK sampling 
DRB436 D 7.2.3 X X X
Full PK sampling 
TMT212D 7.2.3 X X X
Sparse PK sampling 
DRB436 (subset of 
LGG patients)D 7.2.3 X X
Sparse PK sampling 
TMT212 (subset of 
LGG patients)D 7.2.[ADDRESS_967548] D [IP_ADDRESS] X X X

[COMPANY_001] Confidential Page [ADDRESS_967549] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery 8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day  visit 
window
End of treatment (EoT)
Within [ADDRESS_967550] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 5672, 
88-n
Patient Reported Outcomes
Parent Proxy Global 
7+2 Health (LGG 
cohort only)D 7.2.6 X X X X X X X X X X X X
Acceptability/Palatabi
lity Questionnaire –
DabrafenibD 7.2.7 X X
Acceptability/Palatabi
lity Questionnaire –
Trametinib D 7.2.[ADDRESS_967551] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery 8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day  visit 
window
End of treatment (EoT)
Within [ADDRESS_967552] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 5672, 
88-n
Antineoplastic 
therapi[INVESTIGATOR_560022] [IP_ADDRESS] X X X
Survival Follow -up D [IP_ADDRESS] X

[COMPANY_001] Confidential Page [ADDRESS_967553] Treatment 
PeriodCategory
Protocol Section
Pre-TreatmentWeekly  Assessments 
(Weeks 1 to 5) ± 2 day  
visit windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day 
visit 
window
End of treatment (EoT)
Within [ADDRESS_967554] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 81
62
43
24
04
[ZIP_CODE], 
88-n
Obtain Informed 
Consent/Assent for 
post-progression 
treatment on 
dabrafenib with 
trametinibD [IP_ADDRESS] X –at the time of Treatment after Progression of Disease on dabrafenib 
with trametinib
Concomitant 
medications and non -
drug therapi[INVESTIGATOR_565266] [IP_ADDRESS] X –Continuous
Physical exam
Physical examination S [IP_ADDRESS] X X X X X X X X X X X X X X X
Performance status 
(Karnofsky/Lansky)D [IP_ADDRESS] X X X X X X X X X X X X
Height D [IP_ADDRESS] X X X X X X X X X X X
Weight D [IP_ADDRESS] X X X X X X X X X X X X
Vital signs D [IP_ADDRESS] X X X X X X X X X X X X X X X X

[COMPANY_001] Confidential Page [ADDRESS_967555] Treatment 
PeriodCategory
Protocol Section
Pre-TreatmentWeekly  Assessments 
(Weeks 1 to 5) ± 2 day  
visit windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day 
visit 
window
End of treatment (EoT)
Within [ADDRESS_967556] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 81
62
43
24
04
[ZIP_CODE], 
88-n
Laboratory  assessments
Hematology D [IP_ADDRESS].
1X X X X X X X X X X X X X X
Chemistry D [IP_ADDRESS].
2X X X X X X X X X X X X X X
Urinalysis D [IP_ADDRESS].
3X X X X X X X X X X X
Pregnancy test, serum 
(as applicable)D [IP_ADDRESS].
4X
Pregnancy test, urine 
(as applicable)D [IP_ADDRESS].
4X –Day 1 and Monthly thereafter X
Imaging
Tumor evaluation D 7.2.1 X X X X X X X X X X X -until 
PD or off 
study
Treatment after 
Progression of Disease 
on dabrafenib with 
trametinibD [IP_ADDRESS] X -See Section [IP_ADDRESS] for details

[COMPANY_001] Confidential Page [ADDRESS_967557] Treatment 
PeriodCategory
Protocol Section
Pre-TreatmentWeekly  Assessments 
(Weeks 1 to 5) ± 2 day  
visit windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day 
visit 
window
End of treatment (EoT)
Within [ADDRESS_967558] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 81
62
43
24
04
[ZIP_CODE], 
88-n
Safety
Adverse events 
 D 8.1 X –Continuous
Dermatological 
EvaluationD [IP_ADDRESS] X X -Monthly (local qualified physician assessment 
for non -clinic visits)X  –At EOT, [ADDRESS_967559] 
dose of study 
treatment or until start 
of new antineoplastic 
therapy initiated 
ECG D [IP_ADDRESS]
0.1X X X X X X X
Cardiac imaging/ 
ECHOD [IP_ADDRESS]
0.2X X X X X X X
Ophthalmic 
examinationD [IP_ADDRESS] X X X X X X
Study  drug administration
DRB436 administration D 6.1 X -Continuous b.i.d daily dosing
TMT212 administration D 6.1 X –Continuous q.d. daily dosing

[COMPANY_001] Confidential Page [ADDRESS_967560] Treatment 
PeriodCategory
Protocol Section
Pre-TreatmentWeekly  Assessments 
(Weeks 1 to 5) ± 2 day  
visit windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit windowEvery  16 
weeks
±7 day 
visit 
window
End of treatment (EoT)
Within [ADDRESS_967561] Treatment Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months Week 
-28 to -11 2 3 4 5 81
62
43
24
04
[ZIP_CODE], 
88-n
Study  Completion
End of Phase 
DispositionD 7.1.4 X X
Antineoplastic 
therapi[INVESTIGATOR_560022] [IP_ADDRESS] X X X
Survival Follow -up D [IP_ADDRESS] X

[COMPANY_001] Confidential Page [ADDRESS_967562] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit window
End of treatment 
(EoT)
Within [ADDRESS_967563] Treatment 
Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months
Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 56
Obtain Informed 
Consent/AssentD 7.1.2 X
IRT Registration 
(after ICF signature)S [IP_ADDRESS] X
Eligibility checklist 
(within IRT)S [IP_ADDRESS] X
IRT Randomization D 6.5.2 X
Patient History
Demography D [IP_ADDRESS] X
Inclusion/exclusion 
criteriaD 5.2, 5.3 X
Medical History D [IP_ADDRESS] X
Seizure history D [IP_ADDRESS] X

[COMPANY_001] Confidential Page [ADDRESS_967564] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit window
End of treatment 
(EoT)
Within [ADDRESS_967565] Treatment 
Follow up
Every 16 weeks ±[ADDRESS_967566] [IP_ADDRESS] X
Prior antineoplastic 
therapyD [IP_ADDRESS] X
Prior/concomitant 
medications and non -
drug therapi[INVESTIGATOR_565266] [IP_ADDRESS] X X –Continuous
Prior surgical 
proceduresD [IP_ADDRESS] X
Physical exam
Physical examination S [IP_ADDRESS] X X X X X X X X X X X X X X X
Performance status 
(Karnofsky/Lansky)D [IP_ADDRESS] X X X X X X X X X X X X
Height D [IP_ADDRESS] X X X X X X X X X X X
Weight D [IP_ADDRESS] X X X X X X X X X X X X
Vital signs D [IP_ADDRESS] X X X X X X X X X X X X X X X
Laboratory  assessments
Hematology D [IP_ADDRESS].[ADDRESS_967567] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit window
End of treatment 
(EoT)
Within [ADDRESS_967568] Treatment 
Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months
Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 56
Chemistry D [IP_ADDRESS].2 X X X X X X X X X X X X X X
Local laboratory tests D [IP_ADDRESS] X –Weekly or as needed per local practice throughout carboplatin with 
vincristine treatment 
Hepatitis testing for 
clearance (only for 
positive history)D [IP_ADDRESS].5 X
Urinalysis D [IP_ADDRESS].[ADDRESS_967569], 
serum (as applicable)D [IP_ADDRESS].[ADDRESS_967570], urine 
(as applicable)D [IP_ADDRESS].4 X –Day 1 and  Monthly thereafter X
Imaging
Tumor evaluation D 7.2.1 X X X X X X X X X X -until PD 
or off study.
Safety
Adverse events 
 D 8.1 X –Continuous

[COMPANY_001] Confidential Page [ADDRESS_967571] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit window
End of treatment 
(EoT)
Within [ADDRESS_967572] Treatment 
Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months
Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 56
Dermatological 
Evaluation D [IP_ADDRESS] X XX - Monthly (local qualified physician assessment for non-
clinic visits)X  –At EOT, [ADDRESS_967573] dose 
of study treatment or until 
start of new antineoplastic 
therapy initiated 
ECG D [IP_ADDRESS].
1X X X X X X X
Cardiac imaging/ 
ECHOD [IP_ADDRESS].
2X X X X X X X
Ophthalmic 
examinationD [IP_ADDRESS] X X X X X X X
Study  drug administration
Carboplatin D 6.1.2 Weeks 1 – [ADDRESS_967574] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit window
End of treatment 
(EoT)
Within [ADDRESS_967575] Treatment 
Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months
Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 56
Weeks 19 -21
Weeks 25 -27
Weeks 31 -33
Weeks 37 -39
Weeks 43 -45
Weeks 49 -51
Weeks 55 -57
Patient Reported Outcomes
Parent Proxy Global 
7+[ADDRESS_967576] Treatment PeriodCategory
Protocol Section
ScreeningWeekly  
Assessments 
(Weeks 1 to 5) 
± 2 day  visit 
windowEvery  8 Week Assessments
(Weeks 8 to 56)
±7 day  visit window
End of treatment 
(EoT)
Within [ADDRESS_967577] Treatment 
Follow up
Every 16 weeks ±14 day visit 
window
Survival follow up
Every 3 months
Week 
-28 to -11 2 3 4 5 8 16 24 32 40 48 56
End of Phase 
DispositionD 7.1.4 X X X
Antineoplastic 
therapi[INVESTIGATOR_560022] [IP_ADDRESS] X X X
Survival Follow -up D [IP_ADDRESS] X

[COMPANY_001] Confidential Page 117
Protocol Amended Version 05 Protocol No. CDRB436G2201
7.1.1 Molecular pre -screening 
There is no molecular pre- screening for this study. 
7.1.2 Screening
Written informed consent/assent must be obtained prior to any screening procedures. The 
window for screening each patient will be up to [ADDRESS_967578] conducted and 
confirmed negative on Day 1 before dosing . Adverse events will also be recorded at this visit. 
Screening assessments to confirm eligibility  should be performed as per the schedule of 
assessments ( Table 7 -1, Table 7 -2,Table 7 -3). 
Local BRAF V600 mutation result may be used to qualif y patients for enrollment, as part of the 
study  inclusion criteria listed in Section 5.2. The CRF page for method of local BRAF V600 
mutation testi
ng, including the methodology  used for local assessment, must be completed for 
patient s whose tumor sample was tested by a local institutional assay . BRAF V600 mutation 
result must belocally  documen ted prior to Day 1 (HGG cohort) or randomization (LGG cohort) . 
TheBRAF V600 mutation status will be assessed using a validated tissue -based test.Molecular -
based BRAF V600 testing should be used where available and isstrongly preferred over non-
molecular methods, e.g. immunohistochemistry . Liquid biopsy -based BRAF V600 results 
cannot be used to enroll patients. BRAF V600 mutation results will be subjected to retrospective 
central confirmation by a  N ovartis designated laboratory . For the retrospective central 
confirmation all subjects will be required to provide a tumor tissue sample at screening prior to 
study  treatment, as either a tumor block or a minimum of 20FFPE slides (see Table 7-8). Central 
confirmation of BRAF V600 mutation status is not required for enrollment ,if local test results 
are positive for BRAF V600 mutation . 
Patient s will not be excluded if central testing is later 
found to be discordant or uninformative (e.g. inadequate sample).
For patients who do not have a BRAF V600 mutation result documented locally , a tumor sample 
must be submitted for central testing of BRAF mutation status during screening . The minimum 
requirements for this sample are listed in Table [ADDRESS_967579] result(s) that does not satisfy the entrance criteria may have 
the 
test(s) repeated within the screening window (within [ADDRESS_967580] dose). In this 
case, the patient will notbe required to sign another ICF, and the original patient ID number 
assigned will be used. In the event that the laboratory  test(s) cannot be performed within [ADDRESS_967581](s) do not meet the entrance criteria, or
eligibility  criteria have changed and are not met anymore, the patient is considered a screen 
failure.
A new IC F/assent will need to be signed if the investigator chooses to re-screen the patient after 
a patient has screen failed, however the patient ID number will remain the same. All required 
screening activities must be performed when the patient is re-screened for participation in the 
study . 

[COMPANY_001] Confidential Page 118
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Eligibility  screening 
Following registering in the IRT for screening, patient eligibility  will be checked once all 
screening procedures are completed. The key eligibility  check will be embedded in the IRT 
system. Please refer and comply with detailed guidelines in the I RT manual.
[IP_ADDRESS] Information to be collected on screening failures
Patient who signed an Informed Consent Form but failed to be started on treatment for any 
reason will be considered a screen failure. 
The demographic information, informed consent/assent , Inclusion/Exclusion and Screening 
Phase Disposition pages must be completed for screen failure patients. No other data will be 
entered into the clinical database for patients who are screen failures, unless the patient 
experienced a Serious Adverse Event during the Screening Phase (see Section 8 for SAE 
reporting details). 
[IP_ADDRESS] Patient demographics and other baseline characteristics
The data that will be collected on patient characteristics at screening includes:
Demograph y (Year of birth , calculated age, sex, childbearing status, race, ethnicity )
Histologicall y confirmed diagnosis of High Grade Glioma (Grade III or IV glioma ) or 
Low Grade Glioma (Grade I or II glioma), as defined by  [CONTACT_711289], 2016.
Medical history  (e.g., important medical, surgical, an d allergic conditions from the 
patient’s medical history  which could have an impact on the patient’s evaluation) / current 
medical conditions (e.g., all relevant current medical conditions which are present at the 
time of signing informed consent /assent ). Frequency  of seizures prior to the first day  of 
dosing should be assessed and recorded on the Medical History  eCRF. For L GG patients, 
the indication to treatment must be reported which may  include clinical and/or 
neurological s ymptoms. Ongoing medical cond itions, sy mptoms and disease which are 
recorded on the Medical History  eCRF should include the toxicity  grade.
All prior antineoplastic therapi[INVESTIGATOR_14937] -, biologic -, 
immunologic- and radiation- therapi[INVESTIGATOR_711195].
All medications and significant non -drug therapi[INVESTIGATOR_14939] [ADDRESS_967582] be recorded on the Prior and Concomitant medication or 
Surgical and medical procedures eCRF page and updated on a continual basis if there are 
any new changes to the medications.
Furthermore the following assessments will be performed:
 
Central confirmation of HGG histo pathology (HGG cohort onl y)and BRAF V600 
mutation (HGG and LGG cohorts) (Tumor tissue required)
Radiological assessments (e.g. MRI )to confirm measurable disease per RANO response 
criteria (locall y determined andcentral confirmation required before enrollment)

[COMPANY_001] Confidential Page 119
Protocol Amended Version 05 Protocol No. CDRB436G2201
Vital signs
Height, weight
Physical examination
Performance status ( Karnofsky /Lansky )
Laboratory  evaluations (hematology , chemistry , urinaly sis)
Pregnancy  testing (for menstruating females and women of childbearing potential)
Hepatitis testing (for patients with a history  of hepatitis)
ECG
ECHO
Ophthalmology  exam 
Dermatological exam
7.1.[ADDRESS_967583] year; subsequent visits will occur every  16 
weeks. LGG patients randomized to chemotherapy  will follow the same visit schedule for 
protocol assessments, but will be required to return to the clinical site for additional 
chemotherap ydosing visits per Section 6.1.2 .
For details of assessment s, refer t o Table 7 -1,Table 7 - 2 for LGG crossover patients and Table 
7-3.
Concomitant medication, adverse events and SAE monitoring will be continuous throughout 
the trial .
Patients will be treated with study  treatment until disease progression, unacce ptable toxicity , 
death or discontinuation from the study  treatment due to any  other reason. 
[IP_ADDRESS] Treatment after Progression of Disease
Patients will be permitted to continue dabrafenib with trametinib beyond 
investigator- assessed, 
RANO -defined PD, as long as they meet the following criteria:
Investigator assessed clear evidence of clinical benefit 
Tolerance of stud y drug
Continuation of study  treatment is in the best interest of the patient as determined by  [CONTACT_3786]
Patient /legal guardian is willing to continue on the study and signed ICF for treatment 
beyond progression
If the Investigator determines that all above criteria are met, the patient may continue study 
treatment and follow all study  related procedures, including tumor assessments, as scheduled 
in Table 7-1, Table 7-2for LGG crossover patients and Table 7-3. After each tumor assessment, 

[COMPANY_001] Confidential Page [ADDRESS_967584] confirm if the patient is still benefitting from study  treatment, and 
document this in thepatient ’s chart and the appropriate CRF pages .
7.1.4 Discontinuation of study treatment
Patients may voluntarily discontinue from thestudy forany reason atanytime.Ifapatient
decides todiscontinue from the investigational treatment, the investigator should make a 
reasonable effort (e.g. telephone, e-mail,letter) tounderstand theprimary reason forthis
decision and record thisinform ation inthepatient ’schart andonthe appropriate CRF pages. 
They maybe conside redwithdrawn ifthey state an intention towithdraw, failtor eturnfor vis its,
orbeco me lost tofollow - upfor an yother reason.
For patients who discontinue treatment for reasons other than documented disease progression, 
death, lost to follow -up, or withdrawal of consent /assent , tumor assessments must continue to 
be performed every 16weeks until documented disease progression, death, lost to follow -up, 
or wi thdrawal of consent /assent .
Patients must bediscontinued under the following circu mstance s:
Pregnancy
Study  Terminated by  [CONTACT_2728]
Patient/guardian decision
Physician decision ( investigator may discontinue study treatmentfora given patient if,
he/she believes thatcontinu ationwould be detrimental tothe patie nt’sw e ll-being )
Any other protocol deviation that results in a significant risk to the patient’s safet y
Patie nts who discontinue study  treatment should NOT beconsidered withdrawn from the
study .They should return fortheassess ments indicated inSection 
7.2.1. Ifthey failtor eturn
forthese assess ments forunknown reasons, every effort (e.g. telephone, email,letter) should
be m adetocontact [CONTACT_711290] 7.1.7. The investigator mustalso contact[CONTACT_711291]’s discontinuation from the 
study .
In some circumstances patients may  be allowed to continue to receive study  treatment bey ond 
disease progression as per RANO criteria (Section [IP_ADDRESS]). These patients will continue 
assessments as outlined in Table 7-1, Table 7-2for LGG crossover patients or Table 7-3, and 
will complete the End of Treatment visit only after permanent discontinuation of study  
treatmen
t.
[IP_ADDRESS] Replacement policy
Patients will not be replaced on stud y. 
However, if a patient is considered as non -evaluable for the per-protocol set (PPS) , enrollment 
of a new patient will be considered if there is less than the required number of evaluable patien ts. 
7.1.5 Withdrawal of consent
Patients/legal guardian may voluntarily  withdraw assent/ consent toparticipate in thestudy for
any reason atany ti
me.Withdrawal ofassent/ consent occurs only when apatient /legal 
guardian
:

[COMPANY_001] Confidential Page 121
Protocol Amended Version 05 Protocol No. CDRB436G2201
Doesnotwant toparticipa te inthe study anylonger, and
Doesnot allow further collection of personal data.
Ifa patient /legal guardian withdraws assent/ consent, theinvestigator should makea reasonable 
effort (e.g. telephone, e-mail, letter) to understand the primary reason for the patient/legal 
guardian 
decision to withdraw his/her consent and rec ord this inform ation.
Study  treatment m
ust be discontinued andnofurther assess mentsconducted, and the data that 
would have been collected at subsequent visits will be considered missing .
Further attempts to contact [CONTACT_102]/legal guardian are not allowed unless safety  findings 
require communicating or follow -
up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patie nt’s study  withdrawal should be made as detailed in the 
assessment table. 
[COMPANY_001] will continue to keep and use collected study  information (including any data resulting 
from the analy sis of a patient’s samples until their time of withdrawal) according t o applicable 
law.
For US and Japan: All biological samples not yet analyzed at the time of withdrawal may  still 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form. 
For EU and RoW: All biolog ical samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by  [CONTACT_1289]. They will be stored according to applicable 
legal requirements.
7.1.[ADDRESS_967585] dose of study  
treatment as per Table 7 -1,Table 7 - 2 for LGG crossover patients , or Table 7-3.Data collected 
should be added to the Adverse Events eCRF and the Concomitant Medications 
eCRF.
[IP_ADDRESS] Post treatment follow up
After discontinuation of study  treatment, all patients will be followed f or safety  for at least [ADDRESS_967586] dose of study  treatment except in the case of death, loss to follow -up or 
withdrawal of consent /assent . All patients who discontinue study  treatment for reasons other 
than disease progression, death, lost to follow up, or withdrawal of consent /assent will move 
into Post Treatment Follow Up phase. 
Tumor evaluations during this period will continue as per Table 7-1, Table 7-2orTable 7-3
until central independently  confirmed disease progression by [CONTACT_28843], withdrawal of 
assent/ consent b y patient/guardian to tumor status follow -up, or lost to follow -
up. Patients who
start a new anti-cancer therap y prior to disease progression will continue tumor evaluations 
following thesame above schedule until radiographic evidence of disease progression is 
centrall y confirmed .
Skin examinations should be performed at [ADDRESS_967587] dose of study  drug or 
until thestart of anew anti-cancer therapy .Safety  assessments including physical exams and 

[COMPANY_001] Confidential Page 122
Protocol Amended Version 05 Protocol No. CDRB436G2201
growth/developmental follow up will continue according to Table 7-1, Table 7-2orTable 7-3
andSection 7.1.6.
Patients who discontinue study treatment due to disease pr ogression by [CONTACT_711292] , and begin new anti -cancer therapy  at EOT 
will enter Survival follow -
upperiod.
[IP_ADDRESS] Survival follow -up
All patients will be followed for survival once they discontinue study  treatment and complete 
protocol required efficacy  assessments, and the required skin evaluation per Table 7-1, Table 
7-2for LGG crossover patients or Table [ADDRESS_967588] to 
follow -up, the patient /legal guardian withdraws assent/ consent or study  discontinuation .
7.1.[ADDRESS_967589] to fo llow- up
Forpatie ntswhose status is unclear because they fail toappear forstudy  visits without stating 
anintention towithdraw consent /assent ,theinvestigator should show "due diligence" by
[CONTACT_121944], fa mily orfamily physician asa
greed in theinfor medconsent /assent and
by[CONTACT_711293], e.g. dates of
telephone calls, registered letters,etc.Apatie ntsho uldnot be considered losttofollow -upuntil
duediligence has been completed. Patients losttofollow upshould berecorded assuch onthe
appropriate Disposition CRF.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
Tumor response will be assessed locall y and centrally  based on the Response Assessment in 
Neuro -Oncology  (RANO) criteria for solid tumors (Wen, 2010). The imaging assessment 
collection plan is presented in Table 7 -
4. Details of the central review process will be described 
in the independent review charter by [CONTACT_711294] .
Imaging data will be centrally  collected and checked for qualit y by [CONTACT_711295] b y [COMPANY_001]. The decision regarding patient management will remain with the local 
investigator.
Information regarding prior interventions (e.g. radiotherap y), pre-existing radiographic findings 
that mimic metastatic disease at baseline/screening , prior and on
-study interventions, and 
cytology  results should be transmitted to the imaging vendor for review by [CONTACT_711296]. Sites must ensure the data transmitted is consistent with the data entered in 
the clinical database.
For patients who discontinue treatment for reasons other than documented disease progression, 
death, lost to follow -up, or withdrawal of consent /assent , tumor assessments must continue to 
be performed every  [ADDRESS_967590] to follow -up, 
or withdrawal of consent /assent .

[COMPANY_001] Confidential Page 123
Protocol Amended Version 05 Protocol No. CDRB436G2201
Table 7-4 Imag ing A ssessment Collection Plan
Procedure aScreening During Treatment/Follow-up End of Treatment
Tumor evaluation 
Brain MRIMandated Every 8 weeks (+/- 7days) during the 
first 56 weeks .
Every 16 weeks (+/- 7 days) thereafter 
while on treatment as well as during 
post-treatment follow up.
PR and CR must be confirmed by 
[CONTACT_428915] ≥[ADDRESS_967591] met.
At any time there is suspi[INVESTIGATOR_711196].Mandated
MRI Spi[INVESTIGATOR_711197] i nvestigator discretion
a Refer to Section [IP_ADDRESS]
[IP_ADDRESS] Baseline imaging assessments
Imaging assessments will be performed at screening/baseline within 28 days of start of 
treatment (Day  -28 to Day  - 1).
Any imaging assessments alread y completed during the regular work -up of the patient within 
28 da ys prior to start of treatment, including before signing the stud y ICF, can be considered as 
the baseline images for this study . The following assessments are required at screening/baseline:
Brain MRI -Contrast enhanced brain MRI is preferred. H owever, if MRI contrast is 
contraindicated, CT with or without contrast is allowed, but highl y discouraged.
MRI  spi[INVESTIGATOR_711198] y indicated according to investigator discretion
Required conditions for baseline tumor assessment
During screening, patients must have locally  determined and centrally  confirmed 
measurable disease at least twice the imaging slice thickness to be used for efficacy  
assessment
Patie nts with only  non- measurable lesions are not eligible
Any potentiall y measurable lesion that has been previously treated with radiotherap y 
should be considered as a non- measurable lesion. However, if a lesion previously  treated 
with radiotherap y has clearl y progressed since more than 3 weeks from the radiotherap y, it 
can be considered as a measurable lesion.
Since measurable disease is an eligibility  requirement , study  sites should send the baseline 
imaging scans and an y required vendor forms to the imaging CRO immediately  following scan 
acquisition during screening. Rapid image transmission to the imaging CRO may be 
accomplished by [CONTACT_711297] . The baseline imaging will undergo 
expedited central review and the results of the centr al review will be communicated to the site. 
If the central review determines measurable disease, then the patient can be enrolled in the study . 
If the central review does not determine measurable disease, the patient should not be enrolled 
in the study ; additional follow -up can be requested.

[COMPANY_001] Confidential Page 124
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Post -baseline imaging assessments
Imaging assessments as described in Table 7-4should be performed at the time points specified 
using the same imaging modality  used at baseline, irrespective of study  treatment interruption 
or actual dosing (see Table 7-1, Table 7 -2 for LGG crossover patients or Table 7-3). Imaging 
assessments for response evaluation will be performed every  8
 weeks (+/- 7 days) during the 
first y ear, subsequentl y ever y 16 weeks (+/
-7 days) thereafter until disease progression, de ath, 
lost to follow -
up or withdrawal of consent /assent .Imaging assessments should be scheduled 
using the enrollment date as the reference date (not the previous tumor assessment), and should 
be respected regardless of whether study  treatment is temporaril y withheld or unscheduled 
assessments performed.
Local imaging results are to be used for treatment decisions by [CONTACT_093].
Additional imaging assessments may be performed at any time during the study  at the 
investigator’s discretion to support the efficacy  evaluations for a patient , as necessary. Clinical 
suspi[INVESTIGATOR_436650] a physical examination and imaging 
assessments to be performed promptly  rather than waiting for the next scheduled imaging 
assessment. Partial Response (PR) and Complete Response (CR) must be confirmed by  [CONTACT_711298] ≥[ADDRESS_967592]/ph ysician throughout the study  so that the comparison is 
consistent. If an off-schedule imaging assessment is perform ed because progression is 
suspected, subsequent imaging assessments should be performed in accordance with the 
original imaging schedule.
All study  imaging (including any off-schedule imaging studies) should be submitted to the 
designated imaging vendor for qualit y control and central review. 
7.2.2 Safety  and tolerability assessments
Safety  will be monitored by[CONTACT_711299](see Table 7-1, Table 7-2for LGG crossover patients or Table 7-3) . For 
details on AE collection and reporting, refer to Section 8.
For LGG patients randomized to carboplatin and vincristine, investigators should follow local
institutional and local SmPC guidelines for any additional safet y monitoring that may be 
required d
uring administration of carboplatin and vincristine. This includes audiometry  testing 
on patients where there is suspi[INVESTIGATOR_711199].  Events of hearing loss should be reported as 
Adverse Event s and recorded on the electronic case report form ( eCRF ).
Significant findings that were present prior to the signing of informed consent /assent must be 
included in the Medical History  page on the patient’s eCRF. Significant new findings that begin 
or worsen after informed consent /assent must be recorded on the Adverse Event page of the 
patient’s eCRF. 

[COMPANY_001] Confidential Page 125
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Physical examination
A complete physical examination will include the examination of general appearance, 
assessment of the skin, neck (including thyroid), eyes, ears, nose, throat, lungs, heart, abdomen, 
back, lymph nodes, extremities, vascular and neurological. If indicated based on medical history 
and/or sy mptoms, rectal, external genitalia, breast, and pelvic exams will be performed.  
A short physical exam will include the examination of general appearance , assessment of the 
skin, lungs, cardiovascular system, abdomen (liver and spleen), and neurological exam as 
clinically  indicated. A short phy sical exam will be at all visits starting from Week 8. 
 
For the assessment schedule refer to the Visit Evaluation Schedule (Table 7-1, Table 7-2for 
LGG crossover patients or Table 7
-3).
[IP_ADDRESS] Vital signs
Vital signs include blood pressure, body  temperature, pulse measurements. Vital signs should 
be taken before an y study medication is given on each assessment day (i.e. pre -dose).
Blood pressure will be taken:
After the patient has been sitting for five minutes . The appropriate cuff size is used to 
ensure accurate measurement.
Measurements will be taken per local practice.
If the blood pressure reading is outside the age appropriate normal ranges, repeat the 
measurement, waiting 
1-2 minutes between readings, to verify  the initial reading. Repeat 
measurements will be documented in the patient’s eCRF. 
For the assessment schedule refer tothe Visit Evaluation Schedule (Table 7-1, Table 7-2for 
LGG crossover patients or Table 7-3 ).
[IP_ADDRESS] Heig ht and weight
Height in centimeters (cm) will be measured as a requirement to monitor growth, and body 
weight (to the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) will be measured 
where indicated inthe Visit Evaluation Schedule (Table 7-1, Table 7-2for LGG crossover 
patients or Table 7
-3).  

[COMPANY_001] Confidential Page 126
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Performance status
The performance status will be assessed according to Karnofsk y for patients >16 years of age 
or Lansk y for patients ≤16 years of age at screening (see Appendix 2). Performance status will 
be assessed ac cording the scheduled assessment in Visit Evaluation Schedule ( Table 7 -1,Table 
7-2for LGG crossover patients or Table 7 -3).
[IP_ADDRESS] Dermatological Evaluation
Skin examination should be performed prior to initiation of study  treatment, and during the 
study on a monthly  basis throughout therap yand at End of Treatment. After discontinuation of 
study  treatmen t, skin examinations should be performed at [ADDRESS_967593] dose of 
study  treatment or until thestart of anew anti-neoplastic therapy according to the Visit 
Evaluation Schedule (Table 7-1, Table 7-2 for LGG crossover patients or Table 7-3) .
Monitoring of the skin can be performed by  a qualified local phy sician at the discretion of the 
investigator during non -clinic visits. If possible, the same local phy sician should perform each 
exam throughout the study to ensure consistency  between evaluations. 
[IP_ADDRESS] Ophthalmologic exam
Patients are required to have standard age-appropriate ophthalmologis t examinations performed 
by [CONTACT_711300] 
(Table 7-1, Table 7-2for LGG crossover patients or Table 7-3).Based on the investigator’s 
discretion, the examination may include best corrected visual acuit y, tonometry , slit lamp 
biomicroscopic examination, visual field examination, dilated indirect fundoscopy with special 
attention to retinal abnormalities, and optical coherence tomograph y
.During the study , 
ophthalmologic exams may be repeated as clinically warranted. If any changes are noted during 
the required age -appropriate exa m, or otherwise clinically indicated, a detailed ophthalmologic 
exam is mandatory (with sedation if necessary )
.
[IP_ADDRESS] Laboratory  evaluations
A central laboratory  will be used for analy sis of all specimens collected. Details on the 
collections, shipment of sampl es and reporting of results by [CONTACT_711301].
Central laboratory  results should be used to determine study  eligibility , however if there is an 
immediate need to determine study eligibility and commence treatment on study, then local lab 
result may  be used for assessment of eligibility . In this case, c entral laboratory  samples should 
still be collected for evaluation. Sites do not need to wait for the results of centrally -analyzed 
laboratory  assessments when an immediate clinical decision needs to be made, and in those 
cases locally  unscheduled testing may be performed. 
For LGG patients receiving carboplatin plus vincristine, local laboratory results can be used as 
required during chemotherap y when a central lab is not scheduled per Visit Evaluation Schedule 
(Table 7-1, Table 7 - 2 or Table 7-3)or when central lab results will not be received in time for 
dosing . [COMPANY_001] must be provided with a copy  of the local laboratory ’s certification (if 
applicable), and a tabulation of the normal ranges and units of each parameter collected in the 
eCRF. Any changes regarding normal ranges and units for laboratory  values assessed during 

[COMPANY_001] Confidential Page [ADDRESS_967594] be reported via an updated tabulation indicating the new effective date. 
Additionally , if at any time a patient has laboratory  parameters obtained from a different 
(outside) laboratory , [COMPANY_001] must be provided with a copy of the certification and a tabulation 
of the normal ranges and units for this laboratory as well. The investigator is responsible for 
reviewing all laboratory  reports for patients in the study  and evaluating any abnormalities for 
clinical significance.
At an y time during the study, abnormal la boratory parameters which are clinically relevant and 
require an action to be taken with study  treatment (e.g., require dose modification and/or 
interruption of study  treatment, or require therapeutic intervention), whether specificall y 
requested in the protocol or not, will be recorded on the AE eCRF page. Laboratory  data will 
be summarized using the Common Terminology Criteria for Adve rse events (CTCAE) version 
4.03. Additional analyses are left to the discretion of the investigator. The frequency  of the 
assessments is indicated in the Visit Evaluation Schedule (Table 7
-1,Table 7-2for LGG 
crossover patients or Table 7 -
3). 
Table [ADDRESS_967595] Name
[CONTACT_111935], Platelets, W hite blood cells, W BC Morphology with Differential (Basophils, 
Eosinophils, Lymphocytes, Monocytes, Neutrophils , Bands , other )
Chemistry Albumin, Alkaline phosphatase, ALT (SGPT), AST (SGOT), Calcium,  Creatinine, 
Magnesium, Sodium, Potassium, glucose (non-fasting) ,Phosphate, Total bilirubin, direct 
bilirubin ,Total protein, Blood Urea Nitrogen (BUN) or Urea
Urinalysis Macroscopic Panel (Dipstick) (Color, Bilirubin, Blood, Glucose, Ketones,  Nitrite, pH, 
Protein, Specific Gravity, Urobilinogen)
If there are any significant findings on the dipstick then a microscopic evaluation should be 
measured: Microscopic Panel (Red Blood Cells and White Blood Cell sediments, Casts, 
Crystals, Bacteria, Epi[INVESTIGATOR_1663])
Hepatitis For patients with a history of chronic HBV and/or HCV: Viral hepatitis serology, Hepatitis B 
surface antigen and Hepatitis B core antibody (IgM) and/or Hepatitis C RNA
Additional tests Serum pregnancy test at screening (females of childbearing potential) . 
Urine pregnancy test on Da y 1, monthly throughout the study and at EOT (females of 
childbearing potential)
[IP_ADDRESS].1 Hematology
Hematology  tests are to be performed b y the central laboratory according to the Visit Schedule 
outlined in the Visit Evaluation Schedule (Table 7 -1,Table 7 - 2 for LGG crossover patients or 
Table 7-3) . The hematology  panel is listed in Table 7-5 .
[IP_ADDRESS].2 Clinical chemistry
Blood chemistry  assessments are to be performed by [CONTACT_711302] ( Table 7 -1,Table 7 - 2 for LGG crossover 
patients or Table 7-3 ).The clinical chemistry  panel includes items listed in Table 7-5 .

[COMPANY_001] Confidential Page 128
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS].3 Urinalysis
Urinaly sis includes items listed in Table 7-5and will be performed according to the Visit 
Evaluation Schedule (Table 7-1, Table 7-2for LGG crossover patients or Table 7-3). Any
significant findings on dipstick will be followed up with a microscopic evaluation.
[IP_ADDRESS].[ADDRESS_967596] depends on whether the female patient is of 
childbearing potential or non
-childbearing potential. 
Females of child- bearing potential are defined as all females physiologically  capable of 
becoming pregnant. This includes female pediatric patients who are menarchal or who become 
menarchal during the study . All menarchal females and their parents/caregivers should be 
inform ed about the potential risks of pregnancy  and the need to prevent pregnancy  during the 
study . It is important to be sensitive in introducing this issue, as understanding and 
comprehension of puberty , sexual activity , pregnancy  and contraception is influenc ed by [CONTACT_654], 
as well as factors as precocity , socio (educational) economic and familial background. These 
discussions with the patient and her parents/caregivers are therefore best performed by 
[CONTACT_711303]. These discussions should take into account the 
socio- economic, cultural factors and religious beliefs of the participant and her family . The 
investigator should also discuss the management of the pregnancy  test results with the patient 
and her parents/caregivers. The privacy of patient should be considered in accordance with the 
local law and ethics.
All women of child bearing potential must undergo a serum pregnancy  test at screening (Day  -
28 to Da y -1). On Day  [ADDRESS_967597] will be performed as per 
the Visit Evaluation Schedule ( Table 7 -1,Table 7-2for LGG crossover patients or Table 7 - 3).
On Day  1, the urine pregnancy  test must be confirmed negative before dosing. 
Urine pregnancy  test kits willbe provided to patients for administering the test at home using 
the kit provided. For all urine pregnancy  tests performed at home, the site personnel will follow -
up with the patient to collect the date and test results and document the information in the 
patient’s source document and entered in the clinical database. If local requirements dictate 
otherwise, local regulations should be followed. 
Patients with a positive pregnancy  test result during screening must be excluded from the study . 
In case of pregnancy  during study  participation, the patient must permanently  stop study 
treatment immediatel y, and the pregnancy  must be reported on the Clinical Trial Pregnanc y 
Form. If a positive pregnancy  test is performed in between study  visits, the patient must 
immediately  notify  the investigator. 
[IP_ADDRESS].5 Hepatitis screen
Patients with medical history  of Hepatitis B or C may be enrolled in the study  if there is 
laboratory  evidence of cleared HBV and/or HCV at screening. 

[COMPANY_001] Confidential Page 129
Protocol Amended Version 05 Protocol No. CDRB436G2201
 
 
 
 
 
[IP_ADDRESS] Cardiac assessments 
[IP_ADDRESS].1 Electrocardiogram (ECG)
Standard 12- lead ECG should be performed according tothe Visit Evaluation Sched ule (Table 
7-1, Table 7-2for LGG crossover patients or Table 7-3).ECGs will be collected as single 
measurements in the supi[INVESTIGATOR_2547] .  
If an abnormal ECG is obtained at an y time, patient’s electrol ytes must be reviewed and repeat 
ECG measurements must be done after correction of electrol yte abnormalities. I n the event that 
a QTcF value of ≥ 501 ms is observed , obtain two or more additional ECGs over a brief period, 
and then use the average QTc values of the three ECGs to determine if study treatments should 
be interrupted or discontinued as per Section [IP_ADDRESS]. 
An ECG may  be repeated at the discretion of the investigator at any  time during the study  and 
as clinically  indicated.
Interpretation of the tracing must be made by a
 qualified physician and documented on the ECG 
eCRF page. Clinically  significant abnormalities present when the patient signed informed 
consent /assent should be reported on the Medical History  eCRF page. Clinically  significant 
findings must be discussed with [COMPANY_001] prior to enrolling the patient in the study . New or 
worsene d clinicall y significant findings occurring after informed consent /assent must be 
recorded on the Adverse Events CRF page.
Two copi[INVESTIGATOR_664166], to be kept in the 
source documents and in the study  file at the study  site for retrospective collection by [CONTACT_711304] . Each ECG tracing should be labeled with the study  number, patient initials 
(where regulations permit), patient number, and date. 
[IP_ADDRESS].2 Cardiac imaging - Echocardiogram
Echocardiogram will be performed according tothe Visit Evaluation Schedule (Table 7-1,
Table 7
-2for LGG crossover patients or Table 7 -3).
Cardiology  consultations should be performed on patients who experience >10% absolute 
decrease in LVEF from baseline and whose cardiac ejection fraction is less than the institution’s 
LLN. 
Copi[INVESTIGATOR_711200] . 

[COMPANY_001] Confidential Page 130
Protocol Amended Version 05 Protocol No. CDRB436G2201
7.2.3 Pharmacokinetics
Pharmacokinetic blood samples will be collected for the analysis of plasma concentrations of 
dabrafenib, its metabolites hydroxy-dabrafenib, carbox y-dabrafenib, anddesmethy l-
dabrafenib ([COMPANY_004]2285403, [COMPANY_004]2298683 and [COMPANY_004]2167542, respectively ), and trametinib.
Full PK blood samples will be collected asdescribed in Table 7-6for all patients in the HGG 
cohort and the first 20 LGG patients randomized to dabrafenib plus trametinib treatment . For 
the remaining LGG patients on dabrafenib plus trametinib treatment, sparse PK blood samples 
will be collected as described inTable 7 -7. An unscheduled PK blood sample may be collected 
at any time for measurement of plasma drug concentrations if clinicall y indicated or at the 
Investigator’s discretion.  PK samples will not be collected from LGG patients after they 
crossover from carboplatin with vincristine treatment.
The date and exact time of dosing, as well as the date and actual time of blood sampling must 
be recorded on the appropriate eCRF pages. Any sampling problems (e.g., patient took study  
drug before blood sample, scheduled sampling time is missed, sample is not drawn according 
to the schedule) should be noted as a comment on the eCRF.
If vomiting occurs during the course of treatment, no re-dosing of the patient is allowed, and 
medication should resume at the next scheduled dose. The occurrence and frequency  of any 
vomiting must be noted in the adverse 
events section of the eCRF. In addition, the date and 
exact time of vomiting should only be recorded if it occurs within [ADDRESS_967598] time (whenever possible) must be 
noted on the PK Dose and Administration Record eCRF.
Concentrations of dabrafenib , itsmetabolites and trametinib will be summarized; a detailed 
description of the planned PK analy ses is given in 
Section 10.5.2.
[IP_ADDRESS] Pharmacokinetic blood collection and handling
Blood samples will be taken either by [CONTACT_711305] 
(e.g., inserted in a forearm vein, or central venous line). 
At the specified time points described in Table 7 -6and Table 7 -7,one single 1 mL  blood draw 
will be collected into a tube containing EDTA and gently  inverted several times to thoroughly 
mix the anticoagulant. The blood tube will be centrifuged to separate plasma and transferred 
into separate pre-labeled tubes for dabrafenib . Plasma samples will be stored 
frozen in an 
upright position until shipment.
Refer to the [CDRB436G2201 Laboratory Manual] for detailed instructions for the collection, 
handling, and shipment of PK samples.

[COMPANY_001] Confidential Page 131
Protocol Amended Version 05 Protocol No. CDRB436G2201
Table 7-6 Full Pharmacokinetic blood collection log –HGG cohort and subset of 
LGG cohort
Week DayScheduled 
timepointDose 
reference ID 
Dabrafenib* Dose 
reference ID 
Trametinib*PK 
Sampl
e No*Sample volume [mL]
Patient
s 
<10kgPatients 
≥10kg and 
<25kgPatients 
≥25kg
[ADDRESS_967599]-dose 0.5 
hr ±5mins101 201 101 N/A [ADDRESS_967600]-dose 2 hr
±5mins101 201 102 N/A [ADDRESS_967601]-dose 4 hr
±20mins101 201 103 N/A [ADDRESS_967602]-dose 0.5 
hr
±5mins102 202 105 N/A N/A [ADDRESS_967603]-dose 1 hr
±5mins102 202 106 N/A [ADDRESS_967604]-dose 2 
hrs
±5mins102 [ADDRESS_967605]-dose 3
hrs
±20mins102 202 108 N/A [ADDRESS_967606]-dose 4 
hrs
±20mins102 [ADDRESS_967607]-dose 6 
hrs
±20mins102 202 110 N/A N/A [ADDRESS_967608]-dose 8 
hrs
±20mins102 202 111 N/A 1 mL 1 mL
4 1 Pre-dosea
-30mins103 13b203      15b112 1 mL 1mL 1 mL
Unscheduled PK Samplec--- 16d17d1001+ [ADDRESS_967609] Dose Reference ID ( DRID no. ) is for current dose, while the second DRID no. is for the last dose the 
patient received prior to the collection of the PK sample .
cUnscheduled PK samples will be uniquely, sequentially numbered 1001, 1002, etc.
dLast dose the patient received prior to the collection of the unscheduled PK
Note: *DRID and sample numbers implemented in the above table are for [COMPANY_001] internal reference. 
Table 7-7 Sparse Pharmacokinetic blood collection log for subset of LGG cohort
Week DayScheduled 
timepointDose 
reference ID 
Dabrafenib* Dose 
reference ID 
Trametinib*PK 
Sampl
e No*Sample volume [mL]
Patient
s 
<10kgPatients 
≥10kg and 
<25kgPatients 
≥25kg
[ADDRESS_967610]-dosee1-
3 hr301 401 202 N/A N/A 1 mL

[COMPANY_001] Confidential Page 132
Protocol Amended Version 05 Protocol No. CDRB436G2201
Week DayScheduled 
timepointDose 
reference ID 
Dabrafenib* Dose 
reference ID 
Trametinib*PK 
Sampl
e No*Sample volume [mL]
Patient
s 
<10kgPatients 
≥10kg and 
<25kgPatients 
≥25kg
Post-dosef5-
10 hr301 401 203 N/A 1 mL 1 mL
4 1 Pre-dosea
-30mins302 22b402      24b204 1 mL 1 mL 1 mL
Unscheduled PK Samplec--- 25d26d2001+ [ADDRESS_967611] Dose Reference ID (DRID no.) is for current dose, while the second DRID no. is for the last dose the 
patient received prior to the collection o f the PK sample.
cUnscheduled PK samples will be uniquely, sequentially numbered 2001, [ADDRESS_967612] dose the patient received prior to the collection of the unscheduled PK
ePK samples can be collected anytime between 1-3 hours after the morning dose
fPK samples can be collected anytime between 5 -10 hours after the morning dose
Note: *DRID and sample numbers implemented in the above table are for [COMPANY_001] internal reference. 
[IP_ADDRESS] Analytical method
Plasma concentrations of dabrafenib and its metabolites hydroxy-dabrafenib ([COMPANY_004]2285403), 
carbox y-dabrafenib ([COMPANY_004]2298683), and desmethyl -dabrafenib ([COMPANY_004]2167542) and trametinib
will be measured using validated liquid chromatograph y/mass spectrometry/ mass spectrometry
(LC/MS/MS) methods. The lower limit of quantification (LLOQ) for dabrafenib, hydroxy-
dabrafenib and desmethyl -dabrafenib is1 ng/mL and 0.25 ng/mL for trametinib for a 50 L 
aliquot of human plasma. The LLOQ for carbox y-dabrafenib is5ng/mL  for a 25 L aliquot of 
human plasma. Concentrations below the LLOQ will be treated as zero.
 
 
 
[IP_ADDRESS] Meal record
Meal records must be kept for all patients on PK day sas indicated in Table [ADDRESS_967613] be recorded in the CRFs. 

[COMPANY_001] Confidential Page 133
Protocol Amended Version 05 Protocol No. CDRB436G2201

[COMPANY_001] Confidential Page 134
Protocol Amended Version 05 Protocol No. CDRB436G2201
Other assessments
No additional tests will be performed on patients entered i nto this study .
7.2.5 Resource utilization
Not applicable.
7.2.6 Patient reported outcomes (LGG cohort only)
Patient reported outcomes (PRO) will be assessed using the PROMI S Parent Proxy  Global 
Health 7+2forLGG patien ts. The PRO will measure the patient’s overall evaluation of his or 
her physical, mental, and social health. PRO data will be collected using an electronic tablet 
device and administered in the patient’s local language. Patients should be given the 
questionnaire to be completed before any clinical assessments are performed . Site personnel 
must review the questionnaire for completeness, and document patient’s refusal to complete all 
or any part of the questionnaire. Completed questionnaire and any unsolicite d comments written 
by [CONTACT_711306]. If AEs or SAEs are confirmed, investigators should not 
encourage the patient to change responses reported in the completed questionnaire. 
Investigators must follow reporting instructions outlined in Section 8 . Questionnaires are 
administered according to the Table 7-1and Table 7 - 3until the patient disease progression per 
RANO criteria. 
7.2.7 Acceptability and Palatability  Questionnaire s
All patients who receive the dabrafenib oral suspension and/or trametinib oral solution will 
complete the respective questionnaire to evaluate the palatability and acceptability /tolerability
of the pediatric formulations. The dabrafenib oral suspension and trametinib oral solution 
questionnaire s must be completed after the dosing of dabrafenib with trametinib according to
Table 7
-1. 

[COMPANY_001] Confidential Page 135
Protocol Amended Version 05 Protocol No. CDRB436G2201
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), symptom(s), or medical condition(s) that occur after patient’s signed informed 
consent /assent has been obtained.
Abnormal laboratory  values or test results occurri ng after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or requ ire changes in study  medication(s).
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events CRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s eCRF. Adverse event monitoring should 
be continued for at least [ADDRESS_967614] dose of study  treatment. Adverse events 
(including lab abnormalities that constitute AEs) should be described using a diagnosis 
whenever possible, rather than individual underly ing signs and symptoms. When a clear 
diagnosis cannot be identified, each sign or s ymptom should be reported as a separate Adverse 
Event.
Adverse events will be assessed and graded according to the Common Terminology  Criteria for 
Adverse Events (CTCAE) version 4.03. Grade [ADDRESS_967615] for an adverse event, the severit y of mild, moderate, severe, 
and life -threatening, death related to the A Ecorresponding respectively toGrades 1 - 5, will be 
used. Information about any deaths (related to an Adverse Event or not) willalso be collected 
though a Death form .
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
(subject) during the screening process after signing informed consent/assent and at each visit 
during the study . Adverse events also may be detected when they are volunteered by [CONTACT_102] 
(subject) during the screening process or between visits, or 
through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:
1.The severit y grade (CTCAE Grade 1 -5)
2.Its duration (Start and end dates) 
3.Its relationship to the study  treatmen t (Reasonable possibility  that AE is related: No,
Yes, investigational treatment, Yes, the study  treatment (non -investigational), Yes, both 
and/or indistinguishable)
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temp
oraril y interrupted, permanentl y discontinued, unknown, not applicable , 
investigational treatment resumed )

[COMPANY_001] Confidential Page 136
Protocol Amended Version 05 Protocol No. CDRB436G2201
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6.Outcome (not recovered/ not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown) 
7.Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.[ADDRESS_967616] been met
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event eCRF.
Once an adverse event is detected, it should be followed unt il its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently , if necessary ) 
of any changes in severity , the suspected relationship to the study  treatment, the interventions 
required to treat it, a nd the outcome.
Progression of malignancy  (including fatal outcomes), if documented by [CONTACT_15039] ( as per RANO criteria) should not be reported as a serious adverse event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper attribution regarding 
relatedness to the drug.
8.1.[ADDRESS_967617] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute an Adverse event in their own right (are considered 
clinically  significant, induce clinical signs or symptoms, require concomitant therap y or require 
changes in study  treatmen t), should be recorded on the Adverse Events eCRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test resul t as an additional 
event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality  may be required b y 
the protocol in which case the lab abnormality  would still, by [CONTACT_108], be an adverse event 
and must be reported as such.
8.1.[ADDRESS_967618] (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program, for 
which ongoing monitori
ng and rapid communication by  [CONTACT_711307] [ADDRESS_967619] include:
Skin related toxicities
Ocular events
Cardiac related events
Hepatic disorders
Pneumonitis/interstitial lung disea se
Bleeding events
Hypertension
Complicated py rexia and/or grade 3 and grade 4
Pre-Renal and intrinsic renal failure
Uveitis
New primary /secondary  malignancy
Hypersensitivity
Hypergl ycemia
Deep venous thrombosis/pulmonary  embolism
Pancreatitis
Neutropenia
Potential emergent new AEs will be monitored during the course of the study. 
[IP_ADDRESS] Definitions and reporting
Refer to Section 8.1.1. 
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require m edical or surgical intervention to prevent one of the outcomes listed above
Requires inpatient hospi[INVESTIGATOR_1081], 
Note that hospi[INVESTIGATOR_14944]:

[COMPANY_001] Confidential Page 138
Protocol Amended Version 05 Protocol No. CDRB436G2201
Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition 
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since sig ning the informed 
consent /assent
Social reasons and respi[INVESTIGATOR_5316]’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_64007] t fulfilling an y of the definitions of a SAE given above 
is not a serious adverse event
8.2.2 Reporting
To ensure patient safet y, every  SAE, regardless of suspected causality , occurring after the 
patient has provided informed consent /assent and until at least 30days after the patient has 
stopped study  treatment must be reported to [COMPANY_001] within [ADDRESS_967620] be r eported as follow -up to the original epi[INVESTIGATOR_5319] 24 hours of 
the investigator receiving the follow -up information. An SAE occurring at a different time 
interval or otherwise considered completely  unrelated to a previousl y reported one should be 
reported separatel y as a new event.
Any SAEs experienced after the 30 day safety evaluation follow -up period should only be 
reported to [COMPANY_001] if the investigator suspects a causal relationship to the study  treatment.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within [ADDRESS_967621] as the original SAE Report.  Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, and whether the patient 
continued or withdrew from study  participation.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the [COMPANY_001] study  treatment, an oncology  [COMPANY_001] 
Chief Medical office and Patient Safety  (CMO&PS) department associate may urgently  require 
further information from the investigator for Health Authority  reporting. [COMPANY_001] may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 
Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant 

[COMPANY_001] Confidential Page 139
Protocol Amended Version 05 Protocol No. CDRB436G2201
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participating countries .
8.3 Emergency  unblinding of treatment assignment
Since this study  is an open -label study, there is no need for treatment unblinding instructions or 
unblinding codes. 
8.4 Pregnancies
To ensure patient safety , each pregnancy  occurring after signing the informed consent/assent 
and [ADDRESS_967622] be reported to [COMPANY_001] within 24 hours of learning of 
its occurrence. The pregnancy  should be followed up to determine outcome, including 
spontaneous or voluntary termination, details of the birth, and the presence or absence of any 
birth defects, congenital abnormalities, or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_711308] y (CMO&PS) . 
Pregnancy  follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the [COMPANY_001] study  treatment of any pregnancy  outcome. Any 
SAE experienced during pregnancy  must be reported on the SAE Report Form.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
8.5 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator 
Brochure. Additional safety  information collected between IB updates will be com municated 
in the form of Investigator Notifications. This additional safety  information, if any,will be 
included in the patient informed consent/assent and should be discussed with the patient during 
the study  as needed.
8.6 Data Monitoring Committee 
Adata monitoring committee (DMC) will independently  monitor the safety  of patients enrolled 
in this study. The DMC will function independently of all other individuals associated with the 
conduct of this clinical trial, including the site investigators participa ting in the study . The DMC 
will be constituted prior to the randomization of the first patient into the LGG cohort . The DMC 
will be responsible to review safet y data from the HGG and LGG cohort sapproximately  ever y 
[ADDRESS_967623] at a minimum of two physicians with appropriate 
disease area qualifications and one statistician. There will be a meeting with the DMC 
describing their roles and responsibilities and discussing potenti al data format and process 
issues prior to the finalization of DMC charter and the statistical analy sis plan .
8.7 Steering Committee
A steering committee (SC) will be established comprising ofinvestigators participating in the 
trialprior to initiation of the trial. 
The SC will ensure transparent management of the study , both HGG and LGG cohorts,
according to the protocol through recommending and approving modifications as circumstances 
require. The SC will review protocol amendments as appropriate. Together with the clinical 
trial team, the SC will also develop recommendations for publications of study  results including 
authorship rules. The details of the role of the Steering Committee will be defined in a Steering 
Committee charter.
9 Data collection and mana gement
9.1 Data confidentiality
Information about study  patient s will be kept confidential and managed under the applicable 
laws and regulations. Those regulations require a signed patient authorization informing the 
patient of the following:
What protected he alth information (PHI) will be collected from patient s in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research patient to revoke their authorization for use of their PHI .
In the event that a patient revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability  to use all information collected prior to the revocation of patient 
authorization. For patient s that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the patient 
experienced an y new or worsened AEs) at the end of their scheduled study period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individ ually  assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.
Prior to entering key sensitive personally  identifiable information (Patient Initials and exact 
Date of Birth), the system will prompt site to verify  that this data is allowed to be collected. If 
the site indicates that country  rules or ethics committee standards do not permit collection of 
these items, the system will not solicit Patient Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the patient satisfies protocol age requirements and 
to enable appropriate age -related normal ranges to be used in assessing laboratory  test results.

[COMPANY_001] Confidential Page 141
Protocol Amended Version 05 Protocol No. CDRB436G2201
9.2 Site monitoring
Before study  initiatio n, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel will review the protocol and eCRFs with the investigators and their staff. During the 
study , the field monitor will visit the site regularl y to check the completeness of patient records, 
the accuracy  of entries on the eCRFs, the adherence to the protocol to Good Clinical Practice, 
the progress of enrollment, and to ensure that study  treatment is being stored, dispensed, and 
accounted for according to specifications. Key study personnel must be available to assist the 
field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on eCRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed i nformed consent /assent form 
(a signed cop y is given to the patient /legal guardian ).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the eCRF entries. [COMPANY_001] monitoring standards require full verification for 
the presence of informed consent /assent , adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency of the source data with the CRFs 
are performed according to the study -specific monitor ing plan.
9.3 Data collection
Electronic Data Capture (EDC) is used for this study . The designated investigator staff will 
enter the data required by [CONTACT_5374] (eCRF). The 
eCRFs have been built using fully validated secure web-enabled software that conforms to [ADDRESS_967624] been trained. Automatic validation programs check for data discrepancies in the 
eCRFs and, allow modif ication or verification of the entered data by  [CONTACT_6649].
The Principal Investigator [INVESTIGATOR_20115], 
accurate, and that entry and updates are performed in a timely  manner.
Pharmacokineti c (PK)  will be collected in this study . 
Designated investigator staff will enter the required information onto the PK  
sample collection eCRFs.  
 The field monitor will 
review the relevant eCRFs for accuracy  and completeness and will work with the site staff to 
adjust any discrepancies as required. The field monitor will also review requisition forms for 
completeness. 
Radiological scans used for tumor assessments will be centrall y collected and reviewed.
Data entered into IRT will be transferred electronically  to [COMPANY_001] as described in the Data 
Transfer Specifications for designated IRT vendor. 

[COMPANY_001] Confidential Page [ADDRESS_967625], which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be code d using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Samples and/or data will be processed centrall y and the results will be sent electronically to 
[COMPANY_001] (or a designated CRO). Data that will be processed centrally  include:
IRTdata including information regarding screening, drug assignment and discontinuation
Central imaging review (i.e. MRI  scans)
Centrally  anal yzed laboratory  data including clinical, PK,  and safet y 
parameters
Data about all study  treatments dispensed to the patient and all IRT assigned dosage changes 
will be tracked using an Interactive Response Technology . The system will be supplied by a 
vendor(s), who will also manage the database. The data will be sent electronically to [COMPANY_001] 
personnel ( or designated CRO).
At the conclusion of the study , the occurrence of any protocol violations will be determined. 
After these actions have been completed and the data has been verified to be complete and 
accurate, the database will be declared locked and made available for data analysis. 
Authorization is required prior to making any  database changes to locked data, by [CONTACT_711309].
After database lock, the investigator will receive a CD -ROM or paper copi[INVESTIGATOR_436652].
10 Statistical methods and data analy sis
The data from all participating centers in this protocol will be combined. 
The data for the HGG and LGG cohorts will be analy zed independentl y with timing of analyses 
based on specific independent criteria for each cohort outlined in this protocol. 
Note that there may be a need to support the initial submission of an indication based on the 
primary  analysis data with safety  and PKinterim data from both cohorts. Thus the initial 
planning of the primary  analysis for a specific cohort should anticipate that a safety  interim or 
update anal ysis of the other cohort may also be required.
The primary  endpoint for the HGG cohort will be analy zed at the time of the interim analy sis 
and the study  may be stopped for futility  according to the criteria described in the Interim 
Analy sis Section (Section 10.7). If the HGG cohort is not stopped at interim analy sis then the 

[COMPANY_001] Confidential Page [ADDRESS_967626] discontinued earlier. These data w ill be 
summarized in the primary Clinical Stud y Report (CSR). The final analysis of the HGG cohort
will be conducted at the end of the stud y as specified in Section 4.3. All available data from all
HGG c ohort patients up to th e end of stud y cutoff date will be anal yzed.
The primary  analysisfor the LGG cohort will be conducted when all treated 
patients have either 
completed at least 32weeks of treatment or have discontinued earlier. These data will be 
summarized in the primary  CSR. 
The final analysis of LGG cohort will be conducted at the end of the study  as specified in 
Section 4.3 .All available data from all LGG cohort patients up to th e end of study cutoff date 
will be anal yzed.
All data will be summarized by  [CONTACT_711310].
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Analy sis Set (FAS) for the HGG cohort will include all patients towhom study  
treatment has been assigned and w ho receive at least one dose of study  treatment.
For the LGG cohort the FAS comprises all patients to whom stud y treatment has been assigned 
by [CONTACT_711311] . According to the 
intent to treat principle, patients will be analy zed according to the treatment they have been 
assigned to during the randomization procedure.
10.1.[ADDRESS_967627] treatment received if the randomized treatment was never received.
10.1.3 Per-Protocol Set
Not applicable.
10.1.4 Dose -determining analy sis set
Not applicable. 
10.1.5 Pharmacokinetic analy sis set
The pharmacokinetic analy sis set (PAS) for both HGG and LGG cohort consists of all patients 
who receive at least one (full or partial) dose of dabrafenib or trametinib and provide at least 
one evaluable pharmacokinetic (PK) blood sample . 
The definition of an evaluable PK blood sample will be further specified in the SAP.

[COMPANY_001] Confidential Page 144
Protocol Amended Version 05 Protocol No. CDRB436G2201
10.1.6 Other analy sis sets
[IP_ADDRESS] Evaluable set
The Evaluable Set (ES) consists of all evaluable patients in the FAS who have centrall y 
confirmed measurable disease , positive BRAF V600 mutation, an adequate tumor assessment 
at baseline, and a follow -up tumor assessment at least 8weeks after starting treatment (unles s 
disease progression is observed before that time) or have discontinued for any reason. For the 
HGG cohort, the evaluable set also requires that the patient’s tumor is centrally  confirmed by 
[CONTACT_711312].
The evaluable set will be used for sen sitivity  analy ses.
10.2 Patient demographics/other baseline characteristics
For each cohort, d emographic and other baseline data including disease characteristics will be 
summarized descriptively  by [CONTACT_155426]. Categorical data will be 
presented as frequencies and percentages. For continuous data, mean, standard deviation, 
median, 25thand 75thpercentiles, minimum, and maximum will be presented.
Relevant medical histories and current medical at baseline will be summarized separately  by 
[CONTACT_6657].
10.3 Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014], 
compliance)
The safet y set will be used for the analyses below for each cohort .Categorical data will be 
summarized as frequencies and percentages. For continuous data, mean, standard deviation, 
median, 25th and 75th percentiles, minimum, and maximum will be presented.
For the dabrafenib plus trametinib combination in each cohort the duration of exposure in weeks 
to dabrafenib and trametinib as well as the dose intensity (computed as the ratio of actual 
cumulative dose received and actual duration of exposure) and the relative dose intensity 
(computed as the ratio of dose intensity  and planned dose intensity ) will be summarized 
separately  for dabrafenib and trametinib by  [CONTACT_605568] y set. 
The duration of exposure will also be presented for the study  treatment of dabrafenib in 
combination with trametinib . 
For the carboplatin with vincristine control arm in the LGG cohort duration of exposure will be 
analyzed similarl y.
The number of patients with dose adjustments (reductions, interruption, or permanent 
discontinuation) and the reasons will be summarized by [CONTACT_1570] (with the individual 
drugs also summarized separately ) and all dosing data will be listed.
Concomitant medications and significant non-drug therapi[INVESTIGATOR_711201] (ATC) classification sy stem by [CONTACT_34689] . 

[COMPANY_001] Confidential Page 145
Protocol Amended Version 05 Protocol No. CDRB436G2201
10.4 Primary  objective
HGG Cohort:
The primary objective of the HGG cohort is to evaluate the anti -tumor activity  of dabrafenib in 
combination with trametinib, as measured by [CONTACT_34426] (ORR) by [CONTACT_711313] .
LGG Cohort:
The primary objective of the HGG cohort is to compare the anti -tumor activity  of dabrafenib in 
combination with trametinib versus carboplatin with vincristine, as measured by [CONTACT_178975] (ORR) b y independent review asse ssment using RANO criteria.
10.4.1 Variable
For the HGG cohort, t he primar y variable used to evaluate the anti -tumor activity  of dabrafenib
in combination with trametinib is the overall response rate (ORR), defined as the proportion of 
patients with a best overal l confirmed Complete Response (CR) or Partial Response (PR) as 
assessed per Response Assessment in Neuro- Oncology  (RANO) criteria by [CONTACT_481270] . 
For the LGG cohort ,the primary  variable used to evaluate the anti -tumor activity  of dabrafenib 
in combination with trametinib versus carboplatin with vincristine is the overall response rate 
(ORR), defined as the proportion of patients with a best overall confirmed Complete Response 
(CR) or Partial Response (PR) as assessed per Response Assessment in Neuro -Oncology  
(RANO) criteria b y the independent reviewer. 
10.4.[ADDRESS_967628] binomial confidence interval s(CIs) (Clopper and Pearson 1934) of ORR will be provided.
The lower bound of the CIs will be used to provide evidence that the true ORR is greater than 
a certain specific response rate.
The 95% CI, via the lower
limit, is used to establish the levels of response which are exceeded 
by [CONTACT_711314] y according to a robust standard of evidence (i.e. one-sided 
alpha=0.025). For example, out of
[ADDRESS_967629] discontinued treatment earlier, if 14 responses (35% ) are 
observed then the corresponding 95% CI will exclude 20% which is greater ,than the typi[INVESTIGATOR_711202] y observed ( Lashford 2002; Nicholson 2007; Ruggiero 
2006; Warren 2012 ; Hummel 2013 ). 
With respect to the HGG cohort, the study  also aims to provide evidence that trametinib gives 
added value to the dabrafenib and trametinib combination over and above dabrafenib 
monotherap y treatment. Since a lower standard of evidence is usuall y required to show such 
added value the lower limit of an 80% CI is used to identify  the response rates which will be 
exceeded by [CONTACT_711315] a reduced level of evidence (one-sided 
alpha of 0.1). For example, if 18 responses (45%) out of the 40 patients are observed then the 
lower bound of 80% CI will exclude 32%, which is the response rate of dabrafenib monotherap y 

[COMPANY_001] Confidential Page 146
Protocol Amended Version 05 Protocol No. CDRB436G2201
observed from the study  [BFR116013, CDRB436A2102 ]. In additio n, the 95% CI can also be 
used to provide more robust evidence of the added benefit of trametinib. For example, if 20 
responses (50%) are observed, then the lower bound of 95% CI will also exclude 32%. 
LGG Cohort
The primary  efficacy  analysis in the LGG cohort is the comparison of ORR based on 
independent review assessment between the two treatment arms. The following statistical 
hypothesis will be tested: 
H  :     ≤     vs. H  :     >     
where      is the ORR in the Trametinib plus Dabrafenib arm and      isthe ORR in the 
carboplatin with vincristine arm. The analy sis to test these hypotheses and compare the two 
treatment groups will consist of a Mantel Haenszel chi-square test at one-sided 2.5% level of 
significance. 
The primary  efficacy  analy sis will be performed on the FAS.
ORR will be summarized using descriptive statistics (N, %) by  [CONTACT_711224] -
sided exact binomial 95% CI s (Clopper and Pearson 1934
).
10.4.3 Handling of missing values/censoring/discontinuations
Patients with unknown or missing best overall response (BOR) will be counted as failures. If 
there is no baseline tumor assessment, all post -baseline overall lesion respon ses are expected to 
be ‘Unknown’. If no valid post-baseline tumor assessments are available, the best overall 
response must be“Unknown” unless progression is reported. For the computation of ORR, 
these patients will be included in the FAS and will be coun ted as ‘failures’.
10.4.4 Supportive and sensitivity analy ses
The following supportive and sensitivity  analyses will be performed for the HGG and LGG 
cohorts as appropriate.
The primary  analysis on the FAS will be repeated on the evaluable set.The analyses of ORR, 
DOR, and PFS will be repeated based on radiological response assessed by [CONTACT_711316]. In addition, ORR , DO R and PFS will 
be evaluated using a ITTapproach i.e including allresponse assessments irrespective of new 
anti-neoplastic therap y using the FAS. 
If the primary  efficacy  analysis shows that the 95% CI of ORR excludes 20% for HGG and 
statistically  significant for LGG, the following subgroups may  be considered:
The prima ry efficacy  endpoint ORR and secondary endpoint DOR by [CONTACT_711317]. The risk categories will be specifi ed in 
a later SAP amendment prior to database lock .
The SAP will pre -specify anal yses that will be conducted using crossover data, if applicable.
[COMPANY_003]
[COMPANY_001] Confidential Page [ADDRESS_967630] to the HGG cohort, the secondary  objectives are to evaluate the overall response 
rate (ORR) by [CONTACT_3138] , duration of response (DOR), time to response (TTR), 
clinical benefit rate (CBR), progression- free survival (PFS) by [CONTACT_711318], as well as overall survival (OS), and safet y. 
LGG Cohort
With respect to the LGG cohort t he secondary  objectives related to efficacy  in this study  are to 
compare the two treatment groups with respect to the overall response rate (ORR) by 
[CONTACT_3138] , duration of respons e (DOR), time to response (TTR), clinical benefit 
rate (CBR), andprogression -free survival (PFS) by [CONTACT_711319] (OS), safet y, and patient reported outcome 
(PRO) . 
All secondary  efficacy  analyses will be performed based on the FAS and will be repeated for 
the Evaluable set.All secondary  endpoints will be listed and summarized separately  for each 
cohort by [CONTACT_1570]. 
For the LGG cohort, a hierarchical approach will be taken to control for the overall type -I error 
rate for testing of multiple endpoints: PFS will be formally  tested only  if the primary  endpoint 
ORR is statistically  significant and then OS will be formally  tested if PFS is also significant. No 
other multiplicit y adjustments are planned for secondary  endpoints testing.
ORR by [CONTACT_3138] (HGG Cohort)
For the HGG cohort, t he evaluation of ORR will be repeated by  [CONTACT_711320] .ORR will be summarized using descriptive statistics (N, %) along with [ADDRESS_967631] 95% confidence intervals (CIs) (Clopper and Pearson 1934). 80% confidence intervals
will also be provided for the HGG cohort.
ORR by [CONTACT_3138] (LGG Co hort)
For the LGG Cohort the 
evaluation of ORR will be repeated by [CONTACT_711321].
The Cochrane -Mantel -Haenszel chi -square test will be used to compare ORR between the two 
treatment groups, at the one- sided 2.5% lev el of significance.
Duration of response
Among patients with a confirmed response (PR or CR) per RANO, duration of response (DOR) 
is defined as the time from first documented response (PR or CR) to the date of first documented 
disease progression or death due to any cause. DOR will be listed by [CONTACT_711322] 148
Protocol Amended Version 05 Protocol No. CDRB436G2201
described using Kaplan -Meier curves and relevant statistics if appropriate. Only  the subset of 
patient s who show a confirmed complete or partial tumor response will be included. Censoring 
rules forDOR will be outlined in detail in the SAP. DOR will be analyzed as per investigator 
assessment and as per central independent assessment, separately .
Progression free survival
Progression- free survival (PFS) is defined as the time from the date of first dose of study 
treatment (for HGG cohort) or date of randomization (for LGG cohort) to the date of first 
documented disease progression per RANO criteria or death due to an y cause .
A patient who has not progressed or died or has received any further anticancer therapy  at the 
analysis cut-off date, PFS will be censored at the time of the last adequate tumor evaluation 
before the cut-off dateor before the start of the new anticancer therapy  date, whichever is earlier. 
By [CONTACT_15094], if disease progression or death is documented after one single missing tumor 
evaluation, the actual event date of disease progression/death will be used for the PFS event 
date. If disease progression or death is documented after two or more missing tumor evaluations, 
the PFS time of these patients will be censored at the date of the last adequate tumor evaluation 
without PD. Censoring rules for PFS will be described in detail in the S AP.
PFS assessed by [CONTACT_711323] -Meier methods and appropriate summary  statistics. 
For the LGG cohort the hazard ratio for PFS will be calculated, along with its 95% confidence 
interval, using a Cox model. A log-rank test at the one- sided 2.5% level of significance will be 
used to compare the two treatment groups.
PFS estimates (and 95% CI s) for both cohorts will be prov ided for key timepoints (i.e. 12, 24, 
36 months).
Time to response (TTR)
Time to respons e (CR or PR) is the time from start date of study  treatment (for HGG cohort) or 
date of randomization (for LGG cohort) to first documented response of CR or PR (which must 
be confirmed subsequently ) according to RANO criteria. All patients in the FAS will be 
included in the time to response calculation s
.Patients without a confirmed CR or PR will be 
censored at the study -maximum follow -up time (i.e., LPLV-FPFV) for patients with a PFS 
event (i.e., disease progression or death due to any cause), or at the date of the last adequate 
tumor assessment for patients without a PFS event. TTR will be listed and summarized by 
[CONTACT_1570].
The distribution of time to response will be estimated using the Kaplan -Meier method and the 
median time to response will be presented along with 95% confidence interval only if a 
sufficient number of responses is observed. A responders
-only analysis will also be performed 
in this case.
TTR will be analyzed using investigator and independent reviewer assessments separately .

[COMPANY_001] Confidential Page 149
Protocol Amended Version 05 Protocol No. CDRB436G2201
Clini cal Benefit Rate 
Clinical benefit rate ( CBR )is defined as the proportion of patients with a best overall response 
of CR or PR, or an overall lesion response of SD which lasts for a minimum time duration of at 
least [ADDRESS_967632] SD for 24 weeks or longer if a SD response 
is recorded at 23 weeks or later (i.e >= 161 days) from randomization, allowing for the ±1 week 
visit wind ow for tumor assessments.
For the HGG cohort, CBR will be summarized using descriptive statistics (N, %) along with [ADDRESS_967633] 95% confidence intervals (CIs) (Clopper and Pearson 1934 ). 
For the LGG Cohort, CBR will be summarized by [CONTACT_73332] 2-sided ex act 95% 
confidence intervals (CI s). Cochrane -Mantel -Haenszel chi -square test will be used to compare 
CBR between the two treatment groups, at the one -sided 2.5% level of significance.
Overall survival
Overall survival (OS) is defined as the time from the date of first dose of study  treatment (for 
HGG cohort) or date of randomization (for LGG cohort) to the date of death due to any  cause. 
OS time for patients who are alive at the end of the study  or are lost to follow -
up will be 
censored at the date of last contact.
OS will be described using Kaplan -Meier methods and appropriate summary  statistics.
For the LGG cohort, the hazard ratio for OS will be calculated, along with its 95% confidence 
interval, using a Cox model. A log-rank test at the one- sided 2.5% le vel of significance will be 
used to compare the two treatment groups.
In addition, 2-year OS estimate with corresponding 95% CIs will be provided by [CONTACT_98540].
10.5.1 Safety  objectives
Safety  will be assessed separately  for the HGG and L GG cohorts. For the LGG cohort the data 
will be anal yzed by [CONTACT_2939]. 
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_63964] y anal ysesin both cohorts , the safet y set will be used. All listings and tables will be 
presented by [CONTACT_16983] .
The overall observ
ation period will be divided into three mutually  exclusive segments:
1. P re-treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  medication
2. On- treatment period: from day  of first dose of study  medication to [ADDRESS_967634]-treatment period: starting at day  [ADDRESS_967635]-
treatment period flagged.

[COMPANY_001] Confidential Page 150
Protocol Amended Version 05 Protocol No. CDRB436G2201
[IP_ADDRESS] Adverse events (A Es)
Summary  tables for adverse events (AEs) will include only AEs that started or worsened during 
the on-treatment period , the treatment -emergent AEs.
The incidence of treatment -emergent AEs (new or worsening from baseline) will be 
summarized by  [CONTACT_5379]/ or preferred term, severit y (based on CTCAE grades), 
type of AE, and relation to study  treatment. 
Serious adverse events (SAE) , non- serious adverse events andadverse events of special interest
(AESI) during the on -treatment period will be tabulated.
All deaths (on
-treatment and post -treatment) will be summarized.
All AEs, deaths and serious adverse events (including those from the pre and post-treatment 
periods) will be listed and those collected during the pre-treatment and post-treatment period 
will be flagged. A listing of all groupi[INVESTIGATOR_711203].
[IP_ADDRESS] Laboratory  abnormalities
Grading of laboratory  values will be assigned programmaticall y as per NCI Common 
Terminology  Criteria for Adverse Events (CTCAE) version 4.03. The calculation of CTCAE 
grades will be based on the observed laboratory  values only, clinical assessments will not be 
taken into account.
CTCAE G rade 0 will be assigned for all non
-missing values not graded as 1 or higher. Grade 5 
will not be used.
For laboratory tests where grades are not defined by  [CONTACT_3989] v4.03, results will be categorized 
as low/normal/high based on lab oratory  normal ranges .
The following summaries will be generated separately  for hematology , and biochemistry  tests:
Listing of all laboratory  data with values flagged to s
how the corresponding CTCAE 
v4.03 grades if applicable and the classifications relati ve to the laboratory  normal ranges
For laboratory  tests 
where grades are defined b y CTCAE v4.03
Worst post -baseline CTCAE grade (regardless of the baseline status). Each patient will be 
counted only once for the worst grade observed post -baseline.
Shift tables using CTCAE v4.[ADDRESS_967636] on- treatment 
value
For laboratory  tests where grades are not defined by  [CONTACT_3989] y4.03 ,
Shift tables using the low/normal/high/ (low and high) classification to compare baseline 
to the wor st on-treatment value.
A listing of laboratory  values will be provided by [CONTACT_212937], patient, and study  day. A 
separate listing will display  notable laboratory  abnormalities (i.e., newly occurring CTCAE 
grade 3 or 4 laboratory  toxicities).

[COMPANY_001] Confidential Page 151
Protocol Amended Version 05 Protocol No. CDRB436G2201
 
 
[IP_ADDRESS] Other safety  data
ECG
12-lead ECGs including PR, QRS, QT, QTcF, and RR intervals will be obtained for each patient 
during the stud y. ECG data will be read and interpreted locall y. 
Categorical analysis of QT/QTc interval data based on the number of patients meeting or 
exceeding predefined limits in terms of absolute QT/QTc intervals or changes from baseline 
will be presented.  In addition, a listing of these patients will be produced.
Vital signs
Data on vital signs will be tabulated and listed, notable values will be flagged.
Data from other tests (includ ing ECHO, performance status, dermatological evaluation,  
) will be listed and summarized using descriptive statistics as 
appropriate. Notable values may be flagged. Notable/Abnormal values for safety  data will be 
further specified in the SAP and will be used for shift tables. Any other information collected 
will be listed as appropriate.
Analy ses will be performed on the safety  setfor both study  cohorts .
[IP_ADDRESS] Supportive analy ses for secondary  objectives
Not applicable.
[IP_ADDRESS] Tolerability
Tolerability  will be summarized in terms of dose reductions or drug interruption due to an AE.
[IP_ADDRESS] Palatability
Data on palatability  assessments (bitterness, sweetness, texture and overall taste) will be 
summarized and listed. 
10.5.2 Pharmacokinetics
The PAS will be used in all pharmacokinetic data anal ysis and PK summary  statistics for each
cohort .
[IP_ADDRESS] Non- compartmental A nalysis
On Day [ADDRESS_967637] non-compartmental methods using Phoenix WinNonlin (Pharsight, Mountain View, 
[LOCATION_004] in US). The PK parameters listed in Table 10-[ADDRESS_967638] measurable concentration sampling time (tlast) (ng*h/mL)
AUCtau The AUC calculated to the end of a dosing interval (tau) at steady-state (ng*h/mL); tau= 12 hrs
Cmax The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after 
single dose administration (ng/mL)
Tmax The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration 
after single dos e administration (h)
Ctrough Measured concentration at the end of a dosing interval at steady state (taken directly before next 
administration) (ng/mL)The trough (predose) plasma concentration determined directly from the 
raw concentration -time data
[IP_ADDRESS] Basi c table, figure and listing
Validity  of PK samples will be confirmed by [CONTACT_711324], stead y state 
condition and occurrence of vomiting with respect to time of dose. Only  confirmed PK 
concentrations will be used in the anal yses.
Summary  statistics of plasma concentration of dabrafenib, its relevant metabolites and 
trametinib will be reported by  [CONTACT_711325] (i.e. the dose taken on the day  prior 
to the PK sampling day) for all patients that provided at least one evaluable PKsample. 
Summary  statistics include n, arithmetic mean, median, SD, geometric mean, coefficient of 
variation (CV) (%) and geometric CV (%), minimum and maximum. Zero concentrations will 
not be included in the geometric mean calculation Graphical presentation will be provided on 
mean concentration at each scheduled time point for PK sub-population where the full PK 
profile is available.
[IP_ADDRESS] Data handling principles
Plasma concentration values below the lower limit of quantification (LLOQ) will be set to zero 
by [CONTACT_711326], and will be display ed as zero in the listings and flagged. Values below the 
LLOQ will be treated as zero in any  calculations of summary statistics, and treated as missing 
for the calculation of the geometric means and their CV%. Any missing pharmacokinetic 
parameters or concentrations will not be imputed.
 
 
 
 
 
 

[COMPANY_001] Confidential Page 153
Protocol Amended Version 05 Protocol No. CDRB436G2201
 
 
 
 

[COMPANY_001] Confidential Page 154
Protocol Amended Version 05 Protocol No. CDRB436G2201
10.5.4 Resource utilization 
Not applicable.

[COMPANY_001] Confidential Page 155
Protocol Amended Version 05 Protocol No. CDRB436G2201
10.5.5 Patient -reported outcomes
Patient reported outcome (PRO) will only be evaluated in the LGG cohort. One PRO
questionnaire will be used: the PROMI S Parent Prox y Global Health 7+2. The 7+2 item parent 
proxy pediatric global health measure include a one global health score plus a single score from 
pain and a score from fatigue interference item which are scored independently . These two 
items are administered but do not contribute to the global health score. Rather, they are “signal” 
items that provide initial score estimates for pain interference and fatigue. Scoring of PRO data 
and methods for handling of missing items or missing assessments will be according to the 
scoring manual and user guide for each respective patient questionnaire .No imputation 
procedures will be applied for missing items or missing assessments. Descriptive statistics will 
be used to summari ze the scored scales of PROMI S Parent Proxy  Global Health 7+[ADDRESS_967639] baseline score during the treatment period will be 
included in the change from baseline analy ses. In addition, a repeated measures model for 
longitudinal data will be used to estimate differences in PROMI S Paren t Proxy  Global Health 
7+2scores between treatment groups. The number of subjects completing each questionnaire 
and the number of missing or incomplete assessments will be summarized by [CONTACT_711327]. No formal statistical tests will be performed for PRO 
data and hence no multiplicity  adjustment will be applied. The FAS will be used for anal yzing 
PRO data .
10.7 Interim analy sis
10.7.1 HGG Cohort
An interim analysis for futility (HGG cohort only)will be implemented to allow possible 
termination of recruitment and the study  in the event that there is insufficient efficacy . The 
patients for inclusion in the formal interim analysis for futility  will be made shortl y after [ADDRESS_967640] withdrawn earl y. However, an y decision to stop or continue the study  will be made based 
on all data available at the IA cut -off taking the futility  anal ysis into account.

[COMPANY_001] Confidential Page 156
Protocol Amended Version 05 Protocol No. CDRB436G2201
The futility  criteria will be considered met if the observed overall response rate (ORR) assessed 
by [CONTACT_711328] 25% which is considered a threshold for clinical 
relevan ce.This will trigger consideration for stoppi[INVESTIGATOR_711204] . 
The choice of futility  threshold has also taken account of operating characteristics which 
suggest that the chance of the futility  criteria b eing met is high if the true underly ing response 
rate is in a low range ( e.g.<=20%); whereas if the true rate is considerabl y higher, as expected, 
then there is a very  low chance of declaring futility  at the IA. Full details of the futility  criteria 
and o perating characteristics are provided below in Table 10-2 and Table 10 -4. 
Futility criteria 
Given the data observed in the IA, t he probability  of the lower bound of 95% CI at the primary 
analysis exceeding a certain response rate (i.e. 20%) conditional on the observed number of 
responders observed at the IA canbe calculated. The conditional probability canbe calculated 
using beta -
binomial distribution (posterior predictive distribution) . Let Yrepresent the number 
of responders from m future patients at the primary  analy sis and x is the number of responders 
among n patients at the interim analy sis. The (posterior) predictive distribution of Y conditioned 
on the observed data at the interim analy sis (x responders out of n patients) is a beta-binomial 
distribution described by
[CONTACT_711329] a minimally  informative unimodal Beta distribution B(a0, b0) (Neuenschwander et al 
2008) is used with mean equal to 20%,  i.e., the prior distribution will be Beta (0.25, 1) for the 
POS calculations at the interim anal ysis.
Table 10-2 shows the predi ctive probabilities that the 95% CI exclude s 20% at the primary 
analysis under different interim results. For example, w ith 16 patients at IA, if 4responses are 
observed (i.e. 25% response rate) , the probability  of the 95% CI  excluding 20% at the primary 
analysis is 13.7%
.
Table 10-
2 Predictive probability  of the lower bound of 95% CIexceeding 20% at 
the p rimary analy sis under different interim results
# of responsesObserved response rate at 
IA given n=16 (% )Predictive probability  that the 95%  CI excludes 
20% at the primary  analy sis (% )a
1 6.3 < 0.1
2 12.5 0.5
3 18.8 3.5
4 25.0 13.7
5 31.3 34.4
6 37.5 61.0
7 43.8 83.1
8 50.0 94.9
9 56.3 99.0
aThe predictive probabilities are calculated from a beta -binomial distribution.

[COMPANY_001] Confidential Page 157
Protocol Amended Version 05 Protocol No. CDRB436G2201
In addition to the interim futility  analysis described above if the LGG primary  analysis is 
subsequently  reported prior to the HGG primary  analysis then an update/interim analysis of 
HGG safety  data onl y may be required to support the LGG submission.
Also, an additional interim anal ysis of key safet y and PK data of the adolescent patients in the 
HGG cohort may be performed to support a heath authority  request for data in adolescent 
patient s. There will be no efficacy  or futility  conclusion drawn based on this interim analy sis.
10.7.[ADDRESS_967641] two years (or 
otherwise discontinued from the study ). Formal testing of the primary  endpoint with full alpha 
will be performed at the primary  anal ysis.
10.[ADDRESS_967642] 95% and 80% CIs for potential observed ORR for 40 patients are shown in Table 10 -
3.
The 95% CI, via the lower limit, is used to establish the levels of response which are exceeded 
by [CONTACT_711314] y according to a robust standard of evidence (i.e. one
-sided 
alpha=0.025). 
Due to the uncertainties regarding the historical control data there is no specific “success” 
threshold level that we can apply  that the lower limit should be greater than  to give robust 
evidence that dabrafenib and trametinib combination therapy  is better than historical control; 
however, the study  sample size gives reasonable operating characteristics for an illustrative 
threshold historical level of 20%, which is higher than the range expected based on the 
information given in the literature ( Section 1. 1.3).  
The study  also aims to provide evidence that trametinib gives added value to the dabrafenib and 
trametinib 
combination over and above dabrafenib monotherap y treatment. Since a lower 
standard of evidence is usually  required to show such added value, the lower limit of an 80% 
CI is used to identify  the response rates which will be exceeded by [CONTACT_711330] y based on a reduced level of evidence (one-sided alpha of 0.1). Again it is difficult to 
ascertain a definitive  threshold for “success” for evaluation in these circumstances but the 
number of patients in this trial give reasonable operating characteristics for an illustrative 
threshold level of 32%, which is the response rate observed in dabrafenib monotherapy  patients 
in the study  [BRF116013, C DRB436A2102] although based on limited data. Note that the 95% 
CIs can also be used to provide more robust evidence of the benefit of trametinib by  [CONTACT_711331] y response.

[COMPANY_001] Confidential Page [ADDRESS_967643] Binomial 95 and 80 percent Confidence Intervals A round 
Potential Observed ORRs for N= 40
Number of responders Observed ORR (%) 95% exact CI (% ) 80% exact CI (% )
12 30.0 16.6, 46.5 20.5, 41.2
13 32.5 18.6, 49.1 22.7, 43.8
14 35.0 20.6, 51.7 24.9, 46.3
15 37.5 22.7, 54.2 27.1, 48.9
16 40.0 24.9, 56.7 29.4, 51.4
17 42.5 27.0, 59.1 31.7, 53.9
18 45.0 29.3, 61.5 34.1, 56.3
19 47.5 31.5, 63.9 36.4, 58.8
20 50.0 33.8, 66.2 38.8, 61.2
21 52.5 36.1, 68.5 41.2, 63.6
22 55.0 38.5, 70.7 43.7, 65.9
Forexample, out of the 40 patients, with 14responses (35%), the lower bound of 95% CI would 
be higher than 20% ;with 18 responses (45%), the 80% CI would be higher than 32%; and with 
20 responses (50%), the 95% CI  would be higher than 32%.
Table 10-4and Table 10-[ADDRESS_967644] to different criteria. The tables show probability  of meeting the futility  consideration 
criteria (less than 5 responders out of 16 patients), probability  of the confidence interval 
excluding the target response rate at the primary  analysis, and probability  that the futility  criteria 
is not met at IA but the confidence interval does not exclude the target response rate at the 
primary  anal ysis.
At this sample size , when the true ORR is ≤ 20%, 
the probability  of meeting the futility  consideration criteria at interim anal ysisis > 79%,
the probability  of the 95% CI  excluding 20% at the primary  anal ysis is >1.6%, 
and the probabilities of the 95% CI and the 80% CI excluding 32% at the pr imary  anal ysis 
are both < 0.1% respectively . 
Within 40 patients, i f the true ORR is 55% or higher, then 
the probability  of meeting the futility  consideration criteria at IA is < 2%, 
the probabilities of the 95% CI  excluding 20% and the 80% CI excluding 32% at the 
primary  anal ysis areboth > 90% respectivel y
, 
and the probability  that the 95% CI excludes 32% is > 78 %.
Table 10-[ADDRESS_967645] to the 95% CI excluding 20% 
response rate
True 
ORR (%)Probability  to 
meet futility  
consideration 
criteria at IA (%)Probability  that the futility  
consideration criteria is not 
met at IA and the 95%  CI 
exclude s20% at primary  
analy sis (% )Probability  that the futility  consideration 
criteria is not met at IA and the 95%  CI 
does not exclude 20%  at primary  analy sis
(%) 
20 79.8 1.6 18.6
25 63.0 8.5 28.4
30 45.0 25.2 29.8
35 28.9 49.1 22.0

[COMPANY_001] Confidential Page 159
Protocol Amended Version 05 Protocol No. CDRB436G2201
True 
ORR (%)Probability  to 
meet futility  
consideration 
criteria at IA (%)Probability  that the futility  
consideration criteria is not 
met at IA and the 95%  CI 
exclude s20% at primary  
analy sis (% )Probability  that the futility  consideration 
criteria is not met at IA and the 95%  CI 
does not exclude 20%  at primary  analy sis
(%) 
40 16.7 71.7 11.6
45 8.5 87.1 4.4
50 3.8 95.0 1.2
55 1.5 98.3 0.2
60 0.5 99.5 < 0.[ADDRESS_967646] to the 95% and 80% CIs 
excluding 32% response rate
True ORR 
(%)Probability  to 
meet futility  
consideration 
criteria at IA 
(%)Probability  that 
the futility  
consideration 
criteria is not 
met at IA and 
the 95%  CI 
exclude s32% 
at primary  
analy sis (% )Probability  that 
the futility  
consideration 
criteria is not 
met at IA and 
the 95%  CI does 
not exclude 32% 
at primary  
analy sis (% )Probability  that 
the futility  
consideration 
criteria is not 
met at IA and 
the 80%  CI 
excludes 32%
at primary  
analy sis (% )Probability  that 
the futility  
consideration 
criteria is not 
met at IA and 
the 80% CI 
does not 
exclude 32% at 
primary  
analy sis (% )
20 79.8 < 0.1 20.2 < 0.[ADDRESS_967647] a 30% improvement in ORR based on central independent assessed response of 50% 
in the dabrafenib plus trametinib arm vs 20% in thecarboplatin with vincristine arm ( Lassaletta 
2017) with at least 80% power, 102 patients are required to be randomized in the two treatment 
arms in a 2:[ADDRESS_967648] and one
-sided alpha = 
2.5%.
Based on the following assumptions i.e 102 patients, 2:[ADDRESS_967649] and one sided alpha of 2.5%, the study  power scenarios under 
different true ORR are shown in Table 10-6.

[COMPANY_001] Confidential Page 160
Protocol Amended Version 05 Protocol No. CDRB436G2201
Table 10-6 Power scenarios under different true ORR in BRAF V600 mutant
LGG True ORR % (carboplatin with 
vincristine arm vs.dabrafenib plus 
trametinib )Power (%)
20% vs. 55% 90%
20% vs. 50% 80%
20% vs. 45% 67%
15% vs. 50% 90%
25% vs. 50% 66%
10.9 Power for analy sis of key secondary  variables
Not applicable.
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IE C/REB) before study  start. Prior to study  start, the investigator is required 
to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study  in 
accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality  Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedure s
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/REB -approved informed consent (if applicable, or, if 
incapable of doing so, after such consent has been provided by a  l egally acceptable 
representative of the patient. In cases where the patient’s representative gives consent, the 
patient should be informed about the study  to the extent possible given his/her understanding. 
If the patient is capable of doing so, he/she should indicate assent by [CONTACT_711332] a separate assent form).
Informed consent must be obtained before conducting an y stud y-specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source documents. The date when a patient ’s Informed Consent was 
actuall y obtained will be captured in their CRFs.

[COMPANY_001] Confidential Page 161
Protocol Amended Version 05 Protocol No. CDRB436G2201
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/ IEC/REB approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
Additional consent form
Not applicable.
11.4 Discontinuation of the study
[COMPANY_001] reserves the right to discontinue this study  under the conditions specified in the clinical 
study  agreement. Specific conditions for terminating the study are outlined in 
Section 4.4.
11.5 Publicatio
n of study  protocol and results
[COMPANY_001] is committed to the following high ethical standards for reporting study  results for its 
innovative medicines, including the timel y communication and publication of clinical trial 
results, whatever their outcome. No vartis assures that the key  design elements of this protocol 
will be posted on thepublicly  accessible database , e.g.clinicaltrials.gov , before study  start.In 
addition, results of interventional clinical trials in adult patients are posted on 
www.novarti sclinicaltrials.com, a publicl y accessible database of clinical study  results within 
1 year of study  completion (i.e., LPLV), those for interventional clinical trials involving 
pediatric patients within 6 months of study  completion.
[COMPANY_001] follows the I CMJE authorship guidelines ( .icmje.org ) and other specific guidelines of 
the journal or congress to which the publication will be submitted. Authors will not receive 
remuneration for their writing of a publication, either directl y from [COMPANY_001] or through the 
professional medical writing agency . Author(s) may be requested to present poster or oral 
presentation at scientific congress; however, there will be no honorarium provided for such 
presentations.
As part of its commitment to full transparent in public ations, [COMPANY_001] supports the full 
disclosure of all funding sources for the study  and publications, as well as any actual and 
potential conflicts of interest of financial and non-financial nature by [CONTACT_15064], including 
medical writing/editorial support , if applicable. 
For the [COMPANY_001] Guidelines for the Publication of Results from [COMPANY_001] -sponsored Research, 
please refer to .novartis.com . 

[COMPANY_001] Confidential Page [ADDRESS_967650] keepi[INVESTIGATOR_5324], in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality  of patient s. As part of par ticipating in a [COMPANY_001] -sponsored 
study , each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required by  [CONTACT_1289], to copy ) clinical records for the purposes of 
quality  assurance reviews, a udits and evaluation of the study  safet y and progress.
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory  notes, memoranda, patient s’ diaries or evaluation 
checklists, pharmacy  dispensing records, recorded data from automated instr uments, copi[INVESTIGATOR_5117], microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, and patient files and records kept 
at the pharmacy , at the laboratories, and medico -technical departments involved in the clinical 
trial.
Data collection is the responsibility  of the clinical trial staff at the site under the supervision of 
the site Principal I nvestigator. The study  case report form (CRF) is the primary  data collection 
instru ment for the stud y. The investigator should ensure the accuracy, completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported on 
the CRF, that are derived from source documents, should be consisten t with the source 
documents or the discrepancies should be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF should 
be dated, initialed, and explained (if necessary ) and should not obscure the original entry . For 
electronic CRFs an audit trail will be maintained by  [CONTACT_5382]. The investigator should retain 
records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by [CONTACT_5383]/or guidelines. The investigator/institution should take measures to prevent 
accidental or premature destruction of the se documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retent ion for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.[ADDRESS_967651] ensure anon ymity of the patients; patients must not be identified by [CONTACT_5384]. Signed informed consent forms and patient enrollment 
log must be kept strictl y confidential to enable patient identification at the site.

[COMPANY_001] Confidential Page 163
Protocol Amended Version 05 Protocol No. CDRB436G2201
11.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_5385].
11.[ADDRESS_967652] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC/REB it cannot be implemente d. All significant protocol 
deviations will be recorded and reported in the CSR.
12.[ADDRESS_967653] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safet y may be implemented prior to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety  of any patient 
included in this study , even if this action represents a deviation from the protocol. In such cases, 
[COMPANY_001] should be notified of this action and the IRB/IEC at the study  site should be informed 
according to local regulations (e.g. [LOCATION_006] requires the notification of urgent safet y measures 
within 3 day s) but not later than 10 working days.

[COMPANY_001] Confidential Page 164
Protocol Amended Version 05 Protocol No. CDRB436G2201
13 References (available upon request)
Anker CJ, Grossmann KF, Atkins MB, et al. (2016). Avoiding severe toxicity  from combined 
BRAF inhibitor and radiation treatment: Consensus guidelines from the Easatern Cooperative 
Oncology  Group (ECOG). Int J Radiat Oncol Biol Phy s. 95 (2): 632 -646.
Ater J L, Zhou T, Holmes E, et al. (2012). Random ized study  of two chemotherapy  regimens 
for treatment of low -grade glioma in young children: a report from the Children’s Oncology 
Group. J Clin Oncol. 30(21): 2641 -2647.
Bond y ML, Scheurer ME, Malmer B, et al. (2008). Brain tumor epi[INVESTIGATOR_623] : consensus 
from the Brain Tumor Epi[INVESTIGATOR_711205]. Cancer .113:1953–1968
Bode U, Buchen S, Warmuth -Metz M, et al. (2007) Final report of a phase II trial of 
nimotuzumab in the treatment of refractory  and relapsed high -grade gliomas in children and 
adolescents. 
Journal of Clinical Oncology , 2007 ASCO Annual Meeting Proceedings Part I. 
Vol 25, No. 18S (June 20 Supplement), 2007: 2006.
Broniscer A. (2006). Past, present, and future strategies in the treatment of high -grade glioma 
in children. Cancer Invest. 2477–81
Broniscer A, Gajjar A. (2004). Supratentorial high -grade astrocy toma and diffuse brainstem 
glioma: two challenges for the pediatric oncologist . Oncologist . 9197–206
Broom Schiff, Friedman, Medical and Pediatric Oncology  26(2): 105
-110, 1996
CBTRUS (2012). CBTRUS Statistical Report: Primary  Brain and Central Nervous Sy stem 
Tumors Diagnosed in the [LOCATION_002] in 2004 -2008. Source: Central Brain Tumour Registry  
of the [LOCATION_002], Hinsdale, IL .cbtrus.org
CBTRUS (2015). 
CBTRUS Statistical Report: Primay  Brain and Central Nervous System 
Tumors Diagnosed in the [LOCATION_002] in 2008 -2012. Source: Central Brain Tumor Registry  
of the [LOCATION_002], Hinsdale, IL. cbtrus.org
Chamberlain MC. (1997) Recurrent supratentorial malignant gliomas in children. Lo ng-term 
salvage therapy  with oral etoposide. 
Arch Neurol. ;54(5):554-8.
Clopper, CJ, and Pearson, ES, (1934) "The Use of Confidence or Fiducial Limits I llustrated in 
the Case of the Binomial," Biometrika, 26, 404 -413.
Cohen KJ, Pollack IF, Zhou T, et al. (2011). Temozolomide in the treatment of high- grade 
gliomas in children: a report from the Children’s Oncology  Group. Neuro. Oncol. 13:317–323
Doughert y M, Santi M, Brose M, et al. (2010) Activating mutations in BRAF characterize a 
spectrum of paediatric low
-grade gliomas. Neuro Oncol. 2010 Feb 14. [Epub ahead of print]. 
PMID: 20156809.
European Medicines Agency (EMA), 2011. 
wwwema.europa.eu/docs/en_GB/document_library /Report/2011/07/WC500108351.pdf
Fangusaro J., Warren KE. (2012). Abstracts from the 15th Internati onal S ymposium on 
Pediatric Neuro -Oncology , June 24 –27, 2012, Toronto, Ontario, Canada: an internet- based 
survey  evaluating the standard of care in treating children with newl y diagnosed high grade 
glioma. 
Neuro Oncol. 14(Suppl. 1) i56–i68

[COMPANY_001] Confidential Page 165
Protocol Amended Version 05 Protocol No. CDRB436G2201
Finlay  JL, Boyett JM, Yates AJ, et al. (1995). Randomized phase III trial in childhood high -
grade astrocy toma comparing vincristine, lomustine, and prednisone with the eight -drugs -in-
1-day regimen. Childrens Cancer Group. J. Clin. Oncol .13:112–123
Finlay  JL, Dhall G, Bo yett JM, et al. (2008). 
Myeloablative chemotherap y with autologous 
bone marrow rescue in children and adolescents with recurrent malignant astrocy toma: 
outcome compared with conventional chemotherapy : a report from the Children’s Oncology  
Group. Pediatr. Blood Cancer . 51:806 –811
Finlay  JL, Zacharoulis S. (2005). The treatment of high grade gliomas and diffuse intrinsic 
pontine tumors of childhood and adolescence: a historical – and futuristic –perspective. J. 
Neurooncol.75:253–266
Fouladi M, Nicholson HS, Zhou T, et al. (2007) A phase II study  of the farnes yl transferase 
inhibitor, tipi[INVESTIGATOR_7734], in children with recurrent or progressive high -grade 
glioma,medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children’s 
Oncology  Group study . Cancer. ;110(11):2535 -41.
Gaynon PS, Ettinger L J, Baum ES, et al . (1990) Carboplatin in childhood brain tumors. A 
Children's Cancer Stud y Group Phase II trial. Cancer ;15;66(12) :[ADDRESS_967654] D, Thomas F, et al. (2011) Innovative therapi[INVESTIGATOR_711206] I study  of erlotinib in brainstem glioma and relapsing/refractory  brain 
tumors. Neuro Oncol. 13(1): 109 -118. 
Geoerger B, Kieran M, Grupp S, et al . (2012) Phase II trial of temsirolimus in children with 
high-grade glioma, neuroblastoma and rhabdom yosarcoma. Eur J Cancer. 48(2): 253-262. 
Gnekow A, Walker D, Kandels D, et al. (2017). A European randomised controlled trial of the 
addition of etoposide to standard vincristine and carboplatin induction as part of an 18- month 
treatment programme for childhood ( ≤16 hears) low grade glioma –A final report. EJC. 81: 
206-225.
Guruangan S., Dunkel I J, Goldman S., et al. (1998). Myeloablative chemotherap y with
autologous bone marrow rescue in young children with recurrent malignant brain tumors. J.
Clin. Oncol.
16: 2486–2493
Gururangan S, Chi SN, Poussaint TY, et al. (2010) L ack of efficacy  of bevacizumab plus 
irinotecan in children with recurrent malignant 
glioma and diffuse brainstem glioma: A 
pediatric brain tumor consortium study . J Clin Oncol. 28(18): [ADDRESS_967655] JR, Makale MT, et al (2014) Pediatric Phase II trials of poly -ICLC 
in the management of newly  diagnosed and recurrent brai n tumors. J Pediatr Hematol Oncol. 
36(6): 451-457. 
Hauschild A, Grob J, et al. (2012). Dabrafenib in BRAF -mutated metastatic melanoma: a 
multicentre, open -label, phase 3 randomised controlled trial.  Lancet. 380: 358 -365.
Hummel T.R., Wagner L, Ahern C., et al. (2013) A pediatric phase [ADDRESS_967656] tumors: a children’s 
oncology  group phase 1 consortium study . Pediatr. Blood Cancer. 60: 1452 -7.
Hurwitz CA, Strauss L C, Kepner J, et al. (2001) Paclitaxel for the treatment of progressive or 
recur rent childhood brain tumors: a pediatric oncology  phase II study . J Pediatr Hematol 
Oncol.
;23(5):277-81.

[COMPANY_001] Confidential Page 166
Protocol Amended Version 05 Protocol No. CDRB436G2201
Infante JR, Fecher, LA, Falchook GS, et al. (2012). Safet y, pharmacokinetic, 
pharmac odynamic, and efficacy  data for the oral MEK inhibitor trametinib: a phase 1 dose-
escalation trial. Lancet Oncology . 13: 773-781Janeway  KA, Place AE, Kieran MW, et al. 
(2013) Future of Clinical Genomics in Pediatric Oncology . J. Clin. Onco.: 31: [ADDRESS_967657] D. (2012). Paediatric and adult malignant glioma: close 
relatives or distant cousins? Nat. Rev. Clin. Oncol. 9: 400–413.
Jones DTW, Witt O, Pfister SM. (2017). BRAF V600E status alone is not sufficient as a 
prognostic bioma rker in pediatric low -grade glioma. 
J Clin Oncol. 1: 96-96.
Kaatsch P., Rickert C., Kuhl J., et al. (2001) Population-based epi[INVESTIGATOR_711207]. Cancer; 92:3155 -64.
Korshunov A., Ry zhova M., et al.(2015) Integrated anal ysis of pediatric gliobastoma reveals a 
subset of biologicall y favorable tumors with associated molecular prognostic markers. Acta 
Neuropathol ; 129 :669-678.
Lashford LS, Thiesse P, Jouvet A, et al. (2002) Temozolomide in malignant gliomas of 
childhood: a [LOCATION_008] Children's Cancer Study  Group and French Society  for 
Pediatric Oncology  Intergroup Study . J. Clin Oncol. 24: 4684-91.
Lassaletta A, Mistry  M, Arnaldo A, et al .(2016). Inferior outcome a nd poor response to 
conventional therapi[INVESTIGATOR_711208] -grade gliomas harboring the BRAF V600E mutation. 
Neuro -oncology . 18: iii78 -iii96.
Lassaletta A, Zapotock y M, Mistry  M, et al. 
(2017). Therapeutic and prognostic implications 
of BRAF V600E in pedia tric low- grade gliomas. J. Clin Oncol. 35(25): 2934-2941.
Louis DN, Perry  A, Reifenberger G, et al. (2016). The 2016 WHO classification of tumours of 
the centra l nervous s ystem: a summary . Acta Neuropathol. 131(6): 803 -820.
Louis DN, Ohgaki H, Wiestler OD, et al. (2007). The 2007 WHO classification of tumours of 
the central nervous s ystem. Acta Neuropathol .114: 97–109
MacConaill L E, Campbell CD, Kehoe SM, Bass AJ, et al. (2009) Profiling Critical Cancer 
Gene Mutations in Clin ical Tumor Samples. PL oSONE.;4(11):e7887.
MacDonald TJ., Aguilera D., Kramm CM. (2011) Treatment of high -grade glioma in children 
and adolescents. Neuro Oncol. 10:1093
MacDonald TJ, Vezina G, Stewart CF, et al. 
(2013) Phase II stud y of cilengitide in the 
treatment of refractory  or relapses high -grade gliomas in children: A report from the 
Children’s Oncology  Group. Neuro Oncol. 15(10): 1438 -1444. 
Massimino M, Spreafico F, Riva D, et al. (2010) A lower -dose, lower toxicity  cisplatin -
etoposide regimen for ch ildho od progressive low -grade glioma. J. Neurooncol. 100:65-71.
Mistry  M, Zhukova N, Merico D, et al (2015) BRAF Mutation and CDKN2A Deletion Define 
a clinically  distinct subgroup of childhood secondary  high -grade glioma. Journal of Clinical 
Oncology . 33(9 ):1015- 1023.
Neuenschwander B, Branson M, Gsponer T (2008) Critical aspects of the Bay esian approach 
to phase I cancer tri als. Statist. Med. 27;2420 -2439

[COMPANY_001] Confidential Page 167
Protocol Amended Version 05 Protocol No. CDRB436G2201
Nicholson HS, Kretschmar CS, Krailo M, et al. (2007) Phase 2 study  of temozolomide in 
children and adolescents with recurrent central nervous system tumors: a report from the 
Children’s Oncology  Group. Cancer. 110:1542–1550.
Pollack IF, Jakacki RI, Blaney  SM, et al. (2007) Phase I trial of ima tinib in children with 
newly  diagnosed brainsten and recurrent malignant gliomas: A Pediatric Brain Tumor 
Consortium report. Neuro- oncol. 9(2): 145 - 160.
Qaddoumi I, Sultan I , Broniscer A. (2009) Paediatric low -grade gliomas and the need for new 
options for therap y. Cancer Biol Ther. 8:1-7.
Ruggiero A, Cefalo G, Garre ML, et al. (2006) Phase II trial of temozolomide in children with 
recurrent high -grade glioma. J Neurooncol. 77:89-94
Schiffman JD, Hodgson JG, VandenBerg SR, et al. (2010) Oncogenic BRAF mutation with 
CDKN2A inactivation is characteristic of a subset of p aediatric malignant astrocy tomas. 
Cancer Res. 70:512 –519.
Sebolt -Leopold JS. 
(2000) Development of anticancer drugs targeting the MAP kinase 
pathway .  Oncogene ;19(56):6594 - 9.
Turner CD, Gururangan S, Eastwood J, et al. (2002) Phase II stud y of irinotecan ( CPT-11) in 
children with high -risk malignant brain tumors: the Duke experience. Neuro Oncol.;4(2):102 -
Warren K., Jakacki R., Widemann B., et al. (2006). Phase II trial of intravenous lobradamil 
and carboplatin in childhood brain tumors: a report from the Children’s Oncology  
Group. Cancer Chemother. Pharmacol.[ZIP_CODE]–347
Warren KE, Gururangan S, Gey er JR, et al. (2012). 
A phase II stud y of O6 -benzy lguanine and 
temozolomide in pediatric patients with recurrent or progressive high -grade gliomas and 
brainstem gli omas: a Pediatric Brain Tumor Consortium study . J. Neurooncol. 106: 643–649
Wen PY, Chang SM, Van den Bent MJ, et al. 
(2017). Response assessment in neuro -oncology  
clinical trials. J Clin. Oncol. 35(21): 2439-2449. 
Wen PY, Macdonald DR, Reardon DA, et al. (2010). Updated response assessment criteria for 
high-grade gliomas: Response assessment in neuro- oncology  working group. J Clin. Oncol. 
28(11): 1963-1972.
Wolff JE, Driever PH, Erdlenbruch B, et al. (2010) Intensive chemotherap yimproves survival 
in pediatric high -grade glioma after gross total resection: results of the HIT- GBM -C protocol. 
Cancer.;116: 705 –712.
Zanello M, Pages M, Tauziede -Espariat A, et al. (2016). Clinical, imaging, histophatological 
and molecular characterization of anaplastic gang lioglioma. J. Neuropathol .
Exp Neurol. 
75(10): 971-980.

[COMPANY_001] Confidential Page 168
Protocol Amended Version 05 Protocol No. CDRB436G2201
14 Appendices
14.1 Appendix 1 –Concomitant medications
Table 14-[ADDRESS_967658] of medications to be used with caution during study  drug 
treatment
USE WITH CAUTION :  Moderate  inhibitors of CYP3A, or CYP2C8 since concentrations of 
dabrafenib or vincristine may be increased
Class/Therapeutic Area Moderate CYP3A and CYP2C8 Inhibitors
Antiarrhythmics Diltiazem, verapamil
Antibiotic Erythromycin
Antifungal Fluconazole
Miscellaneous Aprepi[INVESTIGATOR_681794] : Co-administration of these drugs with study  treatment may  result in loss of 
efficacy .  Monitor patients for loss of efficacy  or substitute with another medication.
Class/Therapeutic Area CYP3A4, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or Transporter 
Substrates that May  be Affected by  [CONTACT_711333], buprenorphine, celecoxib, codeine, fentanyl, methadone, 
oxycodone
Antiarrhythmics Disopyramide, dronedarone ,mexiletine, propafenone, quinidine
Antibiotics Chloramphenicol, doxycycline, erythromycin, moxifloxacin 
Anticoagulants/ Antiplatelets Cilostazole, warfarin
Anticonvulsants Divalproex, lamotrigine, valproate, zonisamide
Antidepressants and 
AntipsychoticsAripi[INVESTIGATOR_4253], bupropi[INVESTIGATOR_2394], buspi[INVESTIGATOR_5331], desipramine, haloperidol, mirtazapi[INVESTIGATOR_050], 
pi[INVESTIGATOR_3924], quetiapi[INVESTIGATOR_050], trazodone, amitriptyline, clomipramine, imipramine
Antidiabetics Glyburide, saxagliptin, tolbutamide, nateglinide, pi[INVESTIGATOR_051], repaglinide, 
rosiglitazone
Antifungals Caspofungin, fluconazole, terbinafine
Antihistamines Astemizole, chlorpheniramine, ebastine
Antihypertensives Amlodipi[INVESTIGATOR_050], diltiazem, felodipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], nilvadipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050], 
verapamil
Antimigraine Agents Diergotamine, eletriptan, ergotamine
Corticosteroids Dexamethasone, methylprednisolone, oral budesonide
Erectile Dysfunction Agents Sildenafil, tadalafil, vardenafil
HMG-CoA Reductase 
InhibitorsAtorvastatin, lovastatin, simvastatin, rosuvastatin, pravastatin
Hypnotics and Sedatives Alprazolam, brotizolam, diazepam, estazolam, midazolam, triazolam, 
zolpi[INVESTIGATOR_6730], zopi[INVESTIGATOR_681795], sirolimus, tacrolimus
Miscellaneous Aprepi[INVESTIGATOR_053], cisapride, darifenacin, digoxin, disopyramide, leflunomide, 
methohexital, oral contraceptives, quinine, ranitidine, solifenacin, 
sulfasalazine, tramadol, tolvaptan, chloroquine, zopi[INVESTIGATOR_711209]: CYP = cytochrome P450; HMG -CoA = 3-hydroxy -3-methylglutaryl -coenzyme A.

[COMPANY_001] Confidential Page [ADDRESS_967659] of prohibited medications during study  drug treatment
PROHIBITED – strong inducers of CYP3A or CYP2C8, since concentrations of dabrafenib or vincristine
may be decreased
Class/Therapeutic Area Drugs/Agents
Antibiotics Rifamycin class agents (e.g.,  rifampin, rifabutin, rifapentine), 
Anticonvulsant Carbamazepi[INVESTIGATOR_050], phenobarbital, phenytoin, s- mephenytoin 
Miscellaneous bosentan,
PROHIBITED – Strong inhibitors of CYP3A, or CYP2C8 since concentrations of dabrafenib or 
vincristine may be increased
Class/Therapeutic Area Drugs/Agents
Antibiotics Clarithromycin, telithromycin, troleandomycin
Antidepressant Nefazodone
Antifungals Itraconazole, ketoconazole, posaconazole, voriconazole
Hyperlipi[INVESTIGATOR_711210]-retroviral Ritonavir, Saquinavir, Atazanavir
Miscellaneous Conivaptan 

[COMPANY_001] Confidential Page 170
Protocol Amended Version 05 Protocol No. CDRB436G2201
14.2 Appendix 2 –Performance Status Criteria
PERFORMANCE STATUS CRITERIA
Karnofsky and Lansky performance scores are intended to be in multiples of 10
Karnofsky (age ≥16 years of age) Lansky (age <16 years)
Score Description Score Description
[ADDRESS_967660] of his/her needs.60 Up and around, but minimal active play, keeps 
busy with quieter activities.
50 Requires considerable assistance and 
frequent medical care.50 Gets dressed, but lies around much of the day; 
no active play, able to participate in all quiet play 
and activities.
40 Disabled, requires special care and 
assistance.40 Mostly in bed, participates in quiet activities.
30 Severely disabled, hospi[INVESTIGATOR_373].  Death not imminent.30 In bed, needs assistance even for quiet play.
20 Very sick, hospi[INVESTIGATOR_374].  
Death not imminent.20 Often sleepi[INVESTIGATOR_007]; play entirely limite d to very 
passive activities.
10 Moribund, fatal processes progressing 
rapi[INVESTIGATOR_375].10 No play, does not get out of bed.

[COMPANY_001] Confidential Page 171
Protocol Amended Version 05 Protocol No. CDRB436G2201
14.3 Appendix 3 –Response A ssessment in Neuro -oncology  (RANO) 
Criteria
Anti- tumor activity  will be assessed based on clinical evidence and the Response Assessment 
in Neuro- Oncology  (RANO) criteria for solid tumors ( Wen 2010, Wen 2017) .
All measureable and nonmeasureable lesions should be assessed using the same techniques as 
at baseline.  Ideall y, patient s should be imaged on the same MRI  scanner, or at least with the 
same magnet strength, for the duration of the study  to reduce difficulties in interpreting changes.  
The RANO criteria for assessment of LGG differs from that for HGG primarily  in that LGG 
assessments utilize T2/FLA IR imaging while HGG assessments utilize Gadolini um enhanced 
imaging.  For purposes of this protocol, the minor response category  will not be used for 
description of LGG response assessments.
Measurable disease is defined as bidimensionally  contrast enhancing (HGG) or T2/FLAIR 
(LGG) lesions with clearly  defined margins by  [CONTACT_711334], with two perpendicular diameters of 
at least twice the thickness of the imaging slices with 0-mm skip. In the event there are interslice 
gaps, this also needs to be considered in determining the size of measurable lesions at ba seline. 
Measurement of tumor around a cyst or surgical cavity  represents a particularl y difficult 
challenge. In general, such lesions should be considered nonmeasurable unless there is a nodular 
component of at least twice the slice thickness
. The cystic or surgical cavity  should not be 
measured in determining response. 
Nonmeasurable disease is defined as either unidimensionally  measurable lesions, masses with 
margins not clearl y defined, or lesions with maximal perpendicular diameters less than twice 
the 
slice thickness. 
Radiographic response should be determined in comparison to the tumor measurements 
obtained at pretreatment baseline for determination of response .  The smallest tumor 
measurements at either pretreatment baseline or after initiation of therapy should be used for 
determination of progression.  
Response definitions for HGG:
Complete response (CR): Complete disappearance of all enhancing measureable and 
nonmeasureable disease on contrast enhanced MRI  scan sustained for at least 4 weeks, no 
new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. In addition, 
patient must be off steroids or only  on phy siologic replacement doses.  In the absence of a 
confirming scan 4 weeks later, this response will be considered only  stable disease.
Partial response (PR): Greater than or equal to a 50% reduction, compared to baseline, in 
the sum of products of the perpendicular diameters for all measurable lesions for at least 4 
weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved 
nonenhancing (T2/FLAIR) lesions.  I n addition, patient must be on a corticosteroid dose 
not gr eater than the dose at the time of baseline scan and be stable or improving clinicall y.  
In the absence of a confirming scan 4 weeks later, this response will be considered onl y 
stable disease.
Progressive Disease (PD): Greater than or equal to a 25% incre ase in sum of the products 
of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) 
on stable or increasing doses of corticosteroids, OR a significant increase in T2/FLAIR 

[COMPANY_001] Confidential Page [ADDRESS_967661] response after initiation of therapy, not due to comorbid events, OR 
the appearance of an y new lesions, OR clear progression of nonmeasurable lesions, OR 
definite clinical deterioration not attributable to other causes apart from tumor, or to 
decrease in corticosteroid dose.  Failure to return for evaluation as a result of death or 
deteriorating condition should also be considered as progression. 
Stable disease: If patient does not qualify  for CR, PR, or PD and has stable nonenhancing 
(T2/FLAIR) lesions on same or lower doses of corticosteroids compared with baseline 
scan and clinically  stable status.  I n the event that the corticosteroid dose was increased for 
new s ymptoms and signs without confirmation of disease progression on neuroimaging 
and subsequent follow -up imaging shows that this increase in corticosteroid dose was 
required because of disease progression, the last scan considered to show stable disease 
will be the scan obtained when the corticos teroid dose was equivalent to the baseline dose.
Response definitions for LGG:
Complete response (CR): Complete disappearance of all measureable and nonmeasureable 
disease on MRI scan sustained for at least [ADDRESS_967662] be off steroids or only  on phy siologic replacement doses.  In the absence of a 
confirming scan 4 weeks later, this response will be considered only  stable disease.
Partial response (PR): Greater than or equal to a 50% reduction, compared to ba seline, in 
the sum of products of the perpendicular diameters for all measurable lesions for at least [ADDRESS_967663] be on a corticosteroid dose not greater than the dose at the time of baseline scan and 
be stable or improving clinically .  In the absence of a confirming scan 4 weeks later, this 
response will be considered only  stable disease.
Progressive Disease (PD): Greater than or equal to a 25% increase in sum of the prod ucts 
of perpendicular diameters of measurable lesions (compared with baseline if no decrease) 
on stable or incre asing doses of corticosteroids compared with baseline scan or best 
response after initiation of therap y, not due to comorbid events, OR the appe arance of an y 
new lesions, OR clear progression of nonmeasurable lesions, OR definite clinical 
deterioration not attributable to other causes apart from tumor, or to decrease in 
corticosteroid dose.  Failure to return for evaluation as a result of death or deteriorating 
condition should also be considered as progression. 
Stable disease: If patient does not qualify  for CR, PR, or PD and has stable lesions on 
same or lower doses of corticosteroids compared with baseline scan and clinically  stable 
status.  I nthe event that the corticosteroid dose was increased for new s ymptoms and signs 
without confirmation of disease progression on neuroimaging and subsequent follow -up 
imaging shows that this increase in corticosteroid dose was required because of disease 
progression, the last scan considered to show stable disease will be the scan obtained when 
the corticosteroid dose was equivalent to the baseline dose.

[COMPANY_001] Confidential Page 173
Protocol Amended Version 05 Protocol No. CDRB436G2201
Increase in corticosteroid dose alone, in the absence of clinical deterioration related to tumor, 
will not be used as a determinant of progression. Patient s with stable imaging studies whose 
corticosteroid dose was increased for reasons other than clinical deterioration related to tumor 
do not qualify  for stable disease or progression. They  should be observed closel y. If their 
corticosteroid dose can be reduced back to baseline, they will be considered as having stable 
disease; if further clinical deterioration related to tumor becomes apparent, they will be 
considered to have progression. The date of progress ion should be the first time point at which 
corticosteroid increase was necessary .
The definition of clinical deterioration is left to the discretion of the treating physician, but it is 
recommended that a decline in the KPS from [ADDRESS_967664] 7 days, be 
considered neurologic deterioration unless attributable to comorbid events or 
changes in 
corticosteroid dose. Similarly, a decline in the Eastern Cooperative Oncology Group and WHO 
performance scores from 0 or 1 to 2 or 2 to 3 would be considered neurologic deterioration.  
In general, if there is doubt about whether the lesion has progressed, continued treatment and 
close follow -up e valuation will help clarify  whether there is true progression.  If there is 
uncertaint y regarding whether there is progression, the patient may continue on treatment and 
remain under close observation (e.g., evaluated at 4 -week intervals). If subsequent ev aluations 
suggest that the patient is in fact experiencing progression, then the date of progression should 
be the time point at which this issue was first raised.

[COMPANY_001] Confidential Page 174
Protocol Amended Version 05 Protocol No. CDRB436G2201
14.4 Appendix 4 – WHO (20 16) Grading of Tumors of the CNS 

[COMPANY_001] Confidential Page 175
Protocol Amended Version 05 Protocol No. CDRB436G2201
